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ABSTRACT 
 
Natural products have historically been a rich source of ―lead compounds‖ in drug 
discovery. The investigation of terrestrial plants and marine organisms aimed at 
searching new biologically active compounds is a central issue of this kind of 
studies, trough structure elucidation combined with biological tests. My research  
work, described in this PhD thesis, is included in this research topic and was 
addressed at three different topics: - cannabinoids from Cannabis sativa and from 
the Indonesian sponge Dasychalina sp.; - isolation and synthesis of antimalarial 
compounds; - metabolites isolated from plants belonging to the Euphorbiaceae 
family (Jatropha curcas, Euphorbia macroclada and Euphorbia bungei).  
A phytochemical investigation of the fibre cultivar of Cannabis sativa derived 
from the historical Carmagnola variety led to isolation of the novel spiranic 
stilbenoid isocannabispiradienone and the biphenyl-type cannabinoid 
cannabioxepane (CBX), a tetracyclic compound characterized by an 
unprecedented C-5/C-8‘ oxygen bridge and devoid of cannabinoid activity. In the 
same area, from the polar organic extract of the Indonesian sponge Dasychalina 
sp., I have isolated haplosamate A, a unique C28 sterol containing a sulfate group 
at C-3 and a methyl phosphate at C-15, along with its new desulfo analogue. Both 
compounds, as well as their semi-synthetic analogues, have been evaluated for 
interaction with CB1 and CB2 receptors through a binding test. 
Desulfohaplosamate showed a selective affinity for CB2 receptors in the low μM 
range. Haplosamate derivatives represent the first CB receptor ligands belonging 
to the class of steroids.  
The search for antimalarial lead compounds is another main topics of my Ph.D. 
activity discussed in this thesis. On the bases of the previously developed 
pharmacophore of plakortin antimalarials, in this thesis I report a synthesis  of a 
new series of simple endoperoxides, characterized by a 3-methoxy-1,2-dioxane 
scaffold. In particular, I have contributed to the design, the synthesis, the 
biological evaluation of a novel series of compounds obtained by means of an 
efficient one-pot three-component Mn(III)-mediated synthesis which utilizes 
cheap starting materials. The obtained molecules are 3,6,6-trisubstituted 3-
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methoxy-1,2-dioxanes with simple alkyl chains and bearing an ester group at 
position 4, which were tested against Pf.  
As part of the ongoing research aimed at finding new antimalarial leads from 
natural sources, I have carried out a detailed phytochemical investigation of the 
fruit of an African sample of Azadirachta indica, collected in Burkina Faso. Eight 
known and two new triterpenoid derivatives, named neemfruitins A and B, have 
been isolated from the fruits of neem, Azadirachta indica A. Juss., a traditional 
antimalarial plant used by Asian and African populations. In vitro antiplasmodial 
tests carried out with the isolated metabolites evidenced a significant activity of 
the known gedunin and azadirone and the new neemfruitin A, and provided useful 
information about the structure-antimalarial activity relationships in the limonoid 
class.   
Finally, the chemical investigation of Euforbiaceae plants carried out during my Ph.D., 
and described in this thesis, led to isolation of  many diterpenoids. From the root barks 
of Jatropha curcas I isolated spirocurcasone, a diterpenoid possessing the 
unprecedented ―spirorhamnofolane‖ skeleton, along with 11 known and two other 
new diterpenoids. The absolute configuration of spirocurcasone was established 
using quantum mechanical calculation of the electronic circular dichroic (ECD) 
spectrum. Some of the isolated diterpenoids showed a potent activity against 
L5178Y, a mouse lymphoma cell line. The phytochemical investigation of 
Euphorbia macroclada Boiss. and Euphorbia bungei, led to isolation of many 
new diterpenoids belonging to the jatrophane and pre-myrsinane classes. The 
main interest in these compounds is related to their biological activity as 
glycoprotein-P inhibitors and so modulators of multidrug resistance in cancer 
chemotherapy. 
The structures of all new compounds were elucidated using modern spectroscopic 
methods including 2D NMR and HRMS. 
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ABSTRACT (IN ITALIAN) 
 
Le sostanze naturali sono da sempre una ricca fonte di composti guida per la 
scoperta di nuovi farmaci. Lo studio chimico di piante terrestri e organismi marini  
attraverso la determinazione stereostrutturale di nuovi metaboliti in combinazione 
con la valutazione della loro attività biologica costituisce il fulcro della Chimica 
delle Sostanze Naturali. In tale ambito, l‘attività di ricerca condotta durante il 
corso di Dottorato, i cui risultati sono riportati nella seguente tesi, è stata 
focalizzata su  tre tematiche: - isolamento e semisintesi di composti attivi sui 
recettori dei cannabinoidi; - isolamento e sintesi di molecole dotate di azione 
antimalarica; - diterpeni bioattivi da piante appartenenti alla famiglia delle 
Euforbiaceae.  
Nell‘ambito della prima tematica di ricerca è stata analizzata una varietà da fibra 
di Cannabis sativa, denominata varietà Carma, ottenendo l‘isolamento di un 
fitocannabinoide, denominato cannabioxepane (CBX), caratterizzato da un nuovo 
tipo di scheletro tetraciclico, privo di attività cannabinoide. Nella stessa area di 
ricerca è stato analizzato un estratto polare della spugna Dasychalina sp. isolando 
l‘haplosamato A, un C28 sterolo contenente un gruppo solfato ed un metilfosfato, 
insieme al suo nuovo desulfo-derivato. Quest‘ultimo composto ha mostrato 
un‘attività selettiva sul recettore CB2, definendo in tal modo un nuovo chemotipo 
di ligandi di tale recettore.  
La ricerca di nuovi composti antimalarici alternativi agli attuali farmaci in 
commercio è una delle principali tematiche del mia attività di ricerca, inserendomi 
in un ambito già avviato dal mio gruppo di ricerca. È stata dunque, progettata e 
realizzata una sintesi semplice ed economica, basata sull‘azione catalitica di 
composti a base di Mn(III), di derivati 1,2-diossanici dotati di buona attività 
antimalarica. Sono stati attenuti una serie di derivati con una buona variabilità 
stereo strutturale intorno al nucleo endoperossidico, requisito farmacoforico. Tutti 
i prodotti sono stati saggiati su ceppi di P. falciparum CQ-S e CQ-R. L‘analisi 
fitochimica dei frutti di Azadiractha indica, una pianta tradizionale utilizzata da 
popolazioni asiatiche e africane, ha portato all‘ottenimento di dieci limonoidi (di 
cui due nuovi, denominati neenfriutina A e B). Tre dei metaboliti isolati 
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(gedunina, azadirone e  neemfruitina A) hanno mostrato un‘ottima attività, 
fornendo inoltre preziose informazioni sulle relazioni struttura attività nella classe 
dei limonoidi.  
Infine, nell‘ambito dello studio di diterpeni da piante appartenenti alla famiglia 
delle Euphorbiaceae, sono state analizzate due piante appartenenti al genere 
Euphorbia (E. macroclada e E. bungei) ed una del genere Jatropha (J. curcas). 
L‘analisi fitochimica delle prime due piante ha condotto all‘isolamento di 
numerosi nuovi diterpeni a scheletro jatrofanico e premirsinanico, molecole 
biologicamente interessanti in quanto inibitori delle glicoproteina-P e quindi 
potenziali modulatori della multi-drug resistance nella terapia anticancro. 
Dall‘estratto apolare di Jatropha curcas sono stati isolati più di dieci metaboliti, 
tra i quali lo spirocurcasone, un diterpene caratterizzato da  un nuovo scheletro 
carbonioso, che è stato denominato spiro-rhamnofolano. La stereochimica di tale 
composto è stata valutata  attraverso calcoli quantomeccanici dello spettro di 
dicroismo circolare elettronico (ECD). Alcuni dei diterpeni ottenuti hanno 
mostrato una potente attività antiproliferativa su una linea cellulare di linfoma di 
ratto (IC50 nell‘ordine nM).  
La caratterizzazione stereostrutturale di tutti i composti isolati o sintetizzati è stata 
effettuata mediante indagini spettroscopiche (UV, IR, NMR mono- e 
bidimensionale) e spettrometriche (ESI-MS), talvolta includendo derivatizzazioni 
chimiche. 
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CHAPTER I 
INTRODUCTION 
 
1.1. NATURAL PRODUCTS CHEMISTRY 
Nature represents an endless arsenal of new bioactive molecules and the study of 
these metabolites has historically proven of immense benefit in the drug discovery 
process. The history of terrestrial natural products chemistry can readily be traced 
back to the beginning of the XIX century with the first investigation of terrestrial 
plants aimed at finding the molecules responsible of the biological activities of the 
extracts. This is in distinct contrast to the natural products chemistry associated 
with marine species which has emerged only over the past 65 years mainly as a 
result in the improvement of collection techniques, as SCUBA diving. 
Furthermore, the improvements in spectroscopic methods have historically 
stimulated natural products chemistry and the efforts to examine new compounds 
from unusual organisms rapidly and systematically. Nevertheless, natural products 
chemistry suffered a decline from the mid 1990's when major pharmaceutical 
companies disinvested in this area and switched to more "rational" combi-chem 
approaches.
1
 In recent years Natural products chemistry began to flourish also 
through chemical biology and chemical genetics and the realization that natural 
product structures often explore structural space unavailable to combi-chem 
approaches. Summarizing, simple natural organisms are able to create new 
structures in a multitude of different ways and, thus, natural products constitute a 
potentially infinite source of molecular diversity, unmatched by any synthetic 
chemical collection or combinatorial chemistry.  
Natural products have historically been a rich source of lead molecules in drug 
discovery. The searches for new biologically active compounds are based on 
microbial, plant and marine sources. The central issue of such type of studies is 
the structure elucidation combined with biological tests.  
The research work described in this PhD thesis has been performed at the 
Dipartimento di Chimica delle Sostanze Naturali of Università di Napoli 
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"Federico II", and was addressed at different aspects of the research on marine 
and terrestrial natural products. My research was directed to the "core activity" of 
natural product chemistry, i.e. isolation and structure elucidation of new 
compounds accompanied by semisynthesis or total synthesis on the most 
interesting compounds. In particular, my research activity was addressed at three 
different fields:  
a) metabolites isolated from plants belonging to the Euphorbiaceae family 
(Jatropha curcas, Euphorbia macroclada and Euphorbia bungei);  
b) cannabinoids from Cannabis sativa and from the Indonesian sponge 
Dasychalina sp. 
c) isolation and synthesis of antimalarial compounds, c1) a phytochemical 
investigation of the fruit of an African sample of Azadirachta indica, a plant of 
used by African populations against malaria fever; c2) synthesis of monocyclic 
1,2-dioxane derivatives, based on the plakortin scaffold. Plakortin is an 
endoperoxide polyketide with interesting antimalarial properties which was 
isolated from the marine sponge Plakortis simplex. 
 
The results obtained during my Ph.D. have been reported in ten papers (listed at 
the end of this chapter) already published or sent for publication. 
 
1.1.1. An historical perspective
2-4
 
For centuries China led the world in the use of natural products for healing. The 
oldest compilation of Chinese herbs is Shen Nung Pen Ts‘ao, which lists 385 
materials. Pen Ts‘ao Ma catalogue, written by Li-Chen during the Ming Dynasty, 
(1573–1620) mentions 1898 herbal drugs and 8160 prescriptions. The number of 
medicinal herbs used in 1979 in China numbered 5967. One of the most famous 
of the Chinese folk herbs is the ginseng root Panax ginseng, used for health 
maintenance and treatment of various diseases. The active principles were thought 
to be the saponins called ginsenolides. Another popular folk drug, the extract of 
the Ginkgo tree, Ginkgo biloba L. which can improve memory and sharpen 
mental alertness. Numerous psychedelic plants have been used since ancient 
times, producing visions, mystical fantasies, sensation of flying, etc. The Indian 
hemp plant, Cannabis sativa, has been used since 3000 BC, and it is also used as 
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marijuana or hashish. Its constituent, Δ1-THC (tetrahydrocannabinol) is 
responsible for its mind-altering effect. Mechoulam
5
 has been the principal 
worker in the cannabinoids, including structure determination and synthesis of Δ9-
THC. During the 17th century, the Jesuits brought with them from South America 
the bark of the cinchona Cinchona officinalis (called quina-quina by the Indians) 
for the treatment of malaria. In 1820, Pelletier and Caventou isolated from the 
China tree the active compound, quinine. Alkaloids are the major constituents of 
the herbal plants and the extracts used for centuries, but it was not until the early 
nineteenth century that the active principles were isolated in pure form, for 
example morphine (1816), atropine (1819). It was a century later that the 
structures of these compounds were finally elucidated. Modern methods used to 
separate complex organic mixtures utilizing gas-liquid chromatography (GLC), 
high-pressure liquid chromatography (HPLC), and droplet counter-current (DCC) 
chromatography can separate samples rapidly and efficiently in the picogram 
range. This has been impossible until recently. Among the recent outstanding 
contributions to the chemistry of natural products is the conformational analysis 
designed by Derek Barton. Using conformational amalysis, he  determined the 
structures of many key terpenoids such as β-amyrin and cycloartenol. Robert B. 
Woodward was involved in the structural determinations of penicillin, strychnine, 
patalin, terramycin, aureomycin and the synthesis of Vitamin B12. His paper 
published in 1941-42 on empirical rules for estimating the absorption maxima of 
enones and dienes made the general organic chemical community realize that UV 
could be used for structural studies, thus launching the beginning of the 
spettroscopic revolution which soon brought on the applications of IR, NMR and 
MS. As chemical techniques improved, the active constituents were isolated from 
plants, were structurally characterized, and in due course, many were synthesized 
in the laboratory. Sometimes, more active better tolerated drugs were produced by 
chemical modification (semi- synthesis), or by total synthesis of analogues of the 
active principles.  
The investigation on the biosynthesis, a metabolic sequences leading to various 
selected classes of natural products, is of pivotal importance in Natural Product 
Chemistry. The term natural product is generally used to mean a secondary 
metabolite: a small molecule that is not essential to the growth and development 
of the producing organism. Such compounds are found only in specific organisms, 
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or group of organisms, and are an expression of the individuality of species. Well 
over 300,000 secondary metabolites probably exist, generally classified into five 
categories: terpenoids and steroids, fatty acid–derived substances and  
polyketides, alkaloids, nonribosomal polypeptides, and shikimate derived 
compounds. Unraveling the biosynthetic pathways by which natural products are 
made is difficult and time-consuming work, but is fundamental to understand how 
organisms function at the molecular level. The molecules are sometimes complex, 
but the building blocks for their biosynthesis derived from primary metabolism. It 
has been established that the primary synthetic process in nature is photosynthesis 
by which green plants utilize the energy of the sun for the production of organic 
compounds from carbon dioxide. The initial products of photosynthesis are 
carbohydrates. Further metabolic alterations lead to the formation of a pool of 
organic compounds of low molecular weight and simple structures such as 
carboxylic- and amino acids, which are vital for the living organisms. They form 
the synthetic starting materials for specific, genetically controlled, enzymatically 
catalyzed reactions that lead to the complex compounds that characterize the 
secondary metabolism of plants and mammals. In many cases, a suitable cofactor, 
e.g. NAD
+
, PLP, HSCoA, as well as the substrate, may also be bound to 
participate in the transformation. Enzymes have the power to effect these 
transformation more efficiently and more rapidly than the chemical analogy, and 
also under very much milder conditions. Where relevant, they also carry out 
reactions in stereospecific manner. Some of the important reaction frequently 
encountered are alkylation, oxidation and reduction, decarboxylation, aldol and 
Claisen reactions. 
The reaction pathway leading to a particular natural product is called the 
biosynthetic pathway and the corresponding event is known as biogenesis. By far 
the most important building blocks employed in the biosynthesis of secondary 
metabolites are derived from the intermediates acetyl coenzyme A (acetyl-CoA), 
shikimic acid, mevalonic acid, and 1-deoxyxylulose 5-phoshate. These are utilized 
respectively in the acetate, shikimate, mevalonate, and deoxyxylulose phosphate 
pathways.  
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1.1.2. Marine Natural Products 
The study of marine natural products is considerably far behind that of 
compounds of terrestrial origin due to the difficulty in collection and 
identification of marine organisms. However, in spite of these difficulties, the 
marine environment has proven to be a very rich source of extremely potent 
compounds that have demonstrated significant activities in antitumor, anti-
inflammatory, analgesia, immuno-modulation, allergy, and anti-viral assays.
6 
To 
date, more than 25,000 marine natural products have been isolated from 3,000 
marine organisms and reported in about 8,000 publications (these data are referred 
to early 2009). Bioactive products have been isolated from animalia and plantae 
as well as from marine microorganisms such as bacteria and fungi, protozoa and 
chromista. 
The oceans cover more than 70% of the earth‘s surface and contain more than 
300,000 described species of plants and animals.
7,8
 Macroscopic plants and 
animals have adapted to all regions of the oceans, including polar, temperate, and 
tropical areas. The diversity in species is extraordinarily rich on coral reefs, where 
there are around 1,000 species per m
2
 in some areas, and the Indo-Pacific Ocean 
has the world‘s greatest tropical marine biodiversity. The number and the activity 
of the natural products is directly related to the level of biodiversity of a marine 
area. The most interesting and promising marine natural products are small- to 
medium- molecular weight compounds produced principally by marine 
invertebrates (sponges, tunicates, soft corals) and microbes that have stimulated 
interdisciplinary studies by chemists, biologists and pharmacologists. The 
incredible potential of even a single marine organism to produce a large array of 
secondary metabolites can be interpreted by considering the common features of 
the secondary metabolism in all the living organisms as well as some peculiar 
features of the marine environment. Secondary metabolites play an essential role 
for the adaptation of the producer organism to the environment, mainly, but not 
uniquely, in terms of defence; they are practically the sole tool in the hands of 
organisms at lower evolutionary levels or lacking of mechanical or morphological 
way for protecting themselves (this is the case of sessile organisms as plants, 
algae, and the marine invertebrates sponges, tunicates, and bryozoans). It is now 
generally accepted that metabolic pathways of the secondary metabolism are 
intrinsically different from those characterizing the primary metabolism. 
 
14 CHAPTER I - Introduction 
For all the reasons above summarized, it is not surprising that a thorough chemical 
analysis of a single marine invertebrate, carried out with non-destructive modern 
spectroscopic techniques (allowing the stereostructure elucidation of molecules 
isolated in the low milligram range) can afford tens, when not hundreds, of 
secondary metabolites. These products provide a rich source of chemical diversity 
that can be fruitfully used as a ―natural combinatorial library‖, frequently more 
rich and chemically diverse than the libraries obtained through the use of synthetic 
combinatorial chemistry. Ideally, this ―natural library‖ can be screened in order to 
find lead compounds to be used as inspiration to design and develop new 
potentially useful therapeutic agents and to gain the first information about the 
structure-activity relationships.  
In spite of the difficulties associated with the limited availability of the 
compounds under investigation, which is strictly related to the limited supply of 
the biological material correctly protected for environmental concerns, some 
interesting results have been obtained. Through the combined efforts of marine 
natural product chemists and pharmacologists, an astounding array of promising 
compounds have been identified. Some of these molecules are either at advanced 
stages of clinical trials or have been selected as promising candidates for extended 
pre-clinical evaluation. The majority of these products fall within the area of 
antimicrobial and cancer therapies. Just to cite an example, ecteinascidin 743 (ET-
743), an anti-tumour compound especially effective against solid tumours, has 
entered the drug market in Europe. 
 
1.2. STRUCTURAL DETERMINATION METHODS 
Recently, natural products chemistry has undergone explosive growth due to 
advances in isolation techniques, synthetic and biosynthetic approaches as well as 
spectroscopic and chromatographic methods. Structural determination described 
in this thesis is largely based on spectroscopic techniques, mostly mass 
spectrometry (MS) and nuclear magnetic resonance (NMR), even if in some cases 
degradation methods were used. In addition, computational calculations are 
becoming increasingly important for the determination the stereostructure of 
target compound and, therefore, a short paragraph on the prediction of 
configuration with computational methods has been added. 
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1.2.1. Mass Spectrometry 
Mass Spectrometry is an analytical technique, particularly used in organic 
chemistry, which allows to measure molecular masses of unknown compounds 
and thus to determine their elementary formula. Unlike other spectroscopic 
techniques, mass spectrometry is a destructive analytical technique, that is not 
based on the interaction between radiations and matter. Any molecule has first to 
be ionized and transferred to gas phase in the ion source and then it is transmitted 
to the mass analyzer where its mass properties are measured. These 
three fundamental step of the process occur in three different parts of the mass 
spectrometer, namely the ionisation source, the analyser , and the detector. In 
order to obtain a mass spectrum, in the ion source, must be produced ions in a gas-
phase. they are subsequently accelerated, by an electric field, until they get to a 
specific speed and they are transferred to the mass analyzer, which separate 
different ions on the base of their mass/charge (m/z) ratio. The separated ions are 
then measured on the detector and the results displayed. 
Most of compounds described in the following chapters have been analyzed by 
Electrospray Ionisation (ESI) mass spectrometry through an Orbitrap system.  
ESI mass spectrometry allows the determination of non-volatile molecules to  be 
analyzed directly from the liquid phase (Fig.1.1). The electrospray process is 
governed by a large number of chemical and physical parameters that together 
determine the quality of the process. Its start and end can be defined by an  
electrical circuit that drives the spray of liquid-charged droplets. 
 
Figure 1.1. ESI mass spectrometry 
In this process the biomolecule starts out as an entity or complex, usually charged 
and dissolved in a water-rich environment. At the end of the process the same 
biomolecule is represented and harvested through the orifice of a mass analyser as 
a series of ‗naked‘ multicharged ions. In a vacuum, the biomolecular ions then are 
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selectively analysed according to their mass/charge ratio.
 
Because of the electric 
potential of the capillary, each droplet of the spray carries an excess positive or 
negative charge, and this causes extensive protonation or deprotonation of the 
molecules of the sample, which become ions. An uncharged carrier gas such as 
nitrogen is used to help the liquid to nebulize and the neutral solvent in the 
droplets to evaporate. 
Orbitrap is a new type of mass analyzer introduced by Makarov.
9
 The LTQ-
Orbitrap combines the most advanced Ion Trap and Fourier Transform 
technologies into a single instrument with unprecedented analytical power and 
versatility. The instrument provides a high mass resolution, accurate mass 
determinations, and MS
n
 for routine high-throughput analysis. 
In an orbitrap, ions are injected tangentially into the electric field between the 
electrodes and trapped because their electrostatic attraction to the inner electrode 
is balanced by centrifugal forces. Thus, ions cycle around the central electrode in 
rings. In addition, the ions also move back and forth along the axis of the central 
electrode. Therefore, ions of a specific mass-to-charge ratio move in rings which 
oscillate along the central spindle (Fig.1.2). The frequency of these harmonic 
oscillations is independent of the ion velocity and is inversely proportional to the 
square root of the mass-to-charge ratio (m/z ).  
 
Figure 1.2. Ion trajectories in an Orbitrap mass spectrometer. 
By sensing the ion oscillation similar as in the FT-MS (Fourier transform mass 
spectrometry), the trap can be used as a mass analyzer. Orbitraps have a high mass 
accuracy (1-2 ppm), a high resolving power (up to 200,000). Currently, there are 
two commercial LTQ-Orbitrap instruments, the Discovery and XL models. One of 
the primary differences is that the XL has a linear octopole collision cell (absent 
in the Discovery model), in which collisional activation and fragmentation can be 
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performed. Although this feature provides additional versatility to MS/MS 
experiments, the analytical performance and fundamental principles of operation 
of the Orbitrap analyzers in both instruments are identical.
10
 
1.2.2 Nuclear Magnetic Resonance11-13 
Nuclear Magnetic Resonance spectroscopy is a powerful and theoretically 
complex analytical tool used for structure elucidation of the isolated secondary 
metabolites. It involves reorientations of nuclear spins with respect to an applied 
static magnetic field. In addition to standard 
1
H and 
13
C NMR spectra, a large use 
of 2D NMR experiments has been made in the course of my research activity. 
They are superior to their 1D NMR counterparts both for the information on the 
connection of nuclei and for the easier assignment of nuclei resonating in crowded 
regions of the spectra (signal overlapping is much less likely in two dimensions 
than in one). 
The COSY (COrrelation SpectroscopY) experiments allow you to determine the 
connectivity of a molecule by determining which protons are spin-spin coupled. In 
spite of the many modifications which have been proposed along the years, the 
very basic sequence composed of two π/2 pulses separated by the evolution period 
t1 is still the best choice if one is simply dealing with the presence or the absence 
of a given coupling, but not with the value of the relevant coupling constant. 
 The HSQC (Heteronuclear Single Quantum Correlation) experiment is 2D NMR 
heteronuclear correlation experiment, in which only one-bond proton-carbon 
couplings (
1
JCH) are observed. The HSQC experiment correlates the chemical shift 
of  proton with the chemical shift of the directly bonded carbon.  
The HMBC (Heteronuclear Multiple Bond Correlation) experiment is a 
heteronuclear two-and three-bond 
1
H-
13
C correlation experiment; its sequence is 
less efficient than HSQC because the involved 
2,3
JCH couplings are smaller (3-
10Hz). Moreover, while 
1
JCH are all quite close to each other, 
2,3
JCH can be very 
different, making necessary the optimization of the experiment for each type of 
coupling. As a consequence, in many HMBC spectra not all of the correlation 
peaks which could be expected from the structure of the molecule are present. 
Cross peaks are between protons and carbons that are two or three bonds  away 
while direct one-bond cross-peaks are suppressed. This experiment, finally, allow 
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the connection of the fragments and the assembling of the structure of the 
molecules. 
 
1.3. METHODS FOR CONFIGURATION DETERMINATION 
The determination of relative and absolute configuration of a natural substance is 
a key step in the process of its structural characterization. Only by knowing the 
stereochemistry of a molecule can be traced back to its three dimensional structure 
and approach to biological studies, e.g. studies of drug-receptor interaction, 
or chemical, such as the studies related to the total synthesis of complex 
molecules with a good activity pharmacological. Most of the natural compounds 
has one or more chiral centers. Usually, in the configuration determination, we 
start by establishing the relative configuration of chiral centers. NMR can be very 
useful trough the values of chemical shifts (δ), coupling constants (J) and NOE 
effects.  
The chemical shifts of protons are influenced by their chemical around, so the 
protons of two diastereomers have different values. 
The  Karplus‘s equation14 describes the influence of relative arrangements of 
protons in a molecules on the values of coupling constants (JH-H). 
                                                  
3
J= Acosθ2 + Bcosθ + C   
This equation evidences that the values of homonuclear (
3
JH-H) and heteronuclear 
(
3
JC-H) coupling constants are related to the value of the dihedral angle θ between 
atoms. The superscript "3" indicates that a 
1
H atom is coupled to another 
1
H atom 
three bonds away, via H-C-C-H bonds. The magnitude of these couplings are 
generally smallest (0-1,5 Hz) when the torsion angle is close to 90° and largest at 
angles of 0 and 180°. In some cases the axial-axial coupling constant for an 
antiperiplanar 180
o
 H-C-C-H configuration may be more than 9.5 Hz. Indeed for 
rigid cyclohexanes it is around 9-13 Hz, because the dihedral angle is close to 
180
o
, where the orbitals overlap most efficiently. 
Additional information about relative configuration of stereogenic centers can be 
obtained from the so-called NOE effect
15
 (N.O.E.: "Nuclear Overhauser 
Enhancement"). This effect can be observed upon irradiation, during the 
acquisition of the spectra, on a specific signal. In this way, the  relaxation times of 
all the protons surrounding the irradiated proton (distance < 2.5 A°), even though 
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not belonging to the same spin system, are influenced and thus, their height 
changes. The NOE effect establishes a spatial relationship between substituents of 
fixed molecules, but this effect is dependent from the dimensions of the molecule. 
The ROESY (Rotating-frame Overhauser SpectroscopY) experiment is a chemical 
shift homonuclear correlation which can detect ROEs (Rotating-frame Overhauser 
Effect). ROE is similar to NOE, being related to dipolar coupling between nuclei, 
and depending on the geometric distance between the nuclei. While NOE is 
positive for small molecules and negative for macromolecules, ROE is always 
positive. Therefore, the ROESY experiment is particularly useful for mid-size 
molecules, which would show a NOE close to zero. 
1.3.1 Circular Dichroism 
First-principles calculations of electronic circular dichroism (ECD) are widely 
used to determine absolute configurations of chiral molecules. Circular Dichroism 
(CD) is observed when a molecule is optically active, it absorbs right-and left-
handed circularly polarize light to different extents. The CD spectroscopy takes 
advantage of the different absorption shown by chiral compounds of left and right 
circularly polarized UV/Vis light. Plane polarised light can be viewed as being 
made up of 2 circularly polarised components of equal magnitude, one rotating 
counter-clockwise (left handed, L) and the other clockwise (right handed, R). 
Circular dichroism (CD) refers to the differential absorption of these 2 
components (Fig. 1.3).  
 
Figure 1.3. Origin of the CD effect. (a) The left 
(L) and right (R) circularly polarised components 
of plane polarised radiation: (I) the two 
components have the same amplitude and when 
combined generate plane polarised radiation; (II) 
the components are of different magnitude and the 
resultant (dashed line) is elliptically polarised. (b) 
The relationship between absorption and CD 
spectra. Band 1 is not chiral; band 2 has a positive 
CD spectrum with L absorbed more than R; band 
3 has a negative CD spectrum.
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If, after passage through the sample being examined, the L and R components are 
not absorbed or are absorbed to equal extents, the recombination of L and R 
would regenerate radiation polarised in the original plane (Fig. 1.3). However, if 
L and R are absorbed to different extents, the resulting radiation would be said to 
possess elliptical polarization (Fig. 1.3).
16 
In practice, the CD  instrument (spectropolarimeter) does not recombine the 
components but  detects the two components separately; it will then display  the 
dichroism  at a given wavelength of radiation expressed as either the  difference in 
absorbance of the two components: Δε = εL – εR. Δε as a function of the incident 
light frequency ω is called CD spectrum.  
The CD of pure enantiomers differs in sign, but not in magnitude. There is no 
simple relation between the absolute conﬁguration of an enantiomer and the sign 
of its ECD spectrum: CD depends on details of the electronic and geometric 
molecular structure. However, ab initio electronic structure calculations are 
nowadays able to predict ECD accurately and thus allow an assignment of the 
absolute configuration by comparison of experimental and computed ECD 
spectra.  
1.3.2. Computational methods for configuration determination 
The increasing improvement of computer performances and the development of 
methods and algorithms ever more advanced and efficient, has led to the 
emergence of computational chemistry, a branch of chemistry that uses quantum 
mechanical principles to get the realistic representation of the three-dimensional 
structure of a molecule. To determine the conformation of a molecule, using a 
computer and a process called "minimization", the atoms must be moved from 
their positions evaluating the resulting changes of the total energy of the 
system. The geometry corresponding to the minimum energy is the most favored 
and, therefore, the most representative of the structure in solution. It is thus 
possible to compare the distances between protons in different stereoisomers and 
verify which of these corresponds to the spectroscopic data previously obtained. 
The molecular mechanics provides the force field for every molecule that 
 describe the conformation and behavior of molecules. Force field allows to 
calculate the energy of each rearrangement of atoms in a system and allows you to 
evaluate how it changes with the position of the atoms. In this way, it is possible 
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to find the minimum point of this function, determining both conformation and 
minimum energy. This process, known as minimization, leads to a relative 
minimum, while the absolute minimum, in simple cases, can be find with 
processes known as conformational search (systematic search, random search, 
simulated annealing). The experimental information on the conformation of the 
molecule, mainly derived from NMR experiments (NOE effects) may be included 
in the force field to "help" to determine the actual conformation at low energy. In 
simulated annealing method, the molecule is subjected to a molecular dynamics 
simulation, starting at high temperature and gradually lowering the until get to 
absolute zero. At low temperatures the molecule is locked the energetically lowest 
conformer. 
An alternative and complementary method to molecular dynamics for 
configuration determination of compounds structurally complex for flexibility or 
number of stereoisomers, is ab initio method that allow the prediction of chemical 
shifts of protons and carbons by values of coupling constants. Good matching 
between the calculated chemical shifts for one of the potential structures with the 
experimental values constitutes an excellent tool to support structural analysis of 
organic compounds. Density functional theory (DFT) has emerged in recent years 
as a promising alternative to conventional  ab initio methods in quantum 
chemistry.  
All calculations reported in my thesis have been performed using Gaussian 
03.33
17
 while the preliminary conformational search was performed by Simulated 
Annealing in the INSIGHT II package. 
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CHAPTER II 
CANNABINOIDS: ISOLATION AND SYNTHESIS 
OF NEW COMPOUNDS 
 
2.1. PHYTOCHEMISTRY AND MEDICINAL CHEMISTRY OF     
CANNABINOIDS 
A combination of history, chemistry, pharmacology, toxicology, and deep social 
impact makes Cannabis sativa L. (hemp) a unique plant. C. sativa is relatively 
unique in taxonomic terms, since the genus Cannabis has only one species, and 
belongs to a family (Cannabaceae) including only two genera (Cannabis and 
Humulus). Various subspecies of C. sativa have been identified
1
 but they reflect, 
however, mainly geographical and/or chemotypic variants of a single taxonomic 
entity rather than distinct species. From the medicinal point of view, two 
Cannabis phenotypes can be identified: 1) a fiber type Cannabis, rich of 
cannabidiol (CBD, 4) and almost devoid of Δ9-tetrahydrocannabinol (Δ9-THC, 6) 
(generally < 0.2% dry weight), also called hemp and used for textile or seed oil 
purposes, and 2) the drug type Cannabis, the well-known Δ9-THC-rich 
psychotropic cannabis, whose flowering tops are known as marijuana and are used 
to obtain hashish. The recreational use of the Δ9-THC-rich chemotype of C. sativa 
dates back to about 5000 years ago and constitutes now the most widely utilized 
illicit narcotic plant in the world. The psychotropic variety of Cannabis was, 
however, totally unknown to the ancient Mediterranean civilizations and became 
known in Europe only at the times of the Crusades in the XII-XIII centuries. The 
wealth of pharmacological activities discovered for C. sativa secondary 
metabolites make this plant one of the most thoroughly investigated from both the 
phytochemical and the pharmacological point of views, and, at the same time, one 
of the hottest topics in current medicinal chemistry research. 
The chemistry of C. sativa is extremely complex and includes constituents 
belonging to the classes of polyketides, terpenoids (a mixture of about 120 mono- 
and sesquiterpenoids is responsible for the characteristic odour of the plant), 
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modified sugars, alkaloids, flavonoids, stilbenoids, and quinones. The sheer 
observation that more than 500 compounds have been characterized from C. 
sativa can give an idea of the phytochemical diversity of this plant. The 
concentration of these compounds depends on several factors including variety, 
age, growth conditions, harvesting time and storage conditions. Cannabinoids 
include about 100 (to date) meroterpenoids (prenylated polyketides) accumulated 
in tiny epidermal resinous glands and characterized by very specific and potent 
pharmacological activities. Cannabinoids exemplify the impact that natural 
products can have on modern medicinal chemistry and pharmacology. 
Investigation of cannabinoid chemistry has been an important part of the research 
activity during my Ph. D. and in this area I have been co-author of a review 
published on the journal Current Medicinal Chemistry.
2
 In particular, this review 
aimed at giving a survey of the more recent advances in both phytochemistry of 
C. sativa, the medicinal chemistry of cannabinoids, and their distribution in 
plants, highlighting the impact that research in these hot fields could have for 
modern medicinal chemistry and pharmacology.  
Cannabinoids, a class of mono- to tetracyclic C21 (or C22) meroterpenoids, are the 
most important secondary metabolites of C. sativa. The plant elaborates these 
molecules through the assemblage and subsequent modification of two building 
blocks coming from different biogenetic pathways, namely a C12 polyketide unit 
and a monoterpene unit (geranyl pyrophosphate, GPP), originating from the 
deoxyxylulose phosphate/methylerythritol phosphate pathway. The first product 
of the attachment of these two units is cannabigerolic acid, which has been 
identified as the direct precursor (through subsequent cyclizations and 
rearrangements) of the most important phytocannabinoid subclasses.
3
 The parent 
compounds of these classes are cannabichromene (CBC, 2), cannabicyclol (CBL, 
3), cannabidiol (CBD, 4), cannabielsoin (CBE, 5), Δ9-THC (6), and 
cannabicoumaronone (CBCON, 7), with the most recent additions to the 
cannabinoid inventory falling into the CBCON,
4
  CBC and CBG families.
5
 
Despite all these studies, structural diversity within cannabinoids is far from 
having been exhaustedly unravelled, as shown by the recent discovery of 
cannabimovone (CBM, 8, Fig. 2.1).
6
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Figure 2.1. The parent compounds of the cannabinoid structural classes and their     
demonstrated or postulated biogenetic relationships.  
 
The building blocks of cannabinoids, GPP and alkyl resorcinol derivatives, are 
very common in Nature. For example, olivetol is a common lichen constituent, 
while limonene, the terpenoid moiety of CBD (4), is widespread in plants. So far, 
only two cannabinoids (CBG, 1 and its corresponding acid) have been obtained 
from a non-Cannabis source. These compounds are accumulated by a South 
African Helichrysum (H. umbraculigerum)
7
 and plants from this asteraceous 
genus (used in traditional medicine for a host of inflammatory and anti-infective 
conditions) as well as liverworts have also provided compounds related to 
cannabinoids
7
. Helychrysum cannabinoids are prenylated dibenzyls bearing a 
close relationship with cannabinoids, from which they differ for the replacement 
of the n-pentyl (or n-propyl) C-3 side chain with a β-phenylethyl group (e.g. H-
CBG, 9). The two classes of compounds are biogenetically related, differing only 
for the type of ketide starter, which is aliphatic in cannabinoids from hemp, and 
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aromatic in those from Helichrysum. Surprisingly, the bioactivity of Helychrysum 
cannabinoids has not yet been investigated, presumably due to their limited 
availability by isolation or by synthesis.  
OH
HO
9
OH
10
O
 
Figure 2.2. H-CBG (9) from Helichrysum and 10 from Radula 
These prenylated bibenzyl compounds have been found also in tropical liverworts 
from the genus Radula, where they occur with their ortho-derivatives (abnormal 
cannabinoids).
8 
For example, compound 10 strictly resembles Δ9-THC (6) but no 
data on its binding to CB receptors are available so far.  
Natural products with cannabinomimetic activity, whose structures are not related 
to the meroterpenoids of hemp nor to the endocannabinoids (polyunsaturated fatty 
acid amides or esters), are extremely rare. During my research activity, reported in 
this Ph.D. thesis, I have isolated haplosamate A (11) with its new desulfo 
analogue
9
 (12),
 
which, to our knowledge, represents the first CB ligands 
belonging to the class of steroids. 
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The selectivity of desulfohaplosamate (12) for CB2 receptor is particularly 
important and worthy of further investigation, given the involvement of this 
receptor in the immune response and inflammation
10
 and the lack of abuse 
potential and strong central effects related to the use of CB2 ligands. 
In the following paragraphs, I have reported the five most important structural 
classes of cannabinoids from C. sativa, briefly reporting and commenting on their 
biogenetic relationships.   
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2.1.1. Cannabigerol-type 
As shown in Figure 2.3, the polyketide moiety of cannabinoids originates from n-
hexanoylCoA through the tri-fold addition of malonyl-derived acetate units, unit, 
followed by cyclization and aromatization to give olivetolic acid. Condensation 
between olivetolic acid and GPP is catalyzed by a specific prenyltransferase 
identified in the expanding leaves of C. sativa.
11
 The product of this reaction is 
cannabigerolic acid (CBGA), whose decarboxylated analogue is named 
cannabigerol (1, CBG). It is generally accepted that the decarboxylation step for 
CBGA and all the other cannabinoids is non-enzymatic and occurs spontaneously 
during either storage or extraction/purification of the compounds.  
O
CoAS
SCoA
OO
O
O
COOH
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HO C5H11
GPP
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HO C5H11
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CBGA 1  
Figure 2.3. Biogenesis of cannabigerolic acid (CBGA) and cannabigerol (1) 
A series of minor analogues of cannabigerol (1) showing a shorter alkyl chain 
attached to the phenyl ring have been found, e.g. cannabigerovarin
12
 showing a 
linear C3H7 chain. These compounds (cannabivarins) could derive from either 
enzymatic shortening of the CBG pentyl chain or, more likely, from a shorter 
starter unit (butanoylCoA) for the ketide homologation. Similar shortened-side 
chain compounds (also with C4 or C1 side chains) have been found in all the other 
classes of cannabinoids but, for simplicity, they will not be reported here.   
A CBGA analogue showing a Z- double bond in the prenyl unit has been isolated 
and named cannabinerolic acid.
13
 Carmagerol, rac-6',7'-dihydro,6',7'-
dihydroxycannabigerol, has been obtained from the Carma variety of C. sativa 
and also identified as a possible mammalian metabolite of cannabigerol.
14
 Finally, 
a number of hydroxylated and oxidized quinone derivatives of cannabigerol have 
been recently reported from a high-potency Δ9-THC-rich variety of C. sativa.5  
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2.1.2. Cannabichromene- and cannabicyclol-type 
The oxidative intramolecular cyclization of CBGA affords cannabichromenic acid 
(CBCA) and, by decarboxylation, cannabichromene (CBC, 2, Fig.2.4). CBC is 
well represented in psychotropic and fiber–type varieties of C. sativa and has been 
isolated as a racemate.
15
 A [2 + 2] intramolecular cycloaddition of CBCA triggers 
the simultaneous formation of two additional rings (four- and five-membered, 
respectively) affording the tetracyclic system of cannabicyclolic acid (CBLA), 
next turned by decarboxylation into cannabicyclol
16
 (CBL, 3, Fig. 2.4). It is not 
clear if the formation of cannabicyclol is the result of natural irradiation on the 
plant or it is an artifact formed in the crude extract. The photocycloaddition takes 
place with exquisite diastereoselectivity, and the adduct results from the approach 
of the terminal double bond from the face anti to that of the angular pyrane 
oxygen. Also cannabicyclol was isolated as a racemate. 
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Figure 2.4. Biogenesis of cannabichromene- and cannabicylol-type compounds  
2.1.3. Cannabidiol- cannabielsoin- and cannabimovone-type 
Cannabidiolic acid (CBDA) and cannabidiol (CBD, 4) are the main constituent of 
the non-psychotropic (fiber-type) varieties of C. sativa (Fig. 2.5).  
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Fig. 2.5. Biogenesis of cannabidiol (4) and cannabinodiol (13) 
 
These compounds are the result of an oxidative cyclization of CBGA,  resulting  
in the formation of a link between C-1 and C-6 of the prenyl unit. The enzyme 
catalyzing this stereospecific reaction (cannabidiolic acid synthase) has been 
isolated and characterized.
17
 The aromatized analogue of CBD (4) is named 
cannabinodiol
18
 (13), and it is likely an artefact, since its concentration increases 
with the age of the stored plant.  
Both compounds of the cannabielsoin-cannabifuran type and of the 
cannabimovone type likely derive from CBD (4, Fig. 2.6). Although not proven at 
the biochemical level, and uncharacterized in terms of enzyme(s) involved, these 
relationships are supported by model reactions that involve intermediates where 
the trisubstituted double bond of CBD has been epoxidized or dihydroxylated.  
Attachment of one of the two phenolic oxygen atoms at the endocyclic double 
bond of the monoterpene unit generates the dihydrofuran ring of the cannabielsoin 
(CBE)-type compounds shown in figure 2.6 (CBEA and 5). These molecules 
have been both isolated from C. sativa
19
 but they have also been detected during 
studies of the mammalian metabolism of CBD.
20
 It seems to be present a curious 
overlapping of cannabinoid oxygenating enzymes between C. sativa and 
mammals, as already suggested by the isolation of carmagerol, another 
mammalian metabolite of cannabinoids. The aromatized analogue of 
cannabielsoin, dihydrocannabifuran (14) and cannabifuran
21
 (CBF, 15), whose 
presence has been demonstrated also in the smoke condensate of hashish, show a 
 
33 CHAPTER II  -  Cannabinoids: isolation and synthesis of new compounds 
dibenzofurane structure. Cannabielsoin is the only eponimic cannabinoid, and its 
name is a tribute to the technician Elsa Boyanova, who isolated it and shortly 
thereafter passed away. 
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Fig. 2.6. Cannabielsoin- and cannabimovone-type compounds 
 
The chemical investigation of a non-psychotropic variety of C. sativa (Carma) 
carried out during my Ph.D., and described in this thesis, led to isolation of  
cannabioxepane
22
 (CBX, 29)
 
(see below). Its new skeleton bears some 
relationships with some cannabinoids from the CBE family, and particularly with 
the aromatized analogue named cannabifuran,
 
however, noteworthy, no member 
of the CBE family shows a fourth ring. 
Cannabimovone (CBM, 8), also was isolated from a non-psychotropic variety of 
C. sativa (Carma).
6 
CBM shows an unprecedented abeo-menthane terpenoid 
structure, seemingly derived  from CBD (4) by stereoselective dihydroxylation of 
the endocyclic double bond, followed by oxidative cleavage of the glycol system 
and then aldolyzation of the resulting dicarbonyl intermediate. Attempts to 
reproduce this biogenetic scheme afforded only the cronotized analogue of CBM 
(8). Interestingly, this synthetic compound showed a biological profile similar, 
although less potent, to that of Δ9-THC (6), while CBM (8) acted as an analogue 
of CBD
6
 (4).   
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2.1.4. Tetrahydrocannabinol-type 
Tetrahydrocannabinolic acid (THCA) and Δ9-tetrahydrocannabinol (Δ9-THC, 6) 
are the main constituents of the psychotropic varieties of C. sativa. Although a 
rearrangement of CBD (4) precursors could seem a reasonable biogenesis for 
these molecules, the isolation and characterization of the specific FAD-dependent 
enzyme THCA synthase unambiguously demonstrated that these compounds 
actually derive from cyclization of CBGA through a cationic intermediate with 
positive charge at C-3.
23
 Attachment of the phenolic oxygen at C-7 of the 
monoterpene unit and the linkage C-6/C-2 give rise to the tricyclic system of 
THCA and of its decarboxylated analogue Δ9-THC, 6 (for which the widely 
employed dibenzopyrane numbering system is indicated in figure 2.7).  
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Figure 2.7. Tetrahydrocannabinol-type compounds 
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A number of analogues sharing this structural framework have been found. Δ8-
THCA and the decarboxylated (Δ8-THC) show isomerization of the double bond, 
while the completely aromatized analogues are called cannabinolic acid (CBNA) 
and cannabinol (CBN). These molecules are thought to be artifacts since their 
concentration in extracts increases during storage, while simultaneously, the 
concentration of Δ9-THC decreases. The Δ9-THC/CBN ratio is used as indication 
of the age of stored marijuana samples. Hydroxylated CBNA and CBN 
derivatives have been recently reported.
24
 Cannabiripsol is the dihydroxylated 
analogue of Δ9-THC,25 and it differs from the trans- and cis-cannabitriol26 for a 
double bond at the junction with the oxygenated ring. Finally dihydroxy-Δ9-
THC
27
 and cannabitetrol
28
 differ for the position and /or for the number of 
hydroxyl groups. Cannabicitran (CBT) is a cyclized and demethylated analogue of 
Δ9-THC.29 Surprisingly, the configurational aspects of some of these oxygenated 
analogues of Δ9-THC, are still undefined and it is not clear if they were obtained 
in diastereomerically pure form or as mixtures. Isotetrahydrocannabinol (16)
30
 is a 
minor cannabinoid deriving from a different cyclization mode of the cationic 
intermediate produced from CBGA (Fig. 2.8). The main difference between the 
two pathways is that, in this case, the phenolic oxygen atom quenches directly the 
carbocation.  
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Figure 2.8. Biogenetic formation of isotetrahydrocannabinol (16) 
 
2.1.5. Cannabicoumaronone- and cannabichromanone-type 
The carbon skeleton of cannabicoumaronone (7) is, in principle, related to that of 
Δ9-THC (6) via the oxidative cleavage of its trisubstituted double bond 
(interestingly, a similar cleavage, on CBD (4), has been hypothesized for the 
formation of cannabimovone, CBM,8) followed by hemiacetalization/dehydration 
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yielding to the furan ring. A cell suspension culture of C. sativa has been 
demonstrated to be able to  convert Δ9-THC (6) in cannabicoumaronone (7).31 
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Fig. 2.9. Cannabicoumaronone- and cannabichromanone-type compounds 
 
Oxidative cleavage of the aldehyde is the likely biogenetic origin of 
cannabichromanone (17), for which a series of derivatives, including the cyclized 
derivative 18, have been recently reported (Fig. 2.9).
4
 
 
2.2. CANNABINOID RECEPTORS  
Many of the potential therapeutic uses of cannabinoids are related to the 
interaction with (at least) two cannabinoid G-protein coupled receptors (CB1 and 
CB2). Cannabinoid receptors are the primary targets of endogenous cannabinoids 
(endocannabinoids). These G protein-coupled receptors are activated also, by two 
major group of ligands, plant and synthetic cannabinoids. Cannabinoid receptors 
play an important role in many processes, including metabolic regulation, craving, 
pain, anxiety, bone growth, and immune function.  
Both the structure determination of Δ9-THC (6) and the discovery of a specific 
receptor for opioids, two scientific events of the 1960s-1970s, gave a strong 
impulse to the research on the cannabinoid receptors. The idea that, similarly to 
opioids, also the psychoactive constituents from Cannabis could act by interaction 
with a specific receptor located in the CNS, had been long dismissed, also basing 
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on the false assumption that Δ9-THC (6) and its enantiomer had similar mind-
altering activity. Some technical difficulties (e.g. working with highly 
hydrophobic compounds as cannabinoids) and the lower social and health impact 
of   cannabinoids compared to opioid-derived compounds, also contributed to 
slow down the research of a cannabinoid receptor. However, one of the most 
decisive impulse was given by the discovery, in the Pfizer labs, of CP 55,940 (19, 
Fig. 2.10), a synthetic molecule about 20 times more potent than Δ9-THC.32 The 
labelled version of CP 55,940 (19) was used to develop a binding assay for 
cannabinoid receptors, allowing the analysis of their distribution by quantitative 
autoradiography. High levels of cannabinoid receptors were found in cortex, 
hippocampus, amygdala, basal ganglia, and in the cerebellum.  
 
OH
HO
OH
19  
Figure 2.10. The chemical structure of CP 55,940 (19) 
 
Two cannabinoid (CB) receptors have been identified and cloned to date: CB1 and 
CB2. They have a 40% of homology (CB2 being the smallest one) and both share 
the heptahelical structure of G-protein coupled receptors.
33
 The effect of 
interaction with cannabinoid receptors is mediated by a cascade of signal 
transduction pathways including interaction with potassium and calcium channels 
(for CB1) and several kinases (e.g. MAP kinase). Table 2.1 summarizes some 
selected properties of these receptors. The existence of other cannabinoid 
receptors different from CB1 and CB2 has long been pursued, since a number of 
cannabinoid-like effects persist in CB1/CB2 knockout mice. A proposed third 
cannabinoid receptor is the recently identified GPR55,
34
 but its role in the 
pharmacological actions of Δ9-THC and in the physiological effects of 
endogenous cannabinoids are still controversial. GPR55 is activated by 
lysophosphatidylinositol and is expressed in human and mouse osteoclasts and 
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osteoblasts; it suppresses osteoclast formation but stimulates osteoclast function, 
exerting a pivotal role in bone physiology and turnover.  
 
Table 2.1. Some selected features of CB1 and CB2 receptors. 
 CB1 CB2 
Type of receptor G (Gi-Go)-protein coupled G (Gi-Go)-protein coupled 
Localization Mostly CNS; Adipocytes; 
Kidney; Lung; Liver 
Immune system cells; 
Spleen; CNS; Osteo-cells; 
Adipose tissue 
Inducibility Low inducibility Highly inducible 
 
 
The presence of cannabinoid receptors implies the existence of endogenous 
ligands. Mechoulam and Devane identified the first ligand molecule in 1992
35
 and 
called it anandamide (20), from ananda, the Sanskrit word to describe ―delight, 
bliss‖. A number of endogenous CB1 agonist fatty acid amides were then added to 
the list, while the ester derivative 2-arachidonoyl glycerol (2-AG)
36
 (21) proved to 
be more potent than anandamide. Interestingly, virodhamine, an arachidonoyl 
ethanolamine where the two units are joined by an ester linkage in place of the 
amide linkage, is an antagonist of CB1 receptor
37
 and agonist of CB2 receptor. It is 
highly produced in peripheral tissues express CB2. Noladin (22) and other 
endocannabinoids have an ether-linkage in place of the ester linkage between the 
polar head and the apolar tail. Remarkably, all endocannabinoids (Fig. 2.11) 
described to date are either chemical unstable (virodhamine) or rapidly degraded 
by hydrolytic enzymes in vivo. The endocannabinoids are accompanied by 
saturated, and mono- or diunsaturated congeners which are CB1 and CB2 receptor-
inactive. This CB1 or CB2 inactive molecules appear to potentiate the effect of 
anandamide or arachinoyl glycerol (―entourage effect‖).38 In this regard, my 
research group has recently shown
39
 that introduction of a methylene lock on the 
ethanolamide head, thus generating a cyclopropane ring, as in 23, is able to trigger 
strong CB1 affinity in oleolyethanolamide.   
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Figure 2.11. The chemical structures of endocannabinoids 20-22 and the synthetic 
analogue 23  
Apart from the metabotropic cannabinoid receptors CB1, CB2 and (possibly) 
GPR55, cannabinoids also bind to PPAR-gamma and to some thermo-TRPs, a 
series of ion-channels characterized by an intracellular ligand-binding domain and 
involved in pain and inflammation.
40
 The regulation of ionotropic- and 
metabotropic proteins targeted by cannabinoids is, undoubtedly, one of the hottest 
field in cannabinoid research.  
Interaction with CB receptors has been unambiguously associated to a number of 
pharmacological effects, but the most important are: 1) psychotropic effects 
(euphoria) 2) antiemetic effect, 3) analgesic effect, 4) immunomodulation 5) motor 
effects (hypokinesia, ataxia, antispasticity). 
Many of the psychoactive effects of Δ9-THC (6) appear to be mediated by CB1 
receptors , while non-psychoactive cannabinoids (as CBD, 4) have very low 
affinity both for CB1 and CB2. Δ
9
-THC (6) is the phytocannabinoid showing the 
highest affinity to CB receptors, with a Ki around 40 nM for both CB1 and CB2 
(CBD Ki = 3000-4000 nM). Δ
8
-THC (see structure in figure 2.7) is almost 
equipotent to Δ9-THC41 (6). Interaction of Δ9-THC (6) with CB1 receptors on 
presynaptic nerve terminals in the brain is responsible of the euphoric feelings 
associated with Cannabis use. Some data suggest that this effect could be 
beneficial in the treatment of depression, but further studies are needed to clarify 
the role of the cannabinoid system in the neurobiology of this pathology. Since 
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CB1 receptors are not present in the brain region responsible for respiratory and 
cardiovascular functions, cannabinoid consumption cannot be associated to an 
increased risk of respiratory or cardiovascular failures, as happens for opiates.  
Inhibition of gastrointestinal activity has been observed after administration of Δ9-
THC (6), or of anandamide (20). This effect has been assumed to be CB1-
mediated: the location of CB1 receptors in cholinergic nerve terminals of the 
gastrointestinal tract accounts for the THC-induced inhibition of digestive-tract 
motility, whereas the presence of CB1 receptors in the brainstem is responsible of 
the THC-induced inhibition of emesis. The antiemetic effect of Δ9-THC (6) has 
been well established and proposed for treatment of chemotherapy-induced 
emesis
42
, in combination with new generation antiemetic drugs. 
Many studies have reported that Δ9-THC (6) has a stimulatory effect on appetite 
and food intake, which can be co-adjuvant in cancer anorexia.
43
 In 1992, FDA 
approved the use of Δ9-THC (6) to stimulate appetite in AIDS patients suffering 
from wasting syndrome. This effect could be mediated both by CB1 receptors 
present in CNS or in nerve terminals and adipocytes. 
Noteworthy, CB2 receptors are highly expressed in some cells of the immune 
system and they are believed to play a role in the immune cell function, thus 
providing a rationale to the immunomodulatory properties of Δ9-THC44 (6). In 
addition, CB2 receptor is suspected to mediate neuroinflammation, 
atherosclerosis, and bone remodelling.
45
 The localization of both CB1 and CB2 on 
adipocytes, where their activation appears to stimulate lipogenesis, is particularly 
interesting and may have a clinical utility.
46
 
Most likely, the single most important potential therapeutic effect associated to 
the interaction with CB receptors is the analgesic effect, due to the role of CB1 
receptors in the transmission of nociceptive information in several key tissues. Δ9-
THC (6) has been estimated to be as potent as morphine in blocking nociceptive 
stimuli in many animal models,
47
 and, moreover, it can act synergistically with 
opioid-receptor agonists. Many studies are now aimed at establishing the 
beneficial effects of a concomitant administration of these drugs.  
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2.3. CANNABIOXEPANE, A NOVEL TETRACICLIC 
CANNABINOID FROM HEMP, CANNABIS SATIVA L. 
2.3.1. An ancient plant 
C. sativa L. is, arguably, the oldest plant domesticated by man, but its millenary 
history, crossing most of the human civilization, has always been accompanied by 
controversy and harsh contrasts. The 
geographical origin of Cannabis is 
probably Central Asia (Kazakhstan, 
Western China, and the Russian Far 
East), where also hop (Humus lupulus 
L.), its only botanical relative, 
originated
48
. The first known record of 
its use as a medicine was published in 
China 5000 years ago during the reign 
of the Emperor Chen Nung. Another 
important written description of 
Cannabis use dates back to 2350 B.C. 
on a stone of the Egyptian Old Kingdom 
in Memphis, at the end of the Fifth 
Dynasty.
49
 A number of Egyptian 
papyri reporting Cannabis prescriptions (mainly as anti-inflammatory and 
antimicrobial agent) have been found and dated several centuries B.C. In Islamic 
countries the resin of Cannabis plants was better known as hashish, or shadanaj 
(literally, the royal grain) and widely used for its medical attributes, mainly in the 
treatment of pain. The name marijuana refers to the flowers and subtending leaves 
and stalks of mature pistillate of female plants.  
As for the Western countries, the first detailed descriptions of the psychotropic 
variety of hemp dates to the Renaissance. Prosper Alpinus, a Venetian botanist, 
associated these properties to an Egyptian origin, a view long maintained in the 
botanical literature. The first impact in Europe occurred after the Napoleon 
invasion of Egypt. Important members of the French artistic community 
(Baudelaire, Honore´ de Balzac, Alexandre Dumas, and Gustave Flaubert) under 
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the name ―Club des Hashichins‖ (Hashish Club) met monthly in an old mansion 
in Paris.
50
  
Both the fiber and the psychoactive strains became used and investigated but, 
while opiate alkaloids were isolated early in the 19th century, the identification, 
isolation, and synthesis of Δ9-THC (6) was not achieved until 1964.51 
Investigations on the mechanisms of the psychotropic action of Δ9-THC yielded to 
the discovery of the cannabinoid protein receptor family in 1988 and their cloning 
in early 1990s,
24
 and the discovery of its endogenous ligand anandamide (the 
parent compound of the family of endocannabinoids) in 1992.
35
 The last two 
decades of the twentieth century and the first decade of the present century can be 
indicated as the ―cannabis Renaissance‖ due to the exceptional blooming of 
research on Cannabis and its metabolites. Although the clinical translation of this 
research activity is still limited, the recent approval (in Canada, UK and Spain, for 
symptomatic treatment of multiple sclerosis) of Sativex,
TM
 a mixture of natural 
cannabinoids, constitutes a strong hope for the future. Cultivation and use of 
psychotropic Cannabis, even for medicinal purposes, is illegal in many countries 
due to the potentially harmful acute and short-lasting effects of this drug.  
Cannabis  is a genus of flowering plants that includes three putative species, 
Cannabis sativa, Cannabis indica, and Cannabis ruderalis. These three taxa are 
indigenous to Central Asia, and South Asia. Cannabis is an annual, dioecious, 
flowering herb. The leaves are palmately compound or digitate, with serrate 
leaflets. Cannabis normally has imperfect flowers, with staminate "male" and 
pistillate "female" flowers occurring on separate plants. The genus Cannabis was 
formerly placed in the Nettle (Urticaceae) or Mulberry (Moraceae) family, and 
later, along with hops (Humulus sp.), in a separate family, the hemp family 
(Cannabaceae sensu stricto). Recent phylogenetic studies based on cpDNA 
restriction site analysis and gene sequencing strongly suggest that the 
Cannabaceae  sensu stricto arose from within the former Celtidaceae family, and 
that the two families should be merged to form a single monophyletic family, 
the Cannabaceae sensu lato.
52
 Basically, two types of Cannabis have been 
described, and classified as species, subspecies, or varieties: 
 plants cultivated for fiber and seed production, described as low-
intoxicant, non-drug, or fiber types. 
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 plants cultivated for drug production, described as high-intoxicant or drug 
types. 
The phytochemistry of C. sativa has been thoroughly investigated, and several 
hundred compounds, often structurally unique, have been isolated from this plant, 
whose phytochemical profligacy is testified by the presence of alkaloids, fatty 
acids and esters, terpenoids, quinones, flavonoids, stilbenoids, and, above all, 
cannabinoids.
53 
Despite all these studies, structural diversity within cannabinoids 
is far from having been exhaustedly unravelled, as shown by the recent discovery 
of cannabimovone (CBM, 8).
6
 This CBD analogue shows a unique resorcinyl 
abeo-menthane structure, and was isolated from an Italian fibre hemp derived 
from the historical cultivar Carmagnola.
54
 During my Ph.D. studies, I have 
investigated the relatively apolar fractions from an extract of this plant and 
isolated five stilbenoids (24-28), including the new spirane 
isocannabispiradienone (28), and a novel bis-oxygen bridged diphenyl-type 
cannabinoid, which we have named cannabioxepane (29, CBX).  
 
2.3.2. Extraction, isolation and structure elucidation  
Dried female flowerheads of C. sativa were extracted with acetone at room temp. 
Removal of the solvent left a gummy residue that was partitioned between 1:1 
aqueous methanol and petroleum ether. The defatted polar phase was then 
concentrated and extracted with CH2Cl2. The organic phase was dried (Na2SO4) 
and evaporated to afford a black gum, that was purified by flash chromatography 
on RP-18 silica gel (Biotage equipment). Repeated purification of the obtained 
fractions by gravity column chromatography on silica gel (petroleum ether-EtOAc 
mixtures) followed by HPLC yielded to the isolation of cannabispirane (24),
55
 β-
cannabispiranol (25),
56
 α-cannabispiranol (26),57 cannabispiradienone (27),58 and 
two new compounds, isocannabispiradienone (28) and cannabioxepane (29) (Fig. 
2.12).  
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Figure 2.12. The six phenolic compounds isolated from Cannabis sativa L., 
including the new isocannabispiradienone (28) and cannabioxepane (29) 
 
Two polyunsaturated fatty 
acids were also obtained, 
namely 12S-hydroxy-
9Z,13E,15Z-
octadecatrienoic acid (30) 
and 16R-hydroxy-
9Z,12Z,14E-octadecatrienoic acid (31). The known compounds 24-27 were 
identified by comparison of their spectral data with those reported in the 
literature.
55-58
 The fatty acids 30 and 31 have been recently obtained as methyl 
esters from Swertia japonica (Gentianaceae),
59
 but had never been reported form 
C. sativa.  
Isocannabispiradienone (28) has the molecular formula C15H14O3 (by HR-
ESIMS), indicative of nine unsaturation degrees. 
1
H NMR spectrum of 28 
(CDCl3) was reminiscent of that reported for 27, being characterized by two 
coupled 2H doublets at δH 6.86 and 6.26 (J = 10.0 Hz), two coupled 2H triplets at 
δH 3.06 and 2.25 (J = 7.8 Hz), and two m-coupled aromatic protons at δH 6.19 and 
6.36 (J = 2.1 Hz). A methyl singlet resonating at δH 3.61 and an exchangeable 1H 
singlet at δH 4.73 completed the signals of the 
1
H NMR spectrum of 28. All the 
proton signals were associated with those of the directly attached carbon atoms 
with the help of the 2D NMR HSQC spectrum. The presence of a cross-
30
OH
COOH
31
COOH
OH
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conjugated cyclohexadienone moiety was then deduced from the following 
experimental evidences: i) the 
13
C NMR spectrum of 28 showed only 12 signals, 
as a result of the presence of symmetrical cyclohexadienone sub-structure (and the 
accidental isochronicity of two aromatic carbons, see infra); ii) the presence of a 
doubly conjugated ketone (C-12) was suggested by the 
13C NMR resonance at δC 
186.9 and by the IR (KBr) peak at υmax 1650 cm
-1
; iii) the HMBC cross-peaks of 
H-10 = H-14 with C-12, C-14 (= C-10) and with the unprotonated C-9 (δC 52.6). 
The latter carbon atom was subsequently identified as the spiro-carbon connecting 
the dienone ring with a five-membered ring, as indicated by the HMBC cross-
peaks H-10/C-1, H-10/C-8 (δC 121.4), H-1/C-8, H-1/C-9, and H-1/C-3 (δC 147.2). 
The structural framework of isocannabispiradienone (28) is completed by a 
dioxygenated phenyl ring condensed with the five-membered ring. The signal at 
δH 6.36 showed HMBC cross-peaks with C-2, C-3, C-8, with the oxygenated C-5 
(δC 157.6) and with the second aromatic methine carbon (C-6), and therefore it can 
be confidently assigned to H-4. Accordingly, the signal at δH 6.19, showing 
HMBC correlations with both the oxygenated carbons (C-5 and C-7) as well as 
with C-4 and C-8, can be assigned to H-6.  
Unfortunately, the location of the methyl group could not be unambiguously 
achieved through the HMBC spectrum since the carbon resonances of C-5 and C-
7 were incidentally coincident. However, inspection of the ROESY spectrum 
allowed a straightforward solution to this problem. Indeed, the OH signal at δH 
4.73 showed cross-peaks with both H-4 and H-6, while the methoxy singlet at δH 
3.61 showed cross-peak only with H-6, in agreement with its location at C-7, thus 
completely defining the chemical structure of 28.  
A derivation of isocannabispiradienone (28) from cannabispiradienone (27) by 
methyl swapping between the two pheniolic hydroxyl seems unlikely. More 
plausibly, 27 and 28 might derive from the regiochemically divergent oxidative 
coupling of the same dihydrostilbene precursor (Fig. 2.13). Just like 
cannabispiradienone (27) is the alleged precursor of cannabispirane and 
cannabispiranol,
58
 so isocannabispiradienone (28) might be the precursor of 
isocannabispirane.
51 
Therefore, the existence of isocannabispiranols in Cannabis 
extracts could be foreseen.  
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Figure 2.13.  Postulated biogenetic origin of isocannabispiradienone (28).  
HR-ESIMS established the molecular formula of cannabioxepane (CBX, 29) as 
C21H22O2, implying eleven degrees of unsaturation. The 
1
H NMR spectrum of 29 
(CDCl3, Table 2.2) showed a pair of coupled doublets at δ 7.34 and 7.16, four 
singlets between δ 7.10 and 5.40, a methylene broad singlet at δ 4.85, a deshielded 
methyl singlet at δ 2.56 and, finally, five well resolved multiplets between δ 2.70 
and 0.80, which, on the basis of a 2D COSY spectrum, were combined into a 
linear pentyl chain (Fig. 2.14).  
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Figure 2.14. COSY and 
2,3
J H→C HMBC correlations of cannabioxepane (29). 
The 2D NMR HSQC spectrum of 29 made it possible to associate all the proton 
signals with those of the directly linked carbons, revealing that the singlets at δH 
5.88 and 5.44 are actually linked at the same carbon at δC 118.6, and that the 
singlet at δH 4.85 must be an oxymethylene group (δC 75.1). The 
13
C NMR 
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spectrum of 29 (CDCl3, Table 2.2) showed also the signals of nine unprotonated 
carbon atoms, all resonating in the sp
2
 region of the spectrum, between δC 120 and 
158. The above data were strongly suggestive of the presence of two phenyl rings 
and of an additional carbon-carbon double bond. Therefore, to account for the 
nine unsaturations implied by the molecular formula of CBX (29), two additional 
rings were required. A series of key 
2,3
JH,C correlations evidenced by the HMBC 
spectrum (Fig. 2.14) were critical to assemble the skeletal fragments and to draw 
the structure of CBX (29), allowing also the complete assignment of the proton 
and carbon resonances as reported in Table 2.2.  
Table 2.2. 
1
H (500 MHz) and 
13
C (125 MHz) NMR Data of Cannabioxepane (29) in 
CDCl3   
Pos. δC, mult. δH, mult., J in Hz 
   
1 157.5, C  
2 104.4, CH 7.01, s 
3 144.3, C  
4 110.5, CH 6.72, s 
5 155.2, C  
6 112.5, C  
1‘ 125.5, C  
2‘ 153.7, C  
3‘ 120.7, C  
4‘ 127.4, CH 7.16, d, 6.2 
5‘ 118.4, CH 7.34, d, 6.2 
6‘ 131.2, C  
7‘ 142.8, C  
8‘   75.1, CH2 4.85, bs 
9‘a 118.6, CH2 5.88, bs 
9‘b  5.44, bs 
10‘   15.1, CH3 2.56, s 
1‘‘   36.6, CH2 2.70, t, 7.6 
2‘‘   31.4, CH2 1.66, m  
3‘‘   31.2, CH2 1.32, m 
4‘‘   22.7, CH2 1.30, m 
5‘‘   14.3, CH3 0.88, t, 7.0 
     
 
In particular, the three correlations exhibited by H3-10‘ with the oxygenated C-2‘ 
(δC 153.7), with C-3‘ and with the methine carbon C-4‘ (δC 127.4), along with the 
correlations of H-5‘ with C-1‘, C-3‘ and C-6‘ allowed the identification of a 
tetrasubstituted phenyl ring bearing a methyl group and an oxygen atom on 
adjacent positions. The unprotonated sp
2
 carbon C-7‘ was attached at C-6‘ on the 
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basis of the HMBC cross-peaks H-5‘/C-7‘, H2-9‘/C-6‘, H2-9‘/C-7‘, H2-8‘/C-6‘, 
H2-8‘/C-7‘ and, these data, together with the HMBC cross peak H2-9‘/C-8‘ 
allowed also to establish the linkage of both the sp
2
 methylene carbon (C-9‘) and 
the oxygenated sp
3
 methylene (C-8‘) at C-7‘. The second phenyl ring was also 
tetrasubstituted, and its linkage with the pentyl chain at C-3 was indicated by the 
HMBC cross peaks of H2-1‘‘ with C-3 and with the methine carbons C-2 and C-4. 
The pattern of HMBC cross peaks shown by H-2 and H-4 suggested that both C-1 
(δC 157.5) and C-5 (δC 155.2) are oxygenated carbons, and the key HMBC cross-
peak H2-8‘/C-5 indicated the presence of an oxygen bridge to connect C-8‘ and C-
5. Finally, the direct linkage of C-6 with C-1‘ (defining a seven-membered ring) 
and the presence of a second oxygen bridge to connect C-1 with C-2‘ (defining a 
furan ring), builded the dioxygenated tetracyclic structure of cannabioxepane (29), 
allowed the complete rationalization of NMR and MS data and was in perfect 
agreement with biogenetic arguments.        
Cannabioxepane (29, CBX) is characterized by an unprecedented tetracyclic 
skeleton including, in addition to two phenyl rings, a furan and an oxygenated 
seven-membered ring. This skeleton bears some relationships with some 
cannabinoids from the CBE family (Fig. 2.6), and particularly with the aromatized 
analogue named cannabifuran (15),
24 
however, noteworthy, no member of the 
CBE family shows a fourth ring. On the other hand, in the structure of Δ9-THC (6)  
and its derivatives (of their alleged CBG precursors) the oxygen atom at C-5 is 
involved in the formation of a six-membered ring with the unprotonated carbon of 
the isopropyl side chain (C-7‘). CBX (29) is the first cannabinoid to show a 
linkage between the oxygen atom at C-5 and C-8‘, thus giving rise to the 
unprecedented seven-membered ring. From a biogenetical standpoint, CBX could 
be derived from the 7-endo-tet opening of the 7‘-8‘ epoxide of a CBE-like 
precursor, followed by dehydration (Fig. 2.15).  
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Figure 2.15.  Possible biogenesis of CBX (29) from CBD via the epoxide 30. 
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While cyclization of CBD-epoxides strongly favours the formation of pyrane 
derivatives via a 6-exo-tet process, it was noticed that closure of a furan ring 
between C-2‘ and the 1-hydroxyl could steer cyclization toward the formation of 
an alternative 7-endo-tet process, with formation of an oxepane rather than a 
pyran ring.
35 
It seems therefore logic to assume that dehydrocannabifuran epoxide, 
a yet unreported cannabinoid,  is the ultimate precursor of CBX.  
 
2.3.3. Affinity of the cannabioxepane  for cannabinoid receptors 
Pharmacological evaluation of natural cannabinoids and of a number of synthetic 
molecules allowed the formulation of detailed structure-activity relationships for 
the interaction with the cannabinoid receptors (Fig. 2.16). 
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Figure 2.16. A schematic view of the structure-activity relationships for 
interaction with the cannabinoid CB1 receptor. 
 
A free hydroxyl group on ring A is required for activity on CB1; presumably due 
to the formation of hydrogen bonding with the side-chain and the nitrogen atom of 
Lys12 in transmembrane helix 3 of the CB receptor.
60
 The structure of synthetic 
cannabinoid CP-55,244 ( see structure in figure 2.17) highlights the role exerted 
by the so-called northern aliphatic hydroxyl group (NAH) and the southern 
aliphatic hydroxyl group (SAH), both of them absent in the structure of classical 
cannabinoids (Fig. 2.17). Their presence is not crucial for receptor affinity but, 
most likely, they interact positively (and in a stereospecific way) with receptorial 
structures, thus potentiating the activity.   
 
 
50 CHAPTER II  -  Cannabinoids: isolation and synthesis of new compounds 
OH
H
HO
(NAH)
(SAH)  
Figure 2.17. The chemical structure of CP-55,244  
 
Another critical parameter for CB affinity is the length and the ramification of the 
pentyl side chain. A decrease in the length of this side chain results in a reduction 
of potency (THCV is about 75% less potent) and in the appearing of dose-
dependent antagonist behaviour
61
, while an increase to C7 or C8 results in a 
systematic increase in affinity.  
Modifications at ring C have been mostly concentrated on the allylic methyl 
group. A positive effect is shown by nabilone (32), where the methyl group is 
oxidatively cleaved to give a keto group. Nabilone has been introduced into the 
market as antiemetic agent for cancer supporting care and, recently, it has been 
approved in the USA also for the treatment of neuropathic pain.
61
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Figure 2.18. The chemical structure of nabilone (32) 
 
CBX was evaluated for its affinity to CB1 and CB2 receptors but no significant 
activity was detected. Actually, this result was not surprising considering the 
negative effect reported for the etherification of the phenolic 1-hyhdroxyl, and for 
the aromatization of the terpene-derived six-membered ring. 
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2.3.4. Experimental 
Collection, Extraction and Isolation 
Cannabis sativa derived from a greenhouse cultivation at CRA-CIN, Rovigo 
(Italy), where a voucher specimen is kept, and was collected in November 2008. 
The isolation and manipulation of all cannabinoids was done in accordance with 
their legal status (Authorization SP/101 of the Ministero della Salute, Rome, 
Italy). 
Dried flowerheads of C. sativa (500 g) were heated at 120°C for 2.5 h in a 
ventilated oven, to decarboxylate pre-cannabinoids. After cooling to room temp., 
the plant material was extracted with acetone (2 × 10 L). Removal of the solvent 
left a gummy residue that was partitioned between 1:1 aqueous methanol (1 L) 
and petroleum ether (1L). The defatted polar phase was concentrated and 
extracted with CH2Cl2. The organic phase was dried (Na2SO4) and evaporated to 
afford a black gum (10 g), that was purified by flash chromatography on RP-18 
silica gel  (Biotage equipment, 250 mL column,  linear gradient, from MeOH/H2O 
55:45 to 90:10). Overall, five fractions (A1 to A5) were collected. Fraction A2 
was further fractionated by gravity column chromatography on silica gel, using 
acidified (0.5% HOAc) petroleum ether-EtOAc mixtures to obtain 20 subfractions 
(B1 to B20) which were subsequently purified by HPLC. HPLC purification of 
fraction B2 (eluent n-hexane/EtOAc 85:15) yielded cannabispirane (24, 15.0 mg, 
30 ppm on dried plant material). HPLC purification of fraction B3 (eluent n-
hexane/EtOAc 8:2) yielded cannabispiradienone (27, 5.0 mg, 11 ppm on dried 
plant material). HPLC purification of fraction B4 (eluent n-hexane/EtOAc 75:25) 
yielded 12-hydroxy-3,9,15-octadecatrienoic acid (30, 6.0 mg, 12 ppm on dried 
plant material), isocannabispiradienone (28, 2.8 mg, 5 ppm on dried plant 
material), β-cannabispiranol (25, 22.0 mg, 48 ppm on dried plant material) and α-
cannabispiranol (26, 15.0 mg, 30 ppm on dried plant material). HPLC purification 
of fraction B5 (eluent n-hexane/EtOAc 75:25) yielded 16-hydroxy-9Z,12Z,14E-
octadecatrienoic acid (31, 4.0 mg, 9 ppm on dried plant material), The less polar 
fraction A4 was subjected to repeated column chromatographies on silica gel 
(petroleum ether-EtOAc mixtures) to obtain a crude fraction which was further 
purified by HPLC (eluent n-hexane/EtOAc 95:5) to yield cannabioxepane (29, 3.5 
mg, 7 ppm on dried plant material).  
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Isocannabispiradienone (28). Colorless amorphous solid; IR (KBr): υmax 3100, 
1650 cm
-1. UV (MeOH): λmax (ε) 215 (28000), 240 (23300), 277 (3000), 287 
(3000) nm. 
1
H NMR (CDCl3,500 MHz): δ 6.86 (H-10 = H-14, 2H, d, J = 10.0 
Hz), 6.36 (H-4, 1H, d, J = 2.1 Hz), 6.26 (H-11 = H-13, 2H, d, J = 10.0 Hz), 6.19 
(H-6, 1H, d, J = 2.1 Hz), 4.73 (5-OH, 1H, s), 3.61 (7-OMe, 3H, s), 3.06 (H2-2, 2H, 
t, J = 7.8 Hz), 2.25 (H2-1, 2H, t, J = 7.8 Hz). 
13
C NMR (CDCl3,125 MHz): δ 186.9 
(C-12), 158.9 (C-11 = C-13), 157.6 (C-5, C-7), 153.1 (C-10 = C-14), 147.2 (C-3), 
121.4 (C-8), 103.8 (C-4), 97.5 (C-6), 55.9 (7-OMe), 52.6 (C-9), 38.1 (C-1), 31.6 
(C-2). ESI-MS (positive ions) m/z 265 [M + Na]
+
; HREIMS m/z 265.0844 [M + 
Na]
+
 (calcd. for C15H14NaO3 265.0841).   
Cannabioxepane (29). Colorless amorphous solid; 
1
H and 
13
C NMR (CDCl3) see 
Table 2.2. ESI-MS (positive ions) m/z 329 [M + Na]
+
; HREIMS m/z 329.1522 [M 
+ Na]
+
 (calcd. for C21H22NaO2 329.1517).     
12S-hydroxy-9Z,13E,15Z-octadecatrienoic acid (30).  Colorless amorphous solid; 
[α]D = +2 (c = 0.05); CD (MeOH): λ 243 nm (Δε = + 0.3); 
1
H NMR (CDCl3): δ 
6.52 (H-14, 1H, dd, J = 15.5, 11.0 Hz), 5.97 (H-15, 1H, t, J = 11.0 Hz), 5.69 (H-
13, 1H, dd, J = 15.5, 6.0 Hz), 5.54 (H-9, 1H, dt, J = 10.7, 7.2 Hz), 5.42 (H-16, 1H, 
dt, J = 11.0, 7.2 Hz), 5.36 (H-10, 1H, dt, J = 10.7, 7.2 Hz), 4.21 (H-12, 1H, m), 
2.33 (H2-11, 2H, t, J = 7.2 Hz), 2.30 (H2-2, 2H, t, J = 7.2 Hz), 2.18 (H2-17, 2H, q, 
J = 7.2 Hz), 2.09 (H2-8, 2H, q, J = 7.2 Hz), 1.35-1.30 (H2-7, H2-6, H2-5, H2-4, 8H, 
m), 1.60 (H2-3, 2H, q, J = 7.2 Hz), 1.01 (H3-18, 3H, t, J = 7.2 Hz). ESI-MS 
(positive ions) m/z 317 [M + Na]
+
; HREIMS m/z 317.2100 [M + Na]
+
 (calcd. for 
C18H30NaO3 317.2093).  
16R-hydroxy-9Z,12Z,14E-octadecatrienoic acid (31). Colorless amorphous solid; 
CD (MeOH): λ 229 nm (Δε = - 0.8); 1H NMR (CDCl3): δ  6.52 (H-14, 1H, dd, J = 
15.0, 11.0 Hz), 6.00 (H-13, 1H, t, J = 11.0 Hz), 5.69 (H-15, 1H, dd, J = 15.5, 7.0 
Hz), 5.45 (H-12, 1H, dd, J = 11.0, 7.0Hz), 5.40 (H-9, 1H, dd, J = 11.0, 7.0 Hz), 
5.35 (H-10, 1H, dt, J = 11.0, 7.0 Hz), 4.09 (H-16, 1H, m), 2.93 (H2-11, 2H, t, J = 
7.5 Hz), 2.31 (H2-2, 2H, t, J = 7.2 Hz), 2.06 (H2-8, 2H, q, J = 7.2 Hz), 1.60 (H2-3, 
H2-17, 4H, m), 1.35-1.30 (H2-7, H2-6, H2-5, H2-4, 8H, m), 0.88 (H3-18, 3H, t, J = 
7.2 Hz). ESI-MS (positive ions) m/z 317 [M + Na]
+
; HREIMS m/z 317.2090 [M + 
Na]
+
 (calcd. for C18H30NaO3 317.2093). 
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2.4. STEROIDAL CB RECEPTOR LIGANDS FROM THE 
INDONESIAN SPONGE DASYCHALINA sp. 
 
2.4.1 Introduction  
The research on CB receptors is a hot topic of modern pharmacology and 
medicinal chemistry. A few natural products, with the obvious exception of 
meroterpenoids from C. sativa, have been tested as CB receptor ligands
63
. A 
recent example includes the polyine falcarinol (found in carrots, parsley and other 
plants) which exhibited micromolar binding affinity to both human CB 
receptors
64
.  
 
 
 
 
 
 
 
 
Figure 2.19. A specimen of the sponge  
 Dasychalina sp. collected in the area of  
 the Bunaken Marine Park of Manado. 
 
As part of our ongoing screening for biologically active secondary metabolites 
from Indonesian marine invertebrates
65-67
, we had recently the opportunity to 
analyze a specimen of the sponge Dasychalina sp (order Haposclerida, family 
Niphatidae, Fig. 2.19). From the polar organic extract we have isolated consistent 
amounts of two steroidal derivatives, haplosamate A (11) and its new desulfo 
analogue 12. These two compounds, as well as their semi-synthetic analogues 33-
35, have been evaluated for interaction with CB1 and CB2 receptors. 
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2.4.2. Extraction, isolation and structure elucidation 
A specimen of the sponge Dasychalina sp. was collected by hand in the area of the 
Bunaken Marine Park of Manado and kept frozen until sequentially extracted with 
methanol (MeOH) and dichloromethane by soaking the diced sponge tissue (210 g 
wet weight). The extracts were concentrated, combined, and then partitioned 
between ethyl acetate (EtOAc) and water. The polar material has been then 
partitioned between water and butanol to obtain a polar organic phase of 2.67 g. 
This was chromatographed on silica gel, using a gradient solvent system from 
EtOAc to MeOH. Fractions eluted with EtOAc/MeOH 7:3 to 1:1 were combined 
and further purified by reverse-phase HPLC (MeOH/H2O mixtures) to obtain 
consistent amounts of haplosamate A (11, 480.5 mg, 0.2% based on wet weight) 
and the new desulfohaplosamate (12, 12.2 mg) in the pure form.  
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Haplosamate A  (11) is a unique C28 sterol containing seven oxygenated carbons 
and including a rare six-membered ether ring connecting C-16 and C-23, a sulfate 
group at C-3, and a methyl phosphate at C-15. Haplosamate A (11) was first 
isolated from the sponge Xestospongia sp.
68
 and then re-isolated (and structurally 
revised) from another Haposclerida sponge, Cribrochalina sp.
69 
Although 
steroidal sulfates are well represented in marine sponges, the group of natural 
sterols including both sulphate and phoshate groups is restricted to a handful of 
members.
70
  
Compound 12 showed a prominent ion peak at m/z 573 in the ESI-MS spectrum 
(negative ion mode) and high resolution measurements indicated the molecular 
formula C29H50O9P. 
1
H and 
13
C NMR spectra of 12 (CD3OD, Table 2.3) 
resembled parallel spectra of haplosamate A, but marked shifts were observed in 
several resonances.  
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Table 2.3. 
1
H (500 MHz) and 
13
C (125 MHz) NMR Data of Desulfohaplosamate (12) in 
CD3OD 
Pos. δC, mult. δH, mult., J in Hz 
1a   30.3, CH2 1.34
a 
1b  1.29
a 
2a   24.4, CH2 2.04, m 
2b  1.55
a 
3   69.9, CH 3.74, d, 2.5 
4   78.5, CH 3.85, bs 
5   44.9, CH 1.52
a 
6   78.2, CH 3.96, bs 
7   80.0, CH
 
3.28, bd, 10.6 
8   34.5, CH
 
2.29, ddd, 11.0, 10.6, 10.6 
9   54.1, CH
 
0.86, m 
10   36.8, C  
11a   20.0, CH2 1.53
a 
11b  1.44
a 
12a   40.5, CH2 1.84, m 
12b  1.14, m 
13   43.2, C  
14   58.2, CH 1.39, m 
15   81.6, CH 4.72, m 
16   91.8, CH 3.91, dd, 10.0, 3,5 
17   62.5, CH 0.73, m 
18   15.5, CH3 0.99, s 
19   17.5, CH3 1.32, s 
20   33.9, CH 1.82, m 
21   20.5, CH3 0.96, d, 7.0 
22a   40.0, CH2 1.65, m 
22b  0.84, m 
23   82.1, CH 3.45, ddd, 9.5, 8.5, 2.1 
24   44.9, CH 1.41
a 
25   27.8, CH 2.08, m 
26   17.1, CH3 0.81, d, 7.0 
27   21.7, CH3 0.89, d, 7.0 
28   10.2, CH3 0.76, d, 7.0 
-OMe   52.8, CH3 3.60, d, 11.0 
a 
Overlapped with other signals 
 
In particular, the presence of the characteristic O-methyl doublet signal coupled to 
the phosphorous atom (δH 3.60, doublet, J = 11.0 Hz) clearly confirmed the 
presence of the methylphosphate functionality. All the proton resonances were 
associated to those of the directly attached carbon atoms through the 2D NMR 
HSQC experiment and then the proton multiplets were arranged in sequence 
through the COSY experiment, yielding to the single large spin system evidenced 
in bold in figure 2.20.  
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Figure 2.20. COSY and key HMBC cross-peaks (left) and ROESY correlations 
(right) of desulfohaplosamate (12) 
 
HMBC cross-peaks exhibited by Me-18 and Me-19 defined the tetracyclic 
steroidal skeleton, while the key HMBC correlations of H-16 (δH 3.91) with C-23 
(δC 82.1) and H-23 with C-16 indicated the presence of a six-membered ether ring. 
Carbon-phosporous couplings were observed in the 
13
C NMR spectrum of 12 for 
C-14 (
3
JC,P = 8.5 Hz) and C-15 (
2
JC,P = 7.0 Hz), thus placing the methylphosphate 
group at C-15, and completely defining the planar structure of 12. The comparison 
of the pattern of 
1
H-
1
H coupling constants measured for 12 (Table 2.3) with those 
reported for haplosamate A, supported by the series of ROESY cross peaks shown 
in figure 2.20, indicated the relative configuration of 12. Noteworthy, three of the 
four secondary hydroxyl groups are in axial orientation and they are all located on 
the ―southern‖ part of rings A and B. The relatively low-field shifted resonance of 
Me-19 (δH 1.32) is in agreement with the β orientation of both the hydroxyl groups 
at C-4 and C-6. Desulfohaplosamate (12) is only the fourth member of the 
haplosamate group of steroids, in addition to haplosamate A, haplosamate B 
(showing a second phosphate group at C-7) and a minor analogue showing ring A 
contraction.
69
   
2.4.3. Preparation of semisynthetic derivatives of haplosamate A 
Fusetani et al. reported that haplosamate A possessed a moderate inhibitory 
activity toward membrane type 1 matrix metalloproteinase, a key enzyme in tumor 
metastasis.
69
 More recently, a seminal work by Andersen et al.
71
 identified 
haplosamate A as CB1 and CB2 receptor agonists, on the basis of a functional cell-
based bioassay (Spodoptera frugiperda cells expressing one or the other of the 
human cannabinoid receptors) and saturation transfer double-difference NMR 
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experiments.
72
 In the same study, the Authors also suggested that phosphate and 
sulfate groups are not essential for binding to cannabinoid receptors, tentatively 
identifying the ―northern‖ less polar region of the molecule as responsible for this 
interaction. Given our interest for the chemistry of both natural
6
 and synthetic
39
 
cannabinoids, the isolation of haplosamate compounds from Dasychalina sp. 
represented a unique opportunity to investigate the interaction of these steroidal 
derivatives with cannabinoid receptors through a binding test. 
In order to increase the chemical diversity of the tested compounds, we took 
advantage of the relatively high amounts of haplosamate A obtained from the 
sponge to prepare a few simple semi-synthetic derivatives.  
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Scheme 2.1. Preparation of semisynthetic derivatives of haplosamate A (11).  
i. NaIO4; ii. Ac2O/Pyr. 
 
Treatment of haplosamate A (11) with NaIO4 gave in good yields (65%) the 
dialdehyde 33 (Scheme 2.1) originating from the regioselective oxidative cleavage 
of the C-6/C-7 bond. The 
1
H NMR spectrum of compound 33 (CD3OD) showed 
the appearance of two broad singlets at δH 9.81 (H-6) and 10.22 (H-7) and a 
marked downfield shift of the other ring B proton signals (H-5: from δ 1.50 to 
2.56; H-8 from δ 2.26 to 3.15; H-9 from δ 0.90 to 2.35). Inspection of 2D NMR 
COSY, HSQC and HMBC experiments allowed the assignment of all the proton 
and carbon resonances as reported in paragraph 2.4.3. Acetylation of haplosamate 
A (1) in standard conditions (Ac2O/pyr) yielded to the formation of the 7-acetate 
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(34) and of the 4,7-diacetate (35) derivatives (Scheme 2.1). The acetylation 
positions in compounds 34 and 35 were unambiguously determined on the basis of 
the marked downfield shift of the relevant methine protons (e.g. H-7 is shifted 
from δH 3.34 to 4.64 in 34) and of the 
3
JH,C HMBC cross peaks between each of 
these methines and the corresponding ester carbonyls. The easy esterification at C-
7 can be rationalized on the basis of the equatorial position of the hydroxyl group; 
on the contrary, acetylation of the axial hydroxyl at C-4 was somewhat 
unexpected, due to the steric hindrance of Me-19. Noteworthy, Fusetani et al. 
reported that treatment of haplosmate A with benzoyl chloride not only failed to 
give esterification at C-4 but also at C-7, and the phosphotriester 36 (Scheme 2.1), 
formed by ester exchange, was the single reaction product.
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 This markedly 
different behaviour of the same compound upon treatment with benzoyl chloride 
and acetic anhydride appears intriguing.   
The affinity of the natural haplosamates 11 and 12 and of the semisynthetic 
derivatives 33-35 for both human recombinant cannabinoid receptors CB1 and 
CB2 was evaluated (Table 2.4).  
Table 2.4. Effects of haplosamate derivatives 1-5 on cannabinoid receptors 
 Ki at hCB1
a
 
(μM) 
Ki at hCB2
a 
(μM) 
Haplosamate A (11) 19.17 >50 
Desulfohaplosamate (12)        19.47           2.82 
Dialdehyde (33) >50 >50 
Haplosamate A-7-acetate (34)  9.74  8.89 
Haplosamate A-4,7-diacetate (35) 19.98 11.85 
Δ9-Tetrahydrocannabinol (6) 0.0016 0.0024 
a 
Ki values are calculated by applying the Cheng-Prusoff equation.  
 
A comparison of affinity data obtained for haplosamate A (11) and 
desulfohaplosamate (12) appears quite interesting, since these two compounds 
showed an opposite behaviour. Compound 11 exhibited significant affinity only 
for CB1 receptors, its potency in the binding assay being in the mid μM range, 
significantly higher than previously reported using a different type of assay.
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Instead, the desulfated analogue 12 showed a much higher affinity for CB2 
receptors, in the low μM range (Ki = 2.8 μM). The 7-monoacetylated derivative of 
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haplosamate A showed an increase in the affinity for both CB receptors, compared 
to its parent compound, but the further acetylation at C-4 proved to be deleterious 
for affinity on both CB1 and CB2. Finally, the dialdehyde derivative 33 showed a 
complete loss of affinity for both receptors, highlighting the importance of an 
intact steroid nucleus and, in particular, of intact rings A and B. Δ9-THC (6), used 
here as reference compound, was, as expected, about 1000-fold more potent than 
haplosamates in the same binding assays. 
2.4.4. Experimental 
Collection, Extraction and Isolation 
A specimen of the sponge Dasychalina sp. (order Haposclerida, family 
Niphatidae) was collected in January 2008 by hand in the area of the Bunaken 
Marine Park of Manado and kept frozen until extraction. A voucher sample (n° 
MAN08-07) has been deposited at the Dipartimento di Chimica delle Sostanze 
Naturali, Università di Napoli Federico II. The organism (210 g wet weight) was 
exhaustively extracted, in sequence, with methanol (MeOH) and dichloromethane 
(CH2Cl2) by soaking the diced sponge tissue. The extracts were combined and 
then partitioned between ethyl acetate (EtOAc) and H2O. The polar material has 
been then partitioned between H2O and butanol to obtain a polar organic phase 
(2.67 g), which was chromatographed on a silica gel column (230-400 mesh), 
using a gradient solvent system from EtOAc to MeOH. Fractions eluted with 
EtOAc/MeOH 7:3 to 1:1 were combined and further purified by reverse-phase 
HPLC (MeOH/H2O 1:1) to obtain consistent amounts of haplosamate A (11, 480.5 
mg) and the new desulfohaplosamate (12, 12.2 mg) in the pure state.  
Desulfohaplosamate (12). Colorless powder. [α]D = - 3.8 (c = 0.03 MeOH); 
1
H 
and 
13
C NMR (CD3OD): Table 2.3. ESI-MS (negative ions) m/z 573 [M - Na]
-
; 
HREIMS m/z 573.3200 [M - Na]
-
 (calcd. for C29H50O9P 573.3198).  
Oxidative cleavage of haplosamate A. To a solution of haplosamate A (43.4 mg, 
0.062 mmol) in CH2Cl2 (1.2 mL) 50 μL of NaHCO3 sat. solution and 28 mg (0.13 
mmol mmol) of NaIO4 were added. The mixture was left at room temp. for 3 hrs. 
under vigorous stirring. Then, the reaction mixture was treated with dry Na2SO4 
and filtered. The obtained filtrate was purified by RP18 HPLC (H2O/MeOH 1:1) 
to give 27.0 mg (65 % yield) of the dialdehyde 33.   
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Dialdehyde (33).  Colorless amorphous solid; [α]D = - 4.6  (c = 0.05); 
1
H NMR 
(CD3OD, 500 MHz): δ 10.22 (H-7, bs), 9.81 (H-6, s), 4.60 (H-3, bs), 4.37 (H-15, 
m), 4.19 (H-4, bs), 3.68 (H-16, dd, J = 10.5, 2.0 Hz), 3.57 (OMe, d, J = 10.5 Hz), 
3.36 (H-23, t, J = 8.5 Hz), 3.15 (H-8, t, J = 11.0 Hz), 2.56 (H-5, bs), 2.35 (H-9, 
m), 2.14 (H-2a, m), 2.09 (H-25, m), 1.84 (H-12a, overlapped), 1.80 (H-20, 
overlapped), 1.76 (H-2a, overlapped), 1.75 (H-14, overlapped), 1.73 (H-1a, 
overlapped), 1.63 (H-22a, overlapped), 1.60 (H-11a, overlapped), 1.55 (H-11b, 
overlapped), 1.41 (H-24, m), 1.30 (Me-19, s), 1.30 (H-1b, m), 1.27 (H-12b, 
overlapped), 0.96 (Me-18, s), 0.95 (Me-21, d, J = 7.0 Hz), 0.89 (Me-26, d, J = 7.0 
Hz), 0.86 (H-22b, m), 0.81 (Me-27, d, J = 7.0 Hz), 0.80 (Me-28, d, J = 7.0 Hz), 
0.80 (H-17, overlapped). 
13
C NMR (CD3OD, 125 MHz): δ 205.2 (C-7), 204.8 (C-
6), 90.8 (C-16), 82.3 (C-3), 81.4 (C-23), 77.5 (C-15), 70.8 (C-4), 62.0 (C-17), 55.2 
(C-5), 54.0 (OMe), 51.9 (C-14), 44.2 (C-24), 43.5 (C-9), 43.4 (C-13), 40.5 (C-22), 
40.1 (C-8), 37.8 (C-12), 34.3 (C-1), 33.5 (C-20), 33.2 (C-10), 27.2 (C-25), 22.8 
(C-2), 22.5 (C-11), 21.8 (C-27), 20.5 (C-21), 18.5 (C-19), 16.8 (C-26), 15.4 (C-
18), 11.0 (C-28). ESI-MS (negative ions) m/z 651 [M - 2Na + H]
- 
, 673 [M - Na]
-
; 
HR-ESI-MS m/z 673.2421 (calcd. for C29H47NaO12PS m/z 673.2429).  
Acetylation of haplosamate A. Haplosamate A (33.5 mg, 0.048 mmol) was 
dissolved in dry pyridine (0.5 mL) and treated with Ac2O (0.5 mL). After standing 
overnight under stirring at room temp, the reaction was worked up by addition of a 
few drops methanol to destroy the excess Ac2O, water (ca. 1 mL) and EtOAc (ca. 
3 mL). The organic phase was washed sequentially with 2N H2SO4, sat. NaHCO3 
and brine. After drying (Na2SO4) and removal of the solvent, the residue was 
purified by HPLC (H2O/MeOH 6:4) to afford 25.5 mg (75% yield) of the 7-
monoacetate 34 and 8.5 mg (22% yield) of the 4,7-diacetate 35. 
Haplosamate A 7-acetate (34). Colorless powder. [α]D = - 1.4  (c = 0.03);
 1
H NMR 
(CD3OD, 500 MHz): δ 4.64 (H-7, bd, J = 10.5 Hz), 4.43 (H-3, bs), 4.36 (H-15, m), 
4.14 (H-4, bs), 4.00 (H-16, dd, J = 10.5, 2.0 Hz), 3.89 (H-6, bs), 3.64 (OMe, d, J = 
10.5 Hz), 3.52 (H-23, t, J = 8.5 Hz), 2.70 (H-8, t, J = 11.0 Hz), 2.32 (7-OAc, s), 
2.03 (H-2a, m), 2.00 (H-25, m), 1.81 (H-20, overlapped), 1.77 (H-12a, 
overlapped), 1.68 (H-5, bs), 1.55 (H-11a, overlapped), 1.53 (H-22a, overlapped), 
1.51 (H-1a, m), 1.42 (H-24, overlapped), 1.40 (H-11b, overlapped), 1.30 (H-14, 
overlapped), 1.38 (Me-19, s), 1.33 (H-2a, overlapped), 1.27 (H-1b, m), 1.05 (Me-
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18, s), 1.01 (H-9, m), 0.99 (Me-21, d, J = 7.0 Hz), 0.89 (Me-26, d, J = 7.0 Hz), 
0.88 (H-12b, overlapped), 0.86 (H-22b, m), 0.81 (Me-27, d, J = 7.0 Hz), 0.75 (Me-
28, d, J = 7.0 Hz), 0.70 (H-17, overlapped). ESI-MS (negative ions) m/z 695 [M - 
2Na + H]
- 
, 717 [M - Na]
-
; HR-ESI-MS m/z 717.2702 (calcd. for C31H51NaO13PS 
m/z 717.2691). 
Haplosamate A 4,7-diacetate (35). Colorless powder. [α]D = - 10.6  (c = 0.08);
 1
H 
NMR (CD3OD, 500 MHz): δ 5.42 (H-4, bs), 4.64 (H-7, bd, , J = 10.5 Hz), 4.40 
(H-15, m), 4.36 (H-3, bs), 3.99 (H-16, dd, J = 10.5, 2.0 Hz), 3.91 (H-6, bs), 3.67 
(OMe, d, J = 10.5 Hz), 3.55 (H-23, t, J = 8.5 Hz), 2.70 (H-8, t, J = 11.0 Hz), 2.32 
(7-OAc, s), 2.09 (4-OAc, s), 2.03 (H-2a, m), 2.00 (H-25, m), 1.81 (H-20, 
overlapped), 1.77 (H-12a, overlapped), 1.72 (H-5, bs), 1.55 (H-11a, overlapped), 
1.53 (H-22a, overlapped), 1.51 (H-1a, m), 1.42 (H-24, overlapped), 1.40 (H-11b, 
overlapped), 1.35 (H-14, overlapped), 1.33 (H-2a, overlapped), 1.33 (Me-19, s), 
1.27 (H-1b, m), 1.05 (Me-18, s), 1.01 (H-9, m), 0.99 (Me-21, d, J = 7.0 Hz), 0.89 
(Me-26, d, J = 7.0 Hz), 0.88 (H-12b, overlapped), 0.86 (H-22b, m), 0.81 (Me-27, 
d, J = 7.0 Hz), 0.75 (Me-28, d, J = 7.0 Hz), 0.70 (H-17, overlapped). ESI-MS 
(negative ions) m/z 737 [M - 2Na + H]
- 
, 759 [M - Na]
-
; HR-ESI-MS m/z 759.2802 
(calcd. for C33H53NaO14PS m/z 759.2797). 
Cannabinoid CB1 and CB2 receptor binding assays. Membranes from HEK-293 
cells transfected with the human recombinant CB1 receptor (Bmax= 2.5 pmol/mg 
protein) and human recombinant CB2 receptor (Bmax= 4.7pmol/mg protein) were 
incubated with the radiolabelled high affinity ligand [
3
H]-CP-55,940 (0.14 nM, Kd 
= 0.18 nM and 0.084 nM, Kd = 0.31 nM, for CB1 and CB2 receptors, respectively) 
and displaced with 10M WIN 55212-2 as the heterologous competitor for non 
specific binding  (Ki values 9.2 nM and 2.1 nM for CB1 and CB2 receptors, 
respectively). All compounds were tested following the procedure described by 
the manufacturer (Perkin Elmer, Italia). Displacement curves were generated by 
incubating drugs with [
3
H]-CP-55,940 for 90 minutes at 30°C. Ki values were 
calculated by applying the Cheng-Prusoff equation to the IC50 values (obtained by 
GraphPad) for the displacement of the bound radioligand by increasing 
concentrations of the test compound. Δ9-THC was used as the reference 
compound. Data are means of 3 experiments. 
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67 
CHAPTER III 
ISOLATION AND SYNTHESIS OF NEW 
ANTIMALARIAL COMPOUNDS 
 
3.1. MALARIA 
It has been estimated that 300-500 million cases of malaria occur annually with 
1.75 to 2.5 million deaths. Malaria is a particularly important disease in sub-
Saharan Africa, where about 90% of cases and deaths occur, but is also a serious 
public health problem in certain regions of Southeast Asia and South America.
1
 
Human malaria is caused by four species of Plasmodium, namely P. falciparum, 
P. vivax, P. ovale and P. malariae, which are transmitted by female Anopheles 
mosquitoes. P. falciparum is the parasite that causes most severe diseases and 
most fatal cases. The life cycle, immunological defence mechanisms, and clinical 
development of malaria in humans is complex. The sporozoites that develop in the 
salivary glands of the female mosquito are inoculated into the human when then 
the insect bites to acquire a blood meal. The protozoans in the sporozoite form 
invade selectively the parenchymal cells of the human liver. In this stage, the 
patient remains asymptomatic and, after an average incubation period of 5-7 days 
(in the case of P. falciparum), protozoa reach the merozoite stage and are released 
from the liver. The merozoites invade the erythrocytes and start feeding on the 
haemoglobin. After proliferation, the rupture of the erythrocyte membrane and the 
consequent liberation of other merozoites, that invade other erythrocytes, cause 
the massive infection and the symptoms. A small portion of merozoites develops 
into the sexual stage of gametocytes, a form that is able to re-start the life cycle of 
the malaria parasite when a mosquito takes a blood meal from an infected person
2
 
(Fig. 3.1). 
The clinical symptoms of malaria infections are exclusively attributable to 
parasites in the erythrocytic stage. The rupture of infected erythrocytes is 
associated with the release into the blood stream of cell debris responsible for the 
characteristic fever spike patterns. In the lethal cases, a specific protein produced 
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by the protozoan is embedded into the cell membrane of the infected erythrocyte 
and, as a consequence of this modification, the erythrocyte sticks to the walls of 
capillaries causing obstruction of vessels. When this mechanism operates at the 
level of brain vessels, the loss of consciousness is the first symptom, but, if this 
form of cerebral malaria is not treated immediately, it is soon followed by death. 
 
Figure 3.1 The malaria cell cycle 
The treatment of malaria infections holds a venerable place in the history of 
medicinal chemistry and of natural product chemistry. As commonly well-known, 
the first specific treatment for malaria dates back to the 17
th
 century when the bark 
of Cinchona trees was used as the best tool to face infections of malaria, that was 
endemic in Africa, Asia but also in several parts of Europe and North America. 
Later, malaria was the first disease to be treated with an active principle isolated 
from a natural source, quinine (37) isolated from the Cinchona bark in 1820, and, 
later again, the first human disease to be treated with a synthetic drug (methylene 
blue in 1891). 
In the course of 20
th
 century, especially during World War II, a series of effective 
synthetic antimalarial drugs have been developed. Among them, chloroquine (38), 
mefloquine (39), and pyrimethamine (40) (Fig. 3.2), became the drugs of choice 
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in several programs and contributed to the almost complete eradication of malaria 
from Europe and North America. 
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Figure 3.2. First-line antimalarial drugs: quinine (37), choloquine (38), 
mefloquine (39), pyrimetamine (40). 
 
The chemotherapy and prophylaxis of malaria have been undermined by the 
development of worldwide resistance of P. falciparum to the 4-aminoquinoline 
chloroquine, first observed in the 1960s, as well as resistance to the antifolates 
pyrimethamine and cycloguanil. Two major breakthroughs of the past few 
decades have renewed the assault of scientists to this infective disease. The first is 
the complete sequencing of the genome of Plasmodium falciparum that is 
expected to provide useful information for the identification of new drug targets. 
The second is the discovery, by Chinese researchers, of artemisinin (41, 
qinghaosu), an endoperoxide sesquiterpene lactone which is the active principle of 
the sweet wormwood, Artemisia annua, an herbal remedy used in folk Chinese 
medicine for 2000 years. This molecule and its oil soluble (e.g. artemether, 42, 
and arteether) and water soluble (e.g. artesunate, 43, and artelinate) semi-synthetic 
derivatives (Fig. 3.3) have shown excellent efficacy against chloroquine-resistant 
Plasmodium strains and are becoming increasingly used, especially in 
combination with traditional antimalarials (e.g. mefloquine, 39).  
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Figure 3.3. Chemical structures of artemisinin (41) and of its semisynthetic 
derivatives   artemether (42) and artesunate (43). 
 
Unfortunately, in our days malaria still continues to be an extremely important 
threat to the health and economic prosperity of the human race, constituting a 
major cause of morbidity and mortality in tropical countries of Asia, Africa and 
South America. Part of the reason for the failure to control malaria in these areas 
is the emergence and spread of resistance to first-line antimalarial drugs and 
recently to artemisinin (41) too, cross-resistance between the members of the 
limited number of drug families available, and in some areas, multi-drug 
resistance
3
. In addition, the prevalent spreading of the disease to poor countries 
has suggested to many pharmaceutical companies to categorize malaria as a low 
priority. In this context, funds provided by public agencies, as European 
Community, are the good news of recent years. Their specific aim is to encourage 
the antimalarial research in spite of the poor economic interest. The search for 
alternative antimalarials is one of the main topics of my Ph.D. activity discussed 
in this thesis. 
 
3.2. ANTIMALARIAL ENDOPEROXIDES 
In 1972, following an activity-guided fractionation, the sesquiterpene derivative 
artemisinin (in China named qinghaosu: ―the active principle of qinghao‖) was 
isolated from Artemisia annua (Compositae). Later its structure was elucidated 
and it was shown to possess a potent antimalarial activity. This molecule soon 
appeared to constitute a major breakthrough in the antimalarial therapy because 
of: 1) its nanomolar activity on chloroquine-resistant P. falciparum strains (higher 
than the activity on chloroquine-sensitive ones) even on cerebral malaria; 2) its 
fast action; 3) the absence of detectable toxicity at therapeutic doses. 
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Artemisinin (41) is a structurally complex cadinane sesquiterpene lactone bearing 
an endoperoxide group embedded in a 1,2,4-trioxane ring. Since the relatively 
efficient totally synthetic routes developed
 
will very unlikely supplant the natural 
source, an intense scientific activity has been carried out entailed to the chemical 
derivatization of artemisinin. The aim was to obtain compounds with better 
solubility, higher stability, and possibly devoid of the neurotoxic side effects 
detected for the natural molecule. These efforts soon resulted in the recognition 
that the endoperoxide linkage is an essential feature for antimalarial activity, 
given that the acyclic diol and the ether (1,3-dioxolane) analogues of artemisinin 
were completely devoid of activity. Consequently, the lactone group became the 
main site for chemical variations that bore the preparation of the oil-soluble 
artemether (42) (Fig. 3.3), and the water-soluble artesunate (43). Although these 
molecules are now used for treatment of severe malaria with the support of the 
World Health Organization, unfortunately, they still possess neurotoxic activity
4
. 
An essential requirement to design optimized artemisinin derivatives would be a 
perfect knowledge of the mechanism of its antimalarial activity. Unfortunately, 
still today our knowledge appears incomplete. Artemisinin (or its analogues) 
should interact, within the parasite food vacuole, with the Fe(II) center of the 
heme unit released during the digestion of hemoglobin. The interaction of 
artemisinin with the heme ferrous iron would cause the cleavage of the peroxide 
bridge and the formation of alkoxy radicals that, after several rearrangements, 
would result in the formation of free C-centered radicals (Figure 3.5).  
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Figure 3.5. A schematic view of the postulated mechanism of action of 
artemisinin (41). 
These should be toxic to the parasite because they should alkylate not better 
defined ―sensitive‖ macromolecular targets. This hypothesis is based on the 
evidence that, in several experimental models, artemisinin (41) reacts with iron 
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ions and, in particular, it interacts strongly with hemin (ferriprotoporphyrin IX) 
and its ferrous form (ferroprotoporphyrin IX) to give covalent adducts.
5
  
Further experiments would be required to gain more insights into the mechanism 
of action of the endoperoxide-containing antimalarial agents. The isolation of 
different antimalarial endoperoxides from natural sources can evidently help in 
this task. A large number of cyclic peroxides have been isolated from marine 
organisms and some of them have been tested for antimalarial activity.  
Marine sponges belonging to the family Plakinidae contain a series of simple 
endoperoxide derivatives that have been identified as polyketide metabolites 
possessing six- or five-membered 1,2-dioxygenated rings (1,2-dioxane or 1,2-
dioxolane, respectively). A further variation is represented, in some cases, by the 
presence of a 3-methoxy substitution, building a peroxyketal group. The parent 
compound of this group of secondary metabolites is plakortin (44) (Fig. 3.6), that 
was isolated more than 25 years ago from Plakortis halichondroides. This 
interesting secondary metabolite, whose polyketide skeleton suggests the 
involvement of butyrate units in the biogenesis, has been recently re-isolated in 
remarkable amounts from the Caribbean sponge Plakortis simplex,
6
 along with a 
related analogue, named dihydroplakortin (45), (Fig. 3.6). 
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Figure 3.6. Chemical structures of plakortin (44) and dihydroplakortin (45) 
At the time of its first isolation, plakortin was found to be a weak antibacterial 
agent, but a recent study has finally disclosed the antimalarial potential of this 
molecule.
7
 Using the pLDH assay, plakortin (44) and dihydroplakortin (45) were 
assayed against D10, chloroquine-sensitive strain, and W2, chloroquine-resistant 
strain of P. falciparum. The two compounds showed a good activity, that was 
more potent on the W2 strain (IC50 = ab. 250 ng/mL on D10; ab. 180 ng/mL on 
W2). In addition, the two compounds proved to be non-cytotoxic in vitro.  
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Interestingly, in the same investigation
7
 the structurally related, even more 
sterically hindered, five-membered endoperoxide plakortide E (46) (Fig. 3.7) was 
found to be inactive.  
O
O COOCH3
46  
Figure 3.7. Chemical structure of the inactive plakortide E (46) 
 
The chemical structure of these antimalarial leads is remarkably simple and thus 
they could constitute a good probe to establish structure-activity relationships, to 
check the currently postulated mechanisms of action for antimalarial peroxides 
and to prepare semi-synthetic or totally synthetic derivatives. In this area, my 
research group has launched a multidisciplinary investigation (including 
computational and experimental studies) on natural analogues
8,9
 and semi-
synthetic derivatives
10 
that
 
provided some valuable insights about the SARs 
needed for the antimalarial activity of these simple 1,2-dioxanes. These results 
unambiguously indicated the crucial role of the endoperoxide functionality, 
suggested the importance of the ―western‖ alkyl side chain and revealed 
conformation-dependent features critical for antimalarial activity.
10
 
In addition, in a recently reported investigation based on a combined chemical and 
computational approach,
11
 my research group proposed that molecules belonging 
to the plakortin family, upon interaction with Fe(II) undergo a dissociative 
electron transfer (DET) of the endoperoxide bond giving rise to an oxygen-
centered radical. This latter is simultaneously transferred by a ―through space‖ 
1,4- (1) or 1,5- (2) intramolecular radical shift to a western side chain carbon atom 
which, through a radical cascade, leads to the putative toxic species for the 
Plasmodium environment (Scheme 3.1). 
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Scheme 3.1. Proposed antimalarial mechanism of action of plakortin (44) and 
dihydroplakortin (45). 
An indirect support to this mechanism comes from the inactivity of those 
plakortin analogues which experience steric problems to the accessibility of 
reactive iron species to the endoperoxide oxygens (as manadoperoxides), as well 
as from the very low activity of those plakortin analogues for which the 
orientation of reaction partners does not allow the intramolecular radical shift. 
Further information on the structure-activity relationships come from data on 
synthetic and natural 3-alkoxy-1,2-dioxene and 3-alkoxy-1,2-dioxane (both 
peroxyketals) derivatives, which were shown to possess a very good antimalarial 
activity (peroxyplakoric B3 ester, Fig. 3.8, IC50 = 0.12 μM).  
O
O
COOCH3
OCH3
H
CH347  
    Figure 3.8. Chemical structures of peroxyplakoric acid B3 (47) methyl ester.  
Recently, four new peroxyketal polyketides, named manadoperoxides A-D
12
 (48-
51) (Fig. 3.9), were obtained from the organic extract of a specimen of Plakortis 
sp. collected in the Bunaken Marine Park of Manado (North Sulawesi, Indonesia).
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Figure 3.9.  Chemical structures of manadopreoxides A (48), B (49), C (50) and 
D (51). 
These endoperoxide derivatives 48-51 has a moderate antimalarial activity (low 
μM range) against both CQ-R and CQ-S P. falciparum clones (manadoperoxide B 
IC50 = 6.76 μM).
 
The modest antimalarial activity of manadoperoxides is 
particularly surprising for example upon comparison of manadoperoxide B (49) 
with peroxyplakoric B3 ester
13
 (47).
 
In spite of the very small structural 
differences (a methyl group linked at C-2, in 47, in place of C-4, in 49), 
compound 47 exhibited a 56-times higher in vitro antimalarial activity compared 
to 49. This unexpected difference should be caused by the presence of a methyl at 
C-4 on the dioxane ring of manadoperoxides, that induces a preferential chair B 
conformations where two groups are in axial positions. This implies that the 
approach of manadoperoxides to heme iron is complicated (if not prevented) by 
the orientation of groups on the dioxane ring (Fig.3.10).
12
  
Figure 3.10. In manadoperoxides the endoperoxide bond in Chair B (85% pop.) is  
not accessible to heme iron or the evolution of the radical is not possible (Chair A, 
5% population) .   
Chair A Chair B 
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The acquired information suggested that the essential pharmacophoric 
requirements for antimalarial activity should include: i) a 1,2 dioxane ring able to 
react with Fe(II) species through its endoperoxide group forming an oxygen 
radical, ii) a side-chain bearing possible partners for a ―through-space‖ 
intramolecular radical shift to a carbon atom, iii) configurational and 
conformational features which allow accessibility of iron to 1,2-dioxane oxygens 
as well as the correct orientation of all the intramolecular reaction partners, iv) 
iron interacting with additional functionalities that favours the approach to heme 
without interfering with the redox reaction and v) the ability of the generated 
carbon radical to propagate via intermolecular reactions (Fig. 3.11).  
 
 
 
Figure 3.11. Plakortin (44, C atoms, green; O atoms, red) and Dihydroplakortin (45, 
C atoms, yellow; O atoms, red) pharmacophores. 
 
Basing on these information now available for plakortin antimalarials, in this 
thesis I report a synthesis  of a new chemotype of antimalarial agents based on the 
simple, monocyclic 1,2-dioxane scaffold. Ideally, this simplified structure could 
allow an efficient chemical synthesis, amenable to large-scale preparation of new 
antimalarials at low costs. As suggested by the Target Product Profile (TPP) 
published by Medicine for Malaria Venture (MMV) in September 2010, 
cheapness is a crucial requirement for antimalarial drugs of the next generation. 
According to MMV, a likely clinical candidate should have oral activity with 
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SERC (single exposure radical cure) and a cost treatment of less than 1$ for 
uncomplicated malaria.
14
 Taking into account the developed pharmacophore 
model (Fig. 3.11), in the following paragraph I report the design, the synthesis, 
the biological evaluation, and the 3D-SAR studies for a novel series of 1,2-
dioxane antimalarials obtained by means of an efficient one-pot three-component 
Mn(III)-mediated synthesis which utilizes cheap starting materials. The obtained 
molecules are 3,6,6-trisubstituted 3-methoxy-1,2-dioxanes with simple alkyl 
chains and bearing an ester group at position 4, which were tested against Pf.  
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3.3. SYNTHESIS OF SIMPLIFIED ANTIMALARIAL 
ENDOPEROXIDES  
In the last few decades, a large number of synthetic endoperoxides (1,2-
dioxolanes and 1,2-dioxanes),
15
 1,2,4-trioxolanes,
16
 1,2,4-trioxanes
17
 and 1,2,4,5-
tetraoxanes
24-25
 have been synthetized and studied as potential antimalarial drugs 
for treatment of chloroquine (CQ) resistant Pf infections. The current status of 
synthetic peroxides inspired by artemisinin and other naturally occurring 
peroxides has been examined in recent review articles.
18
 
In 1990, Nishino and co-workers reported a seminal research work on the 
synthesis of 1,2-dioxane-3-ol scaffolds (54) by the manganese(III) acetate-
promoted formal [2+2+2] cycloaddition of activated methylene compounds (i.e. 
β-ketoesters 52), olefins (53) and molecular oxygen19 a reaction first reported in 
1989 to proceed under electrochemical oxidation conditions or by AIBN-
promoted radical cascade.
20 
In collaboration with the research group of prof. 
Trombini, at the University of Bologna, my research group has optimizied the 
Nishino conditions to obtain the synthesis of 1,2-dioxane-3-ols as depicted in 
Scheme 3.2.
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Scheme 3.2. Manganese(III) acetate-promoted synthesis of 1,2-dioxane-3-ols 54 
 
The formal catalytic cycle is based on the key generation of enol radicals A by 
oxidation of 52 using Mn(III) acetate, as depicted in Scheme 3.3.
21
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Scheme 3.3. Formal catalytic cycle for the Mn(III) acetate-promoted synthesis of 
1,2-dioxane-3-ols 54 
In terms of structural versatility and flexibility, 1,2-dioxane 54 exhibits three 
interesting features: i) substituents R
1
-R
4
 can be varied as a result of a rational 
choice of the -ketoester 52 and the alkene component 53; ii) the ester attached at 
C-4 offers manifold opportunities for chemical transformations (reductions, amide 
formation, etc), and finally, iii) the hemiketal group on C-3 can be converted into 
the corresponding ketal 55 upon incorporation of a suitable alcohol (R
5
OH, 
Scheme 3.2). Reactions are carried out in glacial acetic acid at room temperature. 
Manganese(III) acetate is insoluble in acetic acid at room temperature but, in the 
presence of an activated methylene compound, it gradually dissolves, suggesting 
the formation of a new Mn(III) complex by ligand exchange. The in situ generated 
Mn(III)-enolate rapidly collapses into the electrophilic carbon radicals A by single 
electron transfer from the electron-rich carbon–carbon double bond to Mn(III). 
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When the reaction is carried out at room temperature in the presence of an olefin 
(typically a gem-disubstituted alkene) and molecular oxygen, A adds first to the 
alkene providing the nucleophilic carbon centered radical B, which then takes up 
oxygen dissolved in acetic acid to produce C. A new one-electron transfer from 
Mn(II) to C restores Mn(III) and generates the hydroperoxy anion D, that rapidly 
collapses to E by ring-chain tautomerism. Acidic quenching by acetic acid affords 
the target 1,2-dioxane-3-ol 54, restoring Mn(III) acetate in solution. The 
electronic properties of the intermediate free-radicals determine the order of the 
radical cascade, and reduce the side-reactions such as the homocouplings of A and 
C, as well as the combination of molecular oxygen, an electrophilic bi-radical, 
with the electrophilic enol radical A. This catalytic process has been reported to 
work efficiently with 1,1-diarylethenes, affording remarkable yields of the 
expected cycloadducts. Considerably lower are the conversions reported with 
gem-disubstituted aliphatic alkenes. In principle, with this family of alkenes, off-
cycle redox reactions can have a significant impact on the final yields in 1,2-
dioxane-3-ol 54. For example, free-radical B may be over-oxidized by Mn(III) to 
carbenium ion that stabilizes upon cyclisation to dihydrofuran 56 (Scheme 3.4). 
Finally, alkene itself may be oxidized by Mn(III) in acetic acid, thus contributing 
to the presence of side-products together with homo-coupling reactions. 
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Scheme 3.4. Manganese(III) acetate promoted over-oxidation of carbon-radical B 
to dihydrofuran 56 
After several optimization runs, the best experimental conditions in terms of 
yields and purity of the products were reached by using: i) a catalytic amount of 
Mn(III) acetate (10 mol %), ii) a stoichiometric amount of Mn(II) acetate, iii) a 
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3:1 molar ratio between the β-ketoester 52 and the alkene 53, and iv) oxygen at 
atmospheric pressure in acetic acid as solvent at room temperature. In all cases, 
the examined products were obtained in fair to good isolated chemical yields (39-
89%). In the case of symmetrically di-substituted (R
3
 = R
4
) alkenes 53, a single 
diasteroisomer of the product 54 was identified in the crude reaction mixture and 
isolated by flash-chromatography, possessing the hydroxyl group at C-3 and the 
carbomethoxy at C-4 in the cis stereo-relationship and adopting a preferred 
conformation with the hydroxyl group in the axial position. This was determined 
through complete assignment of 
1
H NMR resonances followed by interpretation 
of cross-peaks in the 2D NMR ROESY spectrum (correlations H-4/alkyl group at 
C-6; H-4/alkyl group at C-3) (Fig. 3.12). On the other hand, when non-
symmetrically disubstituted alkenes were used, only two of the four possible 
diastereoisomers were obtained and isolated, again possessing a fixed 3,4-cis 
stereo-relationship, but differing for the configuration at C-6 (Fig. 3.12). The 
preferential formation of 3,4-cis stereoisomers was already noticed by Nishino
19-21
 
and it is likely the consequence of the stereospecific attack of the hydroperoxy 
oxygen at the ketone group, determined by the configuration at C-4.  
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Figure 3.12. Most stable conformers of the products isolated from Mn(III) 
acetate-promoted cycloaddition 
 
All the intermediate 1,2-dioxane-3-ols were tested for their in vitro antimalarial 
activity against both chloroquine-sensitive (D10) and chloroquine-resistant (W2) 
Pf strains, and all resulted completely inactive (IC50 > 30 μM). This result was not 
surprising since a very low antimalarial activity has already been reported for 
other hemiketal endoperoxides.
22
 Thus, the 1,2-dioxane-3-ols were transformed 
into the corresponding methyl ketal derivatives 57-63. The ketalization reaction 
proved to be less easy than hoped and, after screening several different reaction 
conditions, we found the best results in terms of yields by using camphorsulfonic 
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acid (CSA) as the promoter in the presence of methyl-orthoformate at room 
temperature for 72 hrs.  
According to this procedure, 1,2-dioxanes 57-63 were prepared (Fig. 3.13) which 
show different permutations of R
1
, R
3
 and R
4
 substituents, corresponding mainly, 
but not exclusively, to methyl- or n-butyl groups.  
 
 
Figure 3.13. (+) 1,2-Dioxanes 57-63. 
 
When the reagent mixture consisted of a single diastereomer (see Table 3.1), two 
diasteromeric products were isolated, deriving from a partial epimerization at C-3 
during the ketalization process, with diastereoselecivities in the 50:50 – 70:30 
range, in favor of the 3,4-cis adduct. When a mixture of two diasteromeric 1,2-
dioxane-3-ols 54 was used (see Table 3.1) a more complex mixture of 
diasteromers was isolated, but the same stereochemical trend was observed. Table 
3.1 summarizes conditions and results of the synthesis of methyl ketals 57-63. Of 
course, all the compounds shown in figure 3.13 and reported in Table 3.1 have 
been obtained as racemic mixtures. 
 
 
 
83 CHAPTER III  -  Isolation and synthesis of new antimalarial compounds 
 
Table 3.1.Synthesis of methyl ketals 57-63
a
  
Substituents 
Comp. 
54, 
Yield 
(%) 
Diastereomeric 
ratio of 54 
Methyl ketals 
57-63,  
Yield (%) 
Diastereomeric 
ratio of  57-63 
(3,4 cis / trans) 
R1 = R3 = R4 = CH3  89 
3,4-cis (100%) 57 (81%) 70:30 
R1 = Et   R3 = R4 = CH3
 
39 
3,4-cis (100%) 
58 (48%) 70:30 
R1 = Bu R3 = R4  = CH3
 
65 
3,4-cis (100%) 59a-59b 
(69%) 
 70:30 
R1 =  R3 = CH3 R
4 = Bu
 
 
54 
3,4-cis-4,6-cis 
(50%) 
60a-60c 
(40%) 
60:40 
3,4-cis-4,6-
trans (50%) 
60b-60d 
(40%) 
60:40 
R1 = R3 =Bu R4 = CH3  
 
64 
3,4-cis-4,6-cis 
(50%) 
61a-61c 
(30%) 
60:40 
3,4-cis-4,6-
trans (50%) 
61b (30%) >95:5
b 
R1 =CH3 R
3 = R4 =Bu  71 
3,4-cis (100%) 62a-62b 
(73%) 
60:40 
R1 =R3 = R4 =Bu  53 
3,4-cis (100%) 63a-63b 
(44%) 
50:50 
a  
Conditions: CSA (5.0 equiv.), methylorthoformate (2 equiv.), MeOH (0.14 M), RT for 72 h. 
b
 The 
minor 3,4-trans-4,6-trans stereoisomer was not detected nor isolated. 
 
All the diastereomeric mixtures were separated by gravity column 
chromatography followed by direct phase HPLC; then complete NMR 
assignments were obtained on the isolated diastereomers through 2D NMR 
spectroscopy (COSY, HSQC, HMBC experiments). Finally, the relative 
configuration around the six-membered ring was determined for each compound 
through inspection of the 2D NMR ROESY experiments. For example, the 
ROESY cross-peaks of H-4 (δ 3.07) with H2-1‘‘ (δ 1.83 and 1.70) and of H-5ax (δ 
2.23) with Me-6 (δ 1.16) and with OMe-3 (δ 3.31) were used to infer the relative 
configuration of compound 60b (Fig. 3.14). 
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Figure 3.14 Determination of relative configuration for compound 60b through 
ROESY correlations. 
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To overcome the partial isomerization at C3 in the acid-catalyzed ketalization 
step, we attempted a different approach to 55 treating 54 with a strong base in 
THF, in the presence of an excess of CH3I. Surprisingly, under these conditions 
no trace of methylketals was detected, on the contrary methylation at C4 did 
occur, only. 
 
3.3.1. In vitro antimalarial activity 
The 1,2-dioxane-3-O-methyl derivatives 57-63 have been tested for their in vitro 
antimalarial activity against both CQ-S (D10) and CQ-R (W2) Pf strains by prof. 
Taramelli at the University of Milan. Results summarized in Table 3.2 show that 
most of these compounds have antimalarial activity in the low μM range. In 
addition, all the compounds showed activity against the CQ-R strain higher than 
against CQ-S strain.  
 
Table 3.2. Antimalarial activity of methyl-ketals 57-63 against chloroquine-
sensitive (D10) and chloroquine-resistant (W2) P. falciparum strains. 
Compound D10 IC50 
 (µM)
a
 
W2 IC50  
(µM)
 a
 57 > 30 > 30 
58 > 30 > 30 
59a 3.7 ± 0.2 1.5 ± 0.5 
59b > 30 > 30 
60a 8.5 ± 3.8 4.9 ± 1.7 
60b 12.6 ± 6.0 11.8 ± 2.2 
60c 17.7 ± 4.0 8.4 ± 2.9 
60d 17.7 ± 2.9 6.4 ± 1.4 
61a 4.2 ± 1.0 1.5 ± 0.4 
61b 2.6 ± 0.2 1.3 ± 0.2 
61c 12.3 ± 1.7 5.0 ± 1.1 
62a 7.4 ± 1.1 2.5 ± 0.7 
62b 2.6 ± 0.7 0.8 ± 0.3 
63a 2.9 ± 0.6 1.2 ± 0.2 
63b 2.3 ± 0.6 1.2 ± 0.3 
Chloroquine 0.029±0.012 0.52 ± 0.02 
44
b
 0.9 ± 0.4 0.4 ± 0.1 
a  
Data are means ± SD of three different experiments in duplicate. 
b
 Data from Ref. 11. 
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When tested for cellular cytotoxicity against a human endothelial cell line, 
HMEC-1, compounds 59a, 61b, 62b and 63a were not toxic (Table 3.3) with a 
therapeutic index ranging from 90 to 250 (calculated on CQ-R strains). These 
results, although incomplete, suggest that this class of compounds is suitable for 
further development. 
 
Table 3.3 Citotoxicity on human microvascular endothelial cell line HMEC-1. 
Compound IC50 (µM)
a
 
59a > 384  
61b 167.3 ± 24.7 
62b 98.3 ± 4.1  
63a 107.9 ± 10.8 
a 
Data are means ± SD of three different experiments in duplicate. 
 
3.3.2. Reaction with Fe(II) chloride  
The exact molecular mechanism underlying the biological activity of artemisinin 
and that of related antimalarial endoperoxides is still a matter of debate. The 
interaction with Fe(II)-heme, and the consequent oxidative stress in the 
plasmodium are believed to play a major role in this bioactivity.
 
It has been 
proposed that the reaction of endoperoxides with Fe(II) involves a one-electron 
reduction leading to the cleavage of the oxygen-oxygen bond with the consequent 
formation of an oxygen anion bound to iron and of an oxygen free radical. Two 
possible evolutions of the generated oxygen radical have been postulated for 
artemisinin (Scheme 3.5), principally on the basis of theoretical studies
23
 and of 
model reactions in vitro with heme or with Fe(II) inorganic salts,
24
 which were 
used to mimic the antimalarial mechanism of action. In pathway 1, the oxygen O1 
radical evolves through an intramolecular 1,5-H shift leading to a secondary 
carbon radical, while, alternatively, in pathway 2, the oxygen O2 radical evolves 
through a homolytic carbon-carbon cleavage of the C3-C4 bond.  
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Scheme 3.5. Schematic representation of the artemisinin (41) postulated 
mechanism of action. 
Assuming that reaction with Fe(II)-inorganic salts could give interesting 
information also in the case of the methyl ketal endoperoxides 57-63, we selected 
three of them (58, 59b and 61b), on the basis of the diversity of their structural 
and bioactivity features, as test compounds to carry out the reaction. Thus, 
compound 61b was allowed to react with FeCl2 (5 equiv.) in CH3CN/H2O 4:1 at 
r.t. for 2 hours, and chromatographic purification of the reaction mixture, afforded 
as major products unreacted 61b and the lactone 64 (Scheme 3.6), whose 
stereostructure has been identified by detailed spectroscopic investigation. When 
compounds 58 and 59b were allowed to react with FeCl2 in the same conditions 
both of them efficiently produced the same lactone 65 (Scheme 3.6).  
 
Scheme 3.6. Reaction of compounds 61b, 58 and, 59b with FeCl2. 
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The formation of compounds 64 and 65 can be rationalized through the 
mechanism shown in Scheme 3.7. Upon interaction with Fe(II) ion, the 
endoperoxide bond would be cleaved with regioselective formation of the oxygen 
radical at O2. Through the expulsion of a butyl (or ethyl) radical, this unstable 
intermediate would give rise to the methyl ester, which would then collapse into 
the final lactone.  
The results of in vitro reaction of 58, 59b, and 61b with FeCl2 would indicate 
carbon-carbon cleavage pathway as responsible for bioactivity. This is in perfect 
agreement with results described by Kobayashi and co-workers
25 
for 
peroxyplakortic derivatives, natural methyl ketal endoperoxides bearing some 
structural relationships with compounds 57-63.
 
Following Scheme 3.7, the in vitro 
activity of these compounds should be ascribed to the toxic action on parasite 
environment exhibited by the alkyl radicals released by means of the homolytic 
carbon-carbon cleavage. However, this mechanistic hypothesis does not agree 
with results obtained for compounds 58, 59b and 61b. Indeed, the fact that the 
active (e.g. 61b, Table 3.2) and inactive (e.g. 58 and 59b, Table 3.2) compounds 
gave, with similar efficiency, the same primary carbon (59b and 61b) or strictly 
related (58) one, is an unambiguous evidence of the lack of any direct correlation 
between the observed carbon-carbon cleavage reactions and the antimalarial 
activity. 
 
 
Scheme 3.7. Mechanism postulated for the formation of compounds 64 and 65.  
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These conclusions are in agreement with structure-activity relationship (SAR) 
studies reported for artemisinins (41) as well as for other endoperoxide 
derivatives,
 
failing to relate the favoured in vitro carbon-carbon cleavage pathway 
with antimalarial activity, which is, instead, related to the intramolecular H-shift 
mechanism. Thus, in the 3-methoxy-1,2-dioxanes 57-63, where both mechanisms 
(H-shift and carbon-carbon cleavage) can operate, the model reaction with FeCl2 
does not meet with the in vivo outcome of the reaction. In this scenario, a separate 
case is represented by non-ketal monocyclic endoperoxides, as plakortins, where 
the carbon-carbon cleavage mechanism does not occur
11
 (see Scheme 3.1), likely 
due to the lack of the driving force conferred by the formation of the stable ester 
group (see Scheme 3.7). Indeed, the reaction of plakortins with FeCl2 evidenced 
exclusively the ―through space‖ intramolecular shift of the oxygen radical,11 
accounting for the observed SARs of plakortins and related non-ketal monocyclic 
endoperoxides. 
 
As we will discuss in the next paragraph, also in the case of 57-63, an 
intramolecular radical shift mechanism can well explain the marked difference of 
activity exhibited by very similar compounds (e.g. 58 and 59a) or even by 
diastereoisomers (e.g. 59a and 59b), giving an overall rationale for all the SARs 
of this series of compounds. 
3.3.3. Structure-Activity Relationship Studies 
An extensive molecular modelling study, including molecular mechanic (MM), 
dynamics (MD), and density functional theory (DFT) calculations, has been  
undertaken by the group of prof. C. Fattorusso to analyze 57-63 structure-activity 
relationships (SARs) (see the Experimental Section for details). Since this part of 
the project has not been carried out in our laboratories, I will report only the most 
significant results. 
As discussed in the previous paragraph, results obtained for compounds 58, 59b, 
and 61b indicated that the antimalarial activity does not relate with the carbon-
carbon cleavage observed in vitro upon their reaction with FeCl2 (Schemes 3.6 
and 3.7). Therefore, the newly designed compounds were subjected to an in-depth 
computational analysis taking into account the ―through space‖ radical shift 
mechanism already reported for plakortins (Scheme 3.1). A simulated annealing 
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procedure followed by molecular mechanics (MM) energy minimization and 
semi-empirical PM6 full geometry optimization was applied. Low energy 
conformers (within 5 kcal/mol from the global minimum) were then classified and 
filtered on the basis of their: i) 1,2-dioxane ring conformation, ii) distance of 
endoperoxide oxygens from a putative partner for an 1,5- or 1,4-intra-molecular 
radical shift, and iii) endoperoxide oxygens lone pairs steric accessibility (see 
Tables 5.1 and 5.2 in the Chapter V). The lowest energy conformers of each 
compound respecting the assumed pharmacophoric requirements were subjected 
to dynamic docking studies in complex with heme. Resulting structures, again 
checked for their pharmacophoric features, represented putative bioactive 
conformations and were then subjected to DFT calculations.  
First, a structural analysis revealed that the electronic repulsion between the ester 
carbonyl oxygen and the endoperoxide oxygen O2 (for atom numbering see 
Figure 3.14), along with the steric repulsion between C-3 and C-4 substituents, 
drive the conformational preference of the 1,2-dioxane ring. Consequently, in 
agreement with NMR data, all compounds showed a definite conformational 
preference for one ring chair conformation, named Chair A, characterized by the 
equatorial position of the ester substituent at C-4 (Table 5.1). On the other hand, 
the steric repulsion between C-3 and C-6 substituents (Figure 3.15a) strongly 
reduced the rate of low energy conformers presenting intramolecular distances 
suitable for the 1,5-H shift (Table 5.2).  
 
Figure 3.15. PM6 conformers of 10a presenting intramolecular distances suitable 
for the 1,5-H shift (a) and 1,4-H shift (b). Atoms numbering is referred to the 
distance between H-shift possible partners. van der Waals volumes of the 
hydrogens responsible for steric hindrance between C-3 and C-6 substituents (a) 
are shown. Atoms are colored by atom type. 
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All the analyzed compounds presented a significant rate of low energy conformers 
able to undergo a 1,4-H shift from C3 and/or C6 alkyl chains to the oxygen radical 
(Table 5.2 and Figure 3.15b). The only exception is, of course, represented by 
compound 57 which possesses only methyl substituents at C3 and C6, while 
compound 58 could undergo a 1,4-H shift but only forming a primary carbon 
radical.  
All the computational investigations concur to suggest that the ability to form a 
carbon centred radical on the alkyl chain installed on C3 and/or C6 of compounds 
57-63, is related to their antimalarial activity. Computational and SAR studies 
suggest that, as in the case of plakortins, the putative toxic carbon radical species 
is formed through an intramolecular hydrogen shift. The presence of the methoxy 
group at C3 drives radical formation resulting in stricter stereochemical 
requirements for antimalarial activity compared to plakortins. Nevertheless, our 
study demonstrated that, according to the hypothesized mechanism of action, the 
antimalarial activity can be improved through rational structural modifications, 
thus disclosing the antimalarial potential of the new 3-methoxy-1,2-dioxane 
scaffold, obtained by means of an efficient and cheap two-pot Mn(III)-mediated 
synthesis. As an example, compound 62b, bearing two n-butyl substituents at C6, 
showed antimalarial activity against CQ-R strains comparable to plakortin and no 
significant toxicity against HMEC-1 cells. 
 
3.3.4. Experimental  
Synthesis of 3-hydroxy-1,2-dioxanes 54. General procedure. The appropriate 
alkene (1 mmol) is added at room temperature to a mixture of the desired β-
ketoester (3 mmol), Mn
III
(OAc)3·2H2O (0.1 mmol, 0.027 g) and 
Mn
II
(OAc)2·4H2O (1 mmol, 0.245 g) in acetic acid (5 mL). In the case of gaseous 
isobutylene (2-methylpropene), an excess of alkene was bubbled at -10 °C to a 
mixture of the desired β-ketoester (3 mmol), MnIII(OAc)3·2H2O (0.1 mmol, 0.027 
g) and Mn
II
(OAc)2·4H2O (1 mmol, 0.245 g) in acetic acid (5 mL). The resulting 
heterogeneous solution was stirred at room temperature for 18-24 h under oxygen 
at atmospheric pressure (O2 filled balloon) and the conversion was monitored by 
TLC. The reaction mixture was neutralized with stoichiometric NaOH (3 M 
aqueous solution) and then made slightly basic with a saturated NaHCO3 solution. 
The aqueous phase is extracted with CH2Cl2 (3 x 10 mL) and the combined 
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organic phases are dried (Na2SO4) and evaporated to dryness. The intermediate 3-
hydroxy-1,2-dioxanes 54 are purified by flash-chromatography on silica gel 
eluting with cyclohexane:ethyl acetate mixtures. 
Synthesis of 3-methoxy-1,2-dioxanes 57-63. General procedure. (1S)-(+)-
Camphorsulfonic acid (5 mmol, 1.16 g) was added at room temperature to a 
solution of the desired 1-hydroxy-1,2-dioxane 54 (1 mmol) and 
trimethylorthoformate (2 mmol, 0.22 mL) in anhydrous methanol (7 mL), and the 
solution was stirred at room temperature for 72 h. The reaction was quenched at 0 
°C with saturated NaHCO3 solution and the aqueous phase is extracted with 
CH2Cl2 (3 x 10 mL). The combined organic phases are dried (Na2SO4) and 
evaporated to dryness. 3-Hydroxy-1,2-dioxanes 57-63 are isolated after flash-
chromatography on silica gel by elution with cyclohexane:ethyl acetate mixtures. 
Compound 57.  ESI-MS: m/z 241 [M + Na]
+
; HR-ESIMS: m/z 241.1059 (calcd for 
C10H18NaO5 241.1052).
 1
H NMR (500 MHz): δ 3.72 (s, COOMe), 3.32 (s, OMe-
3), 2.86 (dd, J = 12.9, 4.9 Hz, H-4), 2.26 (t, J =  12.9 Hz, H-5a), 1.59 (dd, J =  
12.9, 4.9 Hz, H-5b), 1.47 (s, Me-3), 1.36 (s, Me-6ax), 1.21 (s, Me-6eq).
 13
C NMR 
(125 MHz): δ 171.3 (COOMe), 100.4 (C-3), 77.1 (C-6), 51.9 (COOMe), 49.1 
(OMe-3), 45.7 (C-4), 32.7 (C-5), 27.2 (6-Me), 22.3 (6-Me), 19.6 (3-Me). 
Compound 58.  ESI-MS: m/z 255 [M + Na]
+
; HR-ESIMS: m/z 255.1212 (calcd for 
C11H20NaO5 255.1218).
 1
H NMR (500 MHz): δ 3.80 (s, COOMe), 3.31 (s, OMe-
3), 3.10 (dd, J =  12.9, 4.9 Hz, H-4), 2.30 (t, J =  12.9 Hz, H-5a), 1.90 (q, J =  7.2 
Hz, H2-1‘), 1.59 (dd, J =  12.9, 4.9 Hz, H-5b), 1.36 (s, Me-6ax), 1.21 (s, Me-6eq), 
1.03 (t, J =  7.2 Hz, H2-2‘).
 13
C NMR (125 MHz): δ 171.4 (COOMe), 102.3 (C-3), 
77.1 (C-6), 52.0 (COOMe), 51.9 (OMe-3), 48.6 (C-4), 40.4 (C-1‘), 32.6 (C-5), 
26.8 (6-Me), 22.6 (6-Me), 8.5 (C-2‘). 
Compound 59a.  ESI-MS: m/z 283 [M + Na]
+
; HR-ESIMS: m/z 283.1517 (calcd 
for C13H24NaO5 283.1521).  
1
H NMR (500 MHz): δ 3.71 (s, COOMe), 3.31 (s, 
OMe-3), 3.08 (dd, J =  12.9, 4.9 Hz, H-4), 2.29 (t, J =  12.9 Hz, H-5a), 1.86 (m, 
H-1‘a), 1.58 (dd, J =  12.9, 4.9 Hz, H-5b), 1.34 (s, Me-6ax), 1.54 (m, H2-2‘), 1.34 
(m, H2-3‘), 1.20 (s, Me-6eq), 0.92 (t, J =  6.9 Hz, H3-4‘).
 13
C NMR (125 MHz): δ 
171.4 (COOMe), 102.3 (C-3), 65.8 (C-6), 52.0 (COOMe), 52.0 (OMe-3), 48.6 (C-
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4), 40.4 (C-1‘), 32.6 (C-5), 32.2 (C-2‘), 26.8 (6-Me), 22.6 (6-Me), 21.0 (C-3‘), 
13.5 (C-4‘). 
Compound 59b.  ESI-MS: m/z 283 [M + Na]
+
; HR-ESIMS: m/z 283.1522 (calcd 
for C13H24NaO5 283.1521).  
1
H NMR (500 MHz): δ 3.73 (s, COOMe), 3.41 (s, 
OMe-3), 3.06 (dd, J =  13.0, 5.5 Hz, H-4), 1.89 (m, H-1‘a), 1.85 (dd, J =  13.0, 5.5 
Hz, H-5a), 1.72 (t, J =  13.0 Hz, H-5b), 1.54 (m, H2-2‘),1.37 (s, Me-6ax), 1.34 (m, 
H2-3‘), 1.19 (s, Me-6eq), 0.92 (t, J =  6.9 Hz, H3-4‘).
 13
C NMR (125 MHz): δ 
173.4 (COOMe), 104.2 (C-3), 73.8 (C-6), 52.5 (COOMe), 52.0 (OMe-3), 49.3 (C-
4), 40.4 (C-1‘), 35.6 (C-5), 32.2 (C-2‘), 27.1 (6-Me), 21.6 (6-Me), 21.0 (C-3‘), 
13.5 (C-4‘). 
Compound 60a.  ESI-MS: m/z 283 [M + Na]
+
; HR-ESIMS: m/z 283.1519 (calcd 
for C13H24NaO5 283.1521). 
1
H NMR (500 MHz): δ 3.70 (s, COOMe), 3.30 (s, 
OMe-3), 2.85 (dd, J =  12.5, 6.4 Hz, H-4), 2.22 (dd, J =  12.0, 12.0 Hz, H-5a), 
1.53 (dd, J =  12.0, 6.4 Hz, H-5b), 1.50 (m, H2-1‘), 1.35 (m, H2-2‘), 1.30 (m, H2-
3‘), 1.47 (s, Me-3), 1.32 (s, Me-6), 0.93 (t, J =  6.9 Hz, H3-4‘).  
Compound 60b.  ESI-MS: m/z 283 [M + Na]
+
; HR-ESIMS: m/z 283.1529 (calcd 
for C13H24NaO5 283.1521). 
1
H NMR (500 MHz): δ 3.70 (s, COOMe), 3.30 (s, 
OMe-3), 2.84 (dd, J =  12.5, 6.4 Hz, H-4), 2.22 (dd, J =  12.0, 12.0 Hz, H-5a), 
1.80 (m, H2-1‘), 1.64 (dd, J =  12.0, 6.4 Hz, H-5b), 1.55 (m, H2-2‘), 1.30 (m, H2-
3‘), 1.45 (s, Me-3), 1.13 (s, Me-6), 0.93 (t, J =  6.9 Hz, H3-4‘).
 13
C NMR (125 
MHz): δ 171.5 (COOMe), 100.1 (C-3), 79.9 (C-6), 52.5 (COOMe), 49.1 (OMe-3), 
45.5 (C-4), 33.9 (C-1‘), 31.2 (C-5), 26.1 (C-2‘), 23.9 (Me-6), 23.1 (C-3‘), 19.5 
(Me-3), 14.7 (C-4‘).  
Compound 60c.   ESI-MS: m/z 283 [M + Na]
+
; HR-ESIMS: m/z 283.1530 (calcd 
for C13H24NaO5 283.1521). 
1
H NMR (500 MHz): δ 3.73 (s, COOMe), 3.38 (s, 
OMe-3), 2.98 (dd, J =  11.1, 6.4 Hz, H-4), 1.77 (m, H2-5), 1.59 (m, H2-1‘), 1.34 
(m, H2-2‘ and H2-3‘), 1.25 (s, Me-3), 1.12 (s, Me-6), 0.93 (t, J =  6.9 Hz, H3-4‘).
 
13
C NMR (125 MHz): δ 173.2 (COOMe), 105.7 (C-3), 82.1 (C-6), 52.5 
(COOMe), 50.3 (OMe-3), 47.3 (C-4), 39.9 (C-5), 34.4 (C-1‘), 26.1 (C-2‘), 23.6 
(C-3‘), 20.6 (Me-6), 17.8 (Me-3), 14.7 (C-4‘).  
Compound 60d.   ESI-MS: m/z 283 [M + Na]
+
; HR-ESIMS: m/z 283.1512 (calcd 
for C13H24NaO5 283.1521). 
1
H NMR (500 MHz): δ 3.73 (s, COOMe), 3.38 (s, 
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OMe-3), 2.98 (dd, J =  13.8, 3.8 Hz, H-4), 1.89 (dd, J =  14.0, 3.4 Hz, H-5a), 1.69 
(dd, J =  14.0, 12.5 Hz, H-5b), 1.45 (m, H2-1‘), 1.32 (s, Me-6), 1.29 (m, H2-2‘ and 
H2-3‘), 1.26 (s, Me-3), 0.89 (t, J =  6.9 Hz, H3-4‘).
 13
C NMR (125 MHz): δ 172.8 
(COOMe), 105.7 (C-3), 82.1 (C-6), 52.0 (COOMe), 50.3 (OMe-3), 46.9 (C-4), 
36.3 (C-5), 33.4 (C-1‘), 26.0 (C-2‘), 23.4 (C-3‘), 20.6 (Me-6), 17.1 (Me-3), 14.3 
(C-4‘).  
Compound 61a.  ESI-MS: m/z 325 [M + Na]
+
; HR-ESIMS: m/z 325.2000 (calcd 
for C16H30NaO5 325.1991). 
1
H NMR (500 MHz): δ 3.71 (s, COOMe), 3.31 (s, 
OMe-3), 3.07 (dd, J =  12.9, 4.5 Hz, H-4), 2.23 (t, J =  12.9 Hz, H-5a), 1.85 (m, 
H-1‘a), 1.80 (m, H-1‘‘a), 1.79 (m, H-1‘a), 1.70 (m, H-1‘‘b), 1.62 (overlapped, H-
5b), 1.59 (m, H2-2‘ and H2-2‘‘), 1.34 (m, H2-3‘ and H2-3‘‘), 1.30 (s, Me-6), 0.93 
(t, J =  6.9 Hz, H3-4‘ and H3-4‘‘).  
Compound 61b.  ESI-MS: m/z 325 [M + Na]
+
; HR-ESIMS: m/z 325.1987 (calcd 
for C16H30NaO5 325.1991). 
1
H NMR (500 MHz): δ 3.71 (s, COOMe), 3.31 (s, 
OMe-3), 3.07 (dd, J =  12.9, 4.5 Hz, H-4), 2.23 (t, J =  12.9 Hz, H-5a), 1.92 (m, 
H-1‘a), 1.83 (m, H-1‘‘a), 1.82 (m, H-1‘b), 1.70 (m, H-1‘‘b), 1.64 (dd, J =  12.9, 
4.5 Hz, H-5b), 1.54 (m, H2-2‘ and H2-2‘‘), 1.34 (m, H2-3‘ and H2-3‘‘), 1.13 (s, 
Me-6), 0.93 (t, J =  6.9 Hz, H3-4‘ and H3-4‘‘).
 13
C NMR (125 MHz): δ 171.5 
(COOMe), 102.0 (C-3), 79.1 (C-6), 51.8 (COOMe), 48.6 (OMe-3), 40.6 (C-4), 
34.0 (C-5), 33.9 (C-1‘), 32.5 (C-1‘‘), 31.4 (C-2‘), 29.7 (C-2‘‘), 26.1 (C-3‘), 25.8 
(C-3‘‘), 23.0 (Me-6), 14.0 (C-4‘), 13.8 (C-4‘‘).  
Compound 61c.  ESI-MS: m/z 325 [M + Na]
+
; HR-ESIMS: m/z 325.1993 (calcd 
for C16H30NaO5 325.1991). 
1
H NMR (500 MHz): δ 3.73 (s, COOMe), 3.41 (s, 
OMe-3), 3.07 (dd, J =  12.9, 4.5 Hz, H-4), 1.92 (m, H-1‘a), 1.83 (m, H-1‘‘a, H-
1‘b), 1.77 (m, H2-5), 1.70 (m, H-1‘‘b), 1.54 (m, H2-2‘ and H2-2‘‘), 1.34 (m, H2-3‘ 
and H2-3‘‘), 1.11 (s, Me-6), 0.93 (t, J =  6.9 Hz, H3-4‘ and H3-4‘‘).
  
 
Compound 62a.  ESI-MS: m/z 325 [M + Na]
+
; HR-ESIMS: m/z 325.1988 (calcd 
for C16H30NaO5 325.1991). 
1
H NMR (500 MHz): δ 3.71 (s, COOMe), 3.31 (s, 
OMe-3), 2.83 (dd, J =  12.9, 4.5 Hz, H-4), 2.21 (t, J =  12.9 Hz, H-5a), 1.82 (m, 
H-1‘‘a), 1.81 (m, H-1‘a), 1.60 (dd, J =  12.9, 4.5 Hz, H-5b), 1.60 (m, H-1‘‘b, H-
1‘b), 1.54 (m, H2-2‘ and H2-2‘‘), 1.45 (s, Me-3), 1.34 (m, H2-3‘ and H2-3‘‘), 0.91 
(t, J =  6.9 Hz, H3-4‘ and H3-4‘‘). 
13
C NMR (125 MHz): δ 171.5 (COOMe), 100.5 
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(C-3), 81.0 (C-6), 51.8 (COOMe), 49.0 (OMe-3), 45.1 (C-4), 36.1 (C-5), 31.3 (C-
1‘), 29.6 (C-1‘‘), 25.4 (C-2‘), 24.8 (C-2‘‘), 23.2 (Me-3), 19.6 (C-3‘, C-3‘‘), 14.0 
(C-4‘), 13.9 (C-4‘‘).  
Compound 62b.  ESI-MS: m/z 325 [M + Na]
+
; HR-ESIMS: m/z 325.1995 (calcd 
for C16H30NaO5 325.1991). 
1
H NMR (500 MHz): δ 3.74 (s, COOMe), 3.40 (s, 
OMe-3), 3.00 (dd, J =  13.5, 3.5 Hz, H-4), 1.84 (dd, J =  13.5, 3.5 Hz, H-5a), 1.72 
(t, J =  13.5, H-5b), 1.65 (m, H-1‘‘a), 1.60 (m, H-1‘a), 1.57 (s, Me-3), 1.45 (m, H-
1‘‘b, H-1‘b), 1.39 (m, H2-2‘ and H2-2‘‘), 1.34 (m, H2-3‘ and H2-3‘‘), 0.93 (t, J =  
6.9 Hz, H3-4‘), 0.90 (t, J =  6.9 Hz, H3-4‘‘).
 13
C NMR (125 MHz): δ 172.6 
(COOMe), 105.5 (C-3), 83.8 (C-6), 52.0 (COOMe), 49.6 (OMe-3), 46.4 (C-4), 
36.7 (C-5), 32.6 (C-1‘), 32.4 (C-1‘‘), 26.2 (Me-3), 25.4 (C-2‘), 25.2 (C-2‘‘), 23.2 
(C-3‘) 23.1 (C-3‘‘), 14.0 (C-4‘), 13.9 (C-4‘‘).  
Compound 63a.   ESI-MS: m/z 367 [M + Na]
+
; HR-ESIMS: m/z 367.2467 (calcd 
for C19H36NaO5 367.2460). 
1
H NMR (500 MHz): δ 3.71 (s, COOMe), 3.30 (s, 
OMe-3), 3.10 (dd, J =  12.9, 4.5 Hz, H-4), 2.21 (t, J =  12.9 Hz, H-5a), 1.87 (m, 
H2-1‘), 1.78 (m, H2-1‘‘, H2-1‘‘‘), 1.60 (dd, J =  12.9, 4.5 Hz, H-5b), 1.49 (m, H2-
2‘ and H2-2‘‘), 1.25 -1.35 (m, H2-2‘‘‘, H2-3‘ H2-3‘‘, H2-3‘‘‘), 0.91 (t, J =  6.9 Hz, 
H3-4‘ H3-4‘‘, H3-4‘‘‘). 
13
C NMR (125 MHz): δ 171.6 (COOMe), 102.1 (C-3), 
81.0 (C-6), 51.8 (COOMe), 48.6 (OMe-3), 44.2 (C-4), 32.9 (C-1‘), 32.6 (C-1‘‘), 
31.3 (C-5), 26.1 (C-2‘and C-2‘‘), 23.2 (Me- 3), 23.1 (C-3‘ and C-3‘‘), 13.9 (C-4‘ 
and C-4‘‘).  
Compound 63b.  ESI-MS: m/z 367 [M + Na]
+
; HR-ESIMS: m/z 367.2452 (calcd 
for C19H36NaO5 367.2460). 
1
H NMR (500 MHz): δ 3.71 (s, COOMe), 3.30 (s, 
OMe-3), 3.07 (dd, J =  12.9, 3.5 Hz, H-4), 1.85 (dd, J =  12.9, 3.5 Hz, H-5a), 1.72 
(t, J =  12.9 Hz, H-5b), 1.65 (m, H2-1‘), 1.60-1.63 (m, H2-1‘‘, H2-1‘‘‘), 1.40-1.20 
(m, H2-2‘, H2-2‘‘, H2-2‘‘‘, H2-3‘ H2-3‘‘, H2-3‘‘‘), 0.89 (t, J =  6.9 Hz, H3-4‘ H3-
4‘‘, H3-4‘‘‘).
 13
C NMR (125 MHz): δ 172.8 (COOMe), 106.1 (C-3), 83.5 (C-6), 
52.0 (COOMe), 50.0 (OMe-3), 44.2 (C-4), 36.6 (C-1‘), 36.1 (C-1‘‘), 30.5 (C-5), 
29.6 (C-2‘and C-2‘‘), 25.3 (Me- 3), 24.5 (C-3‘ and C-3‘‘), 13.8 (C-4‘ and C-4‘‘). 
Reaction of methylketals with FeCl2. Compound 61b, (12.0 mg, 0.040 mmol) was 
dissolved in CH3CN/H2O 4:1 (5 mL) and freshly purchased FeCl2.4H2O (39 mg, 
0.20 mmol) were added. The reaction mixture was left under stirring at room 
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temperature for 2 hours. Light was excluded from the reaction. Then the obtained 
mixture was partitioned between water and EtOAc. The organic phase, dried over 
Na2SO4, was purified by HPLC (SI60 n-hexane/EtOAc 85:15) affording 
compound 64 (2.7 mg, 0.0124 mmol, 31%) in the pure state. When the reaction 
was repeated with compounds 58 and 59b, in the same conditions, compound 64 
(45%  and 42% yield, respectively) was obtained.  
Compound 64. ESI-MS: m/z 237 [M + Na]
+
; HR-ESIMS: m/z 237.1100 (calcd for 
C11H18NaO4 237.1103). 
1
H NMR (500 MHz): δ 4.12 (m, H-2), 3.90 (s, 9-OMe), 
2.60 (dd, J =  11.5, 4.5 Hz, H-3a), 2.40 (dd, J =  11.5, 6.0 Hz, H-3b), 1.85 (m, H-
5a), 1.70 (m, H-5b), 1.60 (s, Me-10), 1.50 (m, H2-6), 1.30 (m, H2-7), 0.93 (t, J =  
7.2 Hz, Me-8). 
13
C NMR (125 MHz): δ 171.0 (C-1), 169.5 (COO-), 83.9 (C-4), 
51.0 (OMe), 48.5 (C-2), 38.3 (C-5), 36.6 (C-3), 23.8 (C-6), 23.5 (C-10), 23.0 (C-
7), 14.0 (C-8). 
Compound 65. ESI-MS: m/z 195 [M + Na]
+
; HR-ESIMS: m/z 195.0639 (calcd for 
C8H12NaO4 195.0633). 
1
H NMR (500 MHz): δ 3.90 (s, COOMe), 3.73 (t, J = 6.0 
Hz, H-2), 2.55 (dd, J =  11.5, 4.5 Hz, H-3a), 2.32 (dd, J =  11.5, 8.0 Hz, H-3b), 
1.53 (s, H3-5), 1.42 (s, H3-6). 
13
C NMR (125 MHz): δ 171.0 (C-1), 168.5 (COO-), 
83.7 (C-4), 51.0 (OMe), 47.7 (C-2), 38.2 (C-3), 28.3 (C-5), 27.8 (C-6).  
Molecular modeling. 
Molecular modeling calculations were performed on SGI Origin 200 8XR12000 
and E4 Server Twin 2 x Dual Xeon—5520, equipped with two nodes. Each node: 
2 x Intel® Xeon® QuadCore E5520—2,26Ghz, 36 GB RAM. The molecular 
modeling graphics were carried out on SGI Octane 2 workstations.  
Estimation of apparent pKa values of the newly designed compounds 57-63 were 
calculated by using the ACD/pKa DB version 12.00 software (Advanced 
Chemistry Development Inc., Toronto, Canada). All compounds were considered 
neutral in all calculations performed as a consequence of the estimation of 
percentage of neutral/ionized forms computed at the pH of 7.4 (physiological 
value), 7.2 (cytoplasmic pH value) and 5.5 (parasite vacuole pH) using the 
Handerson–Hasselbalch equation.  
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Conformational analysis.  
Compounds 57-63 were built using the Insight 2005 Builder module (Accelrys 
Software Inc., San Diego). Atomic potentials and charges were assigned using the 
CFF91 force field. The conformational space of the compounds was sampled 
through 200 cycles of Simulated Annealing (ε= 1). In simulated annealing, the 
temperature is altered in time increments from an initial temperature to a final 
temperature by adjusting the kinetic energy of the structure (by rescaling the 
velocities of the atoms). The following protocol was applied: the system was 
heated up to 1000 K over 2000 fs (time step = 3.0 fs); the temperature of 1000 K 
was applied to the system for 2000 fs (time step = 3.0 fs) with the aim of 
surmounting torsional barriers; successively, temperature was linearly reduced to 
300 K in 1000 fs (time step = 1.0 fs). Resulting conformations were then 
subjected to molecular mechanic (MM) energy minimization within Insight 2005 
Discover module (CFF91 force field; ε = 1) until the maximum RMS derivative 
was less than 0.001 kcal/Å, using Conjugate Gradient  as minimization algorithm. 
All MM conformers were then subjected to a full geometry optimization by 
semiempirical calculations, using the quantum mechanical method PM6 in the 
Mopac2009 package and EF (Eigenvector Following routine) as geometry 
optimization algorithm. GNORM value was set to 0.01. To reach a full geometry 
optimization the criteria for terminating all optimizations was increased by a 
factor of 100, using the keyword PRECISE. 
Resulting conformers were grouped into families on the basis of their 1,2-dioxane 
ring conformation and ranked by their potential energy values (i.e., ΔE from the 
global energy minimum). Occurrence rates, together with the distance between 
endoperoxide oxygens (O1 and O2) and possible partners for a ‗through space‘ 
(1,4 and 1,5) intramolecular radical shift, were calculated for all conformers 
within 5 kcal/mol from the global minimum. The accessible surface area of 
endoperoxide oxygens lone pairs has been evaluated by calculating Connolly 
surfaces (Insight 2005, Accelrys Software Inc., San Diego). 
In vitro drug susceptibility assay on P. falciparum.  
Plasmodium falciparum cultures were carried out according to Trager and Jensen 
with slight modifications.
 
The CQ-sensitive, strain D10 and the CQ-resistant, 
strain W2 were maintained at 5% hematocrit (human type A-positive red blood 
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cells) in RPMI 1640 (EuroClone, Celbio) medium with the addition of 1% 
AlbuMax (Invitrogen, Milan, Italy), 0.01% hypoxantine, 20 mM Hepes, and 2 
mM glutammine. All the cultures were maintained at 37 °C in a standard gas 
mixture consisting of 1% O2, 5% CO2, and 94% N2. Compounds were dissolved 
in either water or DMSO and then diluted with medium to achieve the required 
concentrations (final DMSO concentration <1%, which is non-toxic to the 
parasite). Drugs were placed in 96-well flat-bottomed microplates (COSTAR) and 
serial dilutions made. Asynchronous cultures with parasitaemia of 1–1.5% and 1% 
final hematocrit were aliquoted into the plates and incubated for 72 h at 37°C. 
Parasite growth was determined spectrophotometrically (OD650) by measuring 
the activity of the parasite lactate dehydrogenase (pLDH), according to a modified 
version of the method of Makler in control and drug-treated cultures.
 
The 
antimalarial activity is expressed as 50% inhibitory concentrations (IC50); each 
IC50 value is the mean and standard deviation of at least three separate 
experiments performed in duplicate. 
Cell cytotoxicity assays 
The long-term human microvascular endothelial cell line (HMEC-1) immortalized 
by SV 40 large T antigen
 
was maintained in MCDB 131 medium (Invitrogen, 
Milan, Italy) supplemented with 10% fetal calf serum (HyClone, Celbio, Milan, 
Italy), 10 ng/ml of epidermal growth factor (Chemicon), 1 µg/ml of 
hydrocortisone, 2 mM glutamine, 100 U/ml of penicillin, 100 l µg/ml of 
streptomycin, and 20 mM Hepes buffer (EuroClone). Unless stated otherwise, all 
reagents were from Sigma Italia, Milan, Italy. For the cytotoxicity assays, cells 
were treated with serial dilutions of test compounds and cell proliferation 
evaluated using the MTT assay already described. Plates were incubated for 72 h 
at 37°C in 5% CO2, then 20 μL of a 5 mg/ml solution of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (M-2128 Sigma) in PBS was added 
for an additional 3 h at 37°C. The plates were then centrifuged, the supernatants 
discarded and the dark blue formazan crystals dissolved using 100 μL of lysing 
buffer consisting of 20% (w/v) of a solution of SDS (Sigma), 40% of N,N-
dimethylformamide (Merck) in H2O, at pH 4.7 adjusted with 80% acetic acid. The 
plates were then read on a microplate reader (Molecular Devices Co., Menlo Park, 
CA, USA) at a test wavelength of 550 nm and a reference wavelength of 650 nm. 
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The results are expressed as IC50, which is the dose of compound necessary to 
inhibit cell growth by 50%. All the tests were performed in triplicate at least three 
times.  
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3.4.  ANTIMALARIAL LIMONOIDS FROM THE NEEM 
PLANT (AZADIRACHTA INDICA)  
A. indica, a plant of the 
Meliaceae family,  has been 
used for centuries by the 
Ayurvedic medicine system as a 
source for the treatment of a 
wide variety of ailments. Since 
the beginning of the 20
th
 century 
it has become part of several 
African pharmacopeias and, 
nowadays, the populations of many tropical and sub-tropical countries use home 
made neem preparations against various illnesses including malaria.
26
 The parts of 
the plant used, the dosage and the method of preparation (more frequently 
aqueous decoctions, but also infusions and macerations) are not well established, 
since they vary from region to region. However, either fruits, seeds, barks or, 
more frequently, leaves are utilized to this aim. Extracts of A. indica seeds and 
leaves are also widely applied as pesticides and insect repellents. The efficacy of 
such products has been unambiguously associated to their content of the highly 
functionalized and rearranged limonoid (C26 tetranortriterpenoid) azadirachtin-A 
(Fig.3.18)  and analogues.
27
 Various biological effects have been evidenced also 
in mosquitoes, illustrating the potential of limonoid-rich products for the control 
of insect disease vectors.
28,29 
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Figure 3.18. Azadirachtin-A structure. 
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Extensive chemical investigations carried out in the last decades have led to the 
identification of a large number of secondary metabolites from A. indica, 
including at least fifty bioactive limonoids with either insecticidal, antibacterial, 
anti-tumor or antiviral properties.
30
 Studies aimed at isolating metabolites 
responsible for the in vitro antimalarial activity of neem extracts seemed to 
indicate that the limonoids nimbolide
31
 and gedunin (66)
32,33
 as the most potent 
components and likely responsible of the activity (Fig. 3.19).  
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Figure 3.19. Two antimalarial limonoids: nimbolide and gedunin (66) 
The mode of action of this natural product group is still unclear. The cytotoxic 
activity of gedunin (66) was moderate (EC50 = 275 μg/mL). Remarkably, gedunin 
(66) has also been recently shown to be a potent Hsp90 inhibitor with potential 
anticancer activity.
34
 On the other hand, although azadirachtin showed a very poor 
antimalarial activity on the erythrocytic stages, a transmission blocking activity of 
azadirachtin-enriched neem seed extracts has been recently demonstrated in vivo 
using a murine malaria model.
35
 
As part of the ongoing research program established by my group and aimed at 
finding new antimalarial leads from natural sources, I have carried out a detailed 
phytochemical investigation of the fruit of an African sample of Azadirachta 
indica, collected in Burkina Faso. This analysis led to the isolation of ten pure 
triterpenoid derivatives (66-75), two of which were new molecules, named 
neemfruitins A (67) and B (68). The following paragraphs describes the structural 
characterization of these new metabolites and reports on the in vitro antimalarial 
activity of all the isolated triterpenoids.   
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3.4.1. Isolation and structure elucidation of new secondary metabolities 
Preceding the detailed phytochemical investigation on the neem fruit, it was 
ascertained that this plant part actually contains antimalarial compounds by testing 
a crude fruit extract in a murine malaria model (Plasmodium berghei). In mice 
treated with the extract at a daily dosage of 200 mg/kg over 9 days and exposed to 
infectious mosquito bites on day 3 of treatment, parasitaemia levels reduced by 
45% (CI95 40%-50%;  p<0.001) compared to control animals were observed, 
confirming the choice of this plant part as study object.  
Dried fruits (25 g) of A. indica were exhaustively extracted with MeOH and the 
obtained material was then partitioned between H2O and EtOAc to yield a brown 
organic extract (2.75 g). The water layer was further partitioned against n-BuOH 
yielding a polar organic extract (2.50 g) and a water extract (8.1 g). These three 
phases were subjected to a preliminary screening on P. falciparum blood stage 
cultures to assess the in vitro antimalarial activity. The results clearly indicated 
the EtOAc phase was the most promising for further investigation (Table 3.5). It 
was therefore subjected to MPLC chromatography over silica gel followed by 
repeated HPLC purifications to yield in the pure state the new limonoid 
neemfruitin A (67) and the new apotirucallane neemefruitin B (68), in addition to 
the known metabolites azadirone (69),
36
 azadiradione (70),
37
 epoxyazadiradione 
(also called nimbinin) (71),
38
 gedunin (66),
39
 deacetylgedunin (72),
40
 
desmethyllimocin B (73),
41
 protoxylocarpin G (74),
42
 and  spicatin (75).
43 
Protoxylocarpin G (74) has been very recently isolated from seed kernels of 
Xylocarpus granatus
42
 and this is the first report of its presence in A. indica. As 
already noticed in other studies, the neem fruit extract did not contain any 
azadirachtin.
44 
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Figure 3.20. The new limonoids neemfruitin A (67) and B (68)  
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Figure 3.21. The known limonoids (66, 69-73) and apotirucallanes (74-75) 
isolated from fruits of A. indica 
HR-ESIMS data established the molecular formula of neemfruitin A (67) as 
C30H44O7. The 
1
H NMR spectrum of 67 (Table 3.4, CDCl3) showed seven methyl 
singlets, two of which (δH 2.09 and 1.98) belonging to acetyl groups, four broad 
singlets between δH 5.00 and 5.50 and a number of multiplets between δH 3.00 and 
4.20. A combined analysis of 
13
C NMR (Table 3.4) and HSQC data revealed the 
presence of three carbonyl resonances (two ester carbonyls at δC 170.5 and 170.1 
and a ketone carbonyl at δC 213.8) and of a trisubstituted double bond (δC 159.2; 
δH 5.30, δC 119.1), accounting for four of the nine unsaturation degrees implied by 
the molecular formula. Neemfruitin A (67) must be, therefore, pentacyclic. The 
13
C NMR spectrum of 67 contained also the resonances of two oxygenated 
methine carbons (δH 5.05, δC 76.7; δH 5.22, δC 74.6), of one oxymethylene (δH 
4.20 and 3.44, δC 72.2) and of an hemiacetal group (δH 5.48, δC 97.8).   
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Table 3.4 
1
H (500 MHz)  and 
13
C (125 MHz) NMR data of neemfruitins A (67) 
and B (68)
*
 
Pos. 67
  68  
 δH, mult., J in Hz δC, mult. δH, mult., J in Hz δC, mult. 
1 5.05, bs 76.7, d 7.12, d, 10.2 161.8, d 
2a 3.04, dd, 17.1, 3.6  5.84, d, 10.2 127.2, d 
2b 2.48, dd, 17.1, 1.5    
3     213.8, s  205.8, s 
4  42.4, s  44.3, s 
5 2.31
a
  47.8, d 2.07
a
 44.7, d 
6a 1.98
a
 25.1, t 1.85
a
 
 
24.0, t 
6b 1.80, m
 
 1.80
a
  
7 5.22, bs 74.6, d 3.98, bs 72.0, t 
8  42.5, s 
 
44.8, s 
9 2.50
a
 35.3, d 2.08
a 
36.8, d 
10  41.9, s 
 
40.5, s 
11a 1.80
a 
16.5, t 1.75
a 
16.8, t 
11b 1.70
a 
 1.73
a 
 
12a 1.90
a 
34.0, t 1.84
a
 
 
33.4, t 
12b 1.50
a 
 1.51
a 
 
13  47.2, s  53.1, s
 
14 
 
   159.2, s  161.9, s 
15 5.30, bs    119.1, d 5.52, bd, 6.5 119.9, d 
16a
 
2.20
a 
35.3, t 2.25
a 
35.4, t 
16b
 
2.10
a
  2.20
a 
 
17 1.54, m 59.2, d 1.93
a 
46.7, d 
18 1.00, s 21.3, q 1.03, s 19.5, q 
19 1.18, s  19.1, q 1.10, s  18.9, q 
20 2.63, m 38.4, d 2.37, m 44.7, d 
21a 4.20, t, 8.0 72.2, t 6.26, d, 6.6 96.8, d 
21b 3.44, t, 8.0    
22a 2.49
a
  35.5, t 2.09
a 
32.3, t 
22b 1.58
a
   1.73
a
  
23 5.48, bs  97.8, d 3.95
a
 80.3, d 
24   2.67, d, 7.2 67.0, d 
25    57.8, s 
26   1.33, s 23.2, q 
27   1.29, s 25.9, q 
28 1.08, s  22.0, q 1.08, s 21.3, q 
29 1.18, s  25.2, q 1.16, s 27.1, q 
30 1.19, s  27.3, q 1.12, s 27.4, q 
21-OAc   
 
170.7, s 
   2.07, s 21.2, q 
1-OAc 
 
   170.1, s   
 1.98, s 21.0, q   
7-OAc 
 
   170.5, s   
 2.09, s 21.2, q   
* 
Data taken in CDCl3. For neemfruitin A (67) data of the major epimer have been listed. 
1
H NMR 
data of the minor epimer are reported in the Experimental Section.  
a
 Overlapped with other signals. 
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The 2D NMR COSY spectrum of 67 allowed the arrangement of the proton 
multiplets into four spin systems (indicated in bold in Fig. 3.22), one of which is a 
C7 moiety spanning from the sp
2
 methine at C-15 to the hemiacetal proton and 
including an oxymethylene branching at C-20. The HMBC data (shown in Fig. 
3.22) allowed the connection of the above described moieties and the assembly of 
the protolimonoid-type neemfruitin A planar structure.  
O OAc
O
OH
OAc
COSY
H C  HMBC
 
Figure 3.22. COSY and key H→C HMBC correlations detected for  
neemfruitin A (67) 
 
In particular, cross-peaks of Me-19, Me-28 and Me-29 indicated the structure of 
ring A, including the placement of an oxymethine at C-1 and of the ketone 
carbonyl at C-3. Analogously, cross-peaks of Me-18, Me-19 and Me-30 disclosed 
the structure of rings B, C, and D, placing the second oxymethine at C-7. Both H-
1 and H-7 showed 
3
J HMBC cross-peaks with an ester carbonyl, thus inferring the 
attachment of the two acetyl groups. Finally, the key cross-peak of H-23 with C-
21 indicated the presence of a γ-lactol ring with an oxygen atom connecting C-21 
and the hemiacetal C-23. 
Actually, a series of signals attributable to a minor compound appeared to be 
present in both 
1
H and 
13
C NMR spectra of 67 and all our initial attempts to 
further purify compound 67 failed. However, once the structure of compound 67 
was disclosed, these signals were easily rationalized with the presence of an 
equilibrating mixture (ca. 3:1 ratio) of the two epimers at C-23. 
1
H and 
13
C NMR 
resonances of the minor epimer have been reported in the Experimental Section.  
The relative configuration of neemfruitin A (67) was assigned on the basis of 
ROESY cross-peaks aided by analysis of proton-proton coupling constants. The 
correlation of Me-19 with both Me-29 and Me-30 was indicative of the cis 
orientation of these groups (which is β in all the Azadirachta limonoids), while 
correlations of H-5 with both Me-28 and H-9, and of H-9 with Me-18 indicated 
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their α-orientation. Both H-1 and H-7 must be in equatorial (β) orientation on the 
basis of their very small coupling constants with protons on the adjacent carbons. 
ROESY cross-peaks H-1/Me-19 and H-7/Me-30 further supported this 
assignment. The cross-peak of Me-18 with H-20 indicated the β-orientation of H-
17, but it cannot be used to gain information on the relative orientation at C-20. 
Given the free-rotating nature of the C-17/C-20 bond and the lack of unambiguous 
information, we prefer to leave undetermined the configuration at C-20.  
Neemfruitin B (68) was isolated as a colorless amorphous solid with the 
molecular formula C32H46O6 (established by HR-ESIMS), implying ten 
unsaturation degrees. The stereostructure of 68 (Fig. 3.20) was established on the 
basis of full 1D and 2D (COSY, HSQC, HMBC) NMR analysis, following the 
same approach above reported in detail for compound 67 (complete NMR 
assignment is reported Table 3.4). In particular, combined analysis of COSY and 
HSQC spectra allowed the elucidation of the four spin systems depicted in bold in 
Fig. 3.23, with a large moiety connecting the sp
2
 methine at δH 5.52 (C-15) with 
the oxymethine at δH 2.67 (δC 67.0; C-24) and including a deshielded methine (δH 
6.26 C-21) branching. Analysis of the HMBC cross-peaks (see Fig. 3.23) allowed 
the assembly of the tetracyclic system of rings A-D, whose structure is almost 
identical to that of compounds 69 and 73-75, with the single exception of 
functionalization at C-7, which should be a non-acetylated hydroxyl group (H-7 
resonates at δH 3.98 in 68 and at δH 5.20 in 74).  
 
O OH
O
O
O
COSY
H C  HMBC
O
21
23
26
27
24
 
Figure 3.23. COSY and key H→C HMBC correlations detected for  
neemfruitin B (68) 
 
Since this tetracyclic system included seven unsaturation degrees and two oxygen 
atoms, the side chain moiety should account for the three remaining unsaturation 
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degrees and should include four oxygen atoms. The HMBC cross-peak H-23/C-21 
implied the presence of an oxygen bridge between C-23 and C-21, giving rise to a 
tetrahydrofuran ring. In addition, H-21 showed HMBC cross-peak with an acetyl 
carbonyl (δC 170.7), thus identifying C-21 as an acetylated hemiacetal carbon, in 
agreement with its downfield resonance (δC 96.8). Finally, since both Me-26 and 
Me-27 showed HMBC cross peak with two oxygenated carbons (the unprotonated 
C-25 and the oxymethine C-24), the last unsaturation degree and the last oxygen 
atom can be both accounted by the presence of an epoxide ring connecting C-24 
and C-25. This is also in agreement with resonance of H-24 (δH 2.67), a typical 
value of oxyrane methines. So, the gross structure of neemfruitin B (68) was 
defined  as a new monoacetylated apotirucallane triterpenoid. 
Relative configuration of the tetracyclic core of 68 was assigned by inspection of 
its ROESY spectrum and resulted to exactly parallel that detected for compound 
67. Cross-peaks H-23 with H-20 and H-21 implied the cis relationship of these 
protons. The relative arrangement of H-17 and H-24 with the stereogenic centers 
belonging to the tetrydrofuran ring was deduced through the high similarity of 
1
H/
13
C NMR data of 68 with those of acetyltoosendantriol,
45
 a triterpenoid 
derivative isolated from Melia toosendan possessing the same structure of 68 as 
for ring D and the entire side chain (from C-20 to C-27) and whose 
stereochemical details had been secured by X-ray analysis.
45
 The whole of the 
above evidence is in agreement with the stereochemistry of 68 reported in figure 
3.20. 
3.4.2. Pharmacological activity 
All the triterpenoids isolated from fruits of A. indica (66-75) were assayed in vitro 
against D10 (chloroquine sensitive, CQ-S) and W2 (chloroquine resistant, CQ-R) 
strains of Plasmodium falciparum using the pLDH assay by the group of prof. 
Taramelli at the University of Milan. Results are compiled in Table 3.5.  
Interestingly, the tested compounds were found to be more active on the 
chloroquine-resistant clone (W2), a behavior already observed with antimalarials 
of the endoperoxide class. The most active compounds were the three limonoids 
(C26) azadirone (69), gedunin (66) and neemfruitin A (67), while, on the contrary, 
the apotirucallane (C30) derivative 68 emerged to be the less active compound. In 
addition, comparison of the structures of 74 and 75 with that 69 indicates that 
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their different activities should be attributed to the differences in the side chain. 
Also interesting is the comparison between the activities of 69 and 70, clearly 
indicating that the presence of a second conjugated ketone group at C-16 is 
deleterious for the antimalarial activity.   
Table 3.5. In vitro antimalarial
  
activity of the extracts and of the triterpenoids 
isolated from the fruits of A. indica (66-75) tested against D10 (CQ-S) and W2 
(CQ-R) strains of P. falciparum. 
 D10 
IC50 μg/mL 
W2 
IC50 μg/mL 
Fruit (EtOAc phase) 1.31  0.48 1.92  0.84 
Fruit (BuOH phase) 3.18  0.38 3.35  0.35 
Fruit (H2O phase) > 50 > 50 
Azadirone (69)   0.71  0.10 0.53  0.13 
Azadiradione (70)   2.68  0.34 1.53  0.37 
Epoxyazadiradione (71)   1.54  0.35 1.01  0.34 
Gedunin (66)   0.80  0.18 0.63  0.20 
Deacetylgedunin (72)   2.26  0.54 1.45  0.26 
Desmethyllimocin B (73)   2.19  0.24 1.18  0.32 
Protoxylocarpin G (74)   2.64  0.35 1.27  0.48 
Spicatin (75)   2.94  0.41 1.49  0.43 
Neemfruitin A (67)   1.46  0.36 0.90  0.13 
Neemfruitin B (68)   4.99  0.57 5.28  1.41 
Chloroquine (38)   0.011  0.004   0.11  0.03 
Data are means  SD of three different experiments in duplicate 
 
It is important to notice that gedunin (66) was identified as the most potent 
antimalarial limonoid of both barks
32 
and leaves
33
 of A. indica. We have now 
found that the fruits of the same plant contain two limonoids which are as active 
as gedunin (66), namely azadirone (69) and the new neemfruitin A (67). A 
previous study
35 
identified the conjugated enone system, the furan ring and the 
acetoxy group at C-7 as critical for the antimalarial activity of gedunin (66). The 
comparable activity of neemfruitin A (67), lacking the double bond at C-1/C-2 
and showing a lactol ring in place of the furan ring, indicate that the above 
relationships, found for the D-seco-limonoid gedunin, do not apply to tetra-
carbocyclic limonoids. The pharmacophoric portions for limonoid antimalarials 
are evidently still far from being identified. Only a more detailed investigation on 
the mechanisms of their antimalarial action, which remain still elusive, could 
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allow a better understanding of the structural requirements needed by an active 
molecule.   
In conclusion, the present analysis on the fruits of A. indica revealed the presence 
of two new triterpenoid derivatives, one which, neemfruitin A (67), represents, 
together with gedunin (66) and azadirone (69) (a major component of the organic 
extract), the most active antimalarial limonoid of this part of the tree. Due to the 
importance placed on the traditional use of neem remedies for the treatment of 
malaria patients, this investigation could be potentially useful in the view of 
developing improved standardized herbal formulations that can be produced 
locally in African and Asian countries. 
 
3.4.3. Experimental  
Plant Material. Fresh, uncrushed, ripe neem fruits were collected from the region 
of Oubritenga (Ziniaré), Burkina Faso in June 2008. The tree was identified by 
Prof. Jeanne Millogo, full professor of Botanic of the Life Science Unit, and a 
voucher specimen (N°2 NFE) has been deposited in the Laboratory of Ecology at 
the University of Ouagadougou. 
Extraction and isolation. After elimination of seeds, fruits of A. indica were dried 
(25 g, dry weight) and repeatedly extracted with MeOH (4 x 500 mL) and the 
obtained material was then partitioned between H2O and EtOAc to yield a brown 
organic extract (2.75 g). The water extract was then partitioned against n-BuOH, 
yielding a polar organic (2.50 g) and a water (8.1 g) phase. The EtOAc extracts 
was subjected to chromatography over silica column (230-400 mesh) eluting with 
a solvent gradient of increasing polarity from hexane to EtOAc. Fractions eluted 
with n-hexane/EtOAc 9:1 were subjected to repeated HPLC chromatographies (n-
hexane/EtOAc 95:5) affording azadirone (69, 112.1 mg) and epoxyazadiradione 
(71, 135.4 mg). Fractions eluted with n-hexane/EtOAc 8:2 were re-
chromatogrpahed by HPLC (n-hexane/EtOAc 85:15) to give gedunin (66, 11.3 
mg) and deactylgedunin (72, 7.3 mg). Fractions eluted with n-hexane/EtOAc 7:3 
contained pure azadiradione (70, 118.5 mg). Fractions eluted with n-
hexane/EtOAc 6:4 were subjected to repeated HPLC purifications to yield 
neemfruitin B (68, 4.5 mg), protoxylocarpin G (74, 2.2 mg), and 
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desmethyllimocin B (73, 14.6 mg). Fractions eluted with n-hexane/EtOAc 1:1 
were re-chromatographed by HPLC (n-hexane/EtOAc 55:45) affording pure 
neemfruitin A (67, 3.5 mg) and spicatin (75, 2.8 mg). 
Neemfruitin A (67): Colorless amorphous solid; [α]D -17.2 (c 0.2 in CHCl3); 
1
H 
NMR (CDCl3, 500 MHz) Table 3.4; 
1
H NMR data for the minor epimer (only 
resonances differing from those of the major epimer are reported):
 δH 5.54 (1H, H-
23, bs), 3.98 (1H, H-21a, t, J = 8.0 Hz) 3.60 (1H; H-21b, t, J = 8.0 Hz), 2.81 (1H, 
H-20, m), 2.25 (1H, H-22a, overlapped), 1.63 (1H, H-22a, overlapped), 0.96 (3H, 
Me-18, s); 
13
C NMR (CDCl3, 125 MHz) Table 3.4; (+) ESI-MS m/z 539 [M + 
Na]
+
. HR-ESIMS m/z 539.2979; (calcd for C30H44O7Na 539.2985). 
Neemfruitin B (68): Colorless amorphous solid; [α]D + 5.3 (c 0.4 in CHCl3); 
1
H 
NMR (CDCl3, 500 MHz) Table 3.4; 
13
C NMR (CDCl3, 125 MHz) Table 3.4; (+) 
ESI-MS m/z 549 [M + Na]
+
. HR-ESIMS m/z 549.3200 (calcd for C32H46O6Na 
549.3192). 
In vitro drug susceptibility assay on P. falciparum: see paragraph 3.3.4 
In vivo antimalarial activity: The in vivo antimalarial activity was assessed with 
the rodent malaria model Plasmodium berghei - Anopheles stephensi - BALB/c 
mice. Groups of six mice (5 weeks old females) were treated for nine days with an 
ethanol extract of neem fruits, administered orally twice a day at a dose of 100 
mg/kg (200 mg/kg/d), or with control solution. On treatment day 3, mice were 
exposed to 20 bites of infectious mosquitoes, i.e. Anopheles females  harboring 
P.berghei sporozoites in their salivary glands. The day following the last 
treatment (day 10), percent parasitaemia was assessed by the examination of 
Giemsa-stained thin blood smears at the light microscope (1000 x magnification). 
Reduction in parasite proliferation as a result of treatment was estimated by 
comparing the mean parasitaemia values of treated and control group mice from 2 
experimentations using the Student‘s t test. 
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CHAPTER IV 
DITERPENOIDS FROM PLANTS OF THE 
FAMILY EUPHORBIACEAE 
 
Plant secondary metabolites can be divided into three broad categories, (a) 
terpenes or terpenoids, (b) alkaloids and (c) phenolic compounds. The compounds 
classified as terpenes contribute arguably the largest and most diverse class of 
natural products.
1
  
The family Euphorbiaceae includes 300 genera and about 7,500 species. Despite 
the common knowledge that many species of Euphorbiaceae are toxic, many 
species have also found commercial importance (example: Hevea for rubber, 
Ricinus for castor oil and Manihot for cassava) also as ornamental plantsand. 
Euphorbiaceae plants are a recognized source of structurally diverse diterpenoids 
and triterpenoids which have been shown to possess various biological activities 
(example: cytotoxic, anti-proliferative and wound healing), including also 
controversial biological activities such as tumor promoting and antitumor 
activity.
2
 Diterpenoid polyesters are the most peculiar group of secondary 
metabolites obtained from plants of the Euphorbiaceae family.
3
 The first member 
of this class was serendipitously discovered over a century ago while 
manipulating lamp oil from the caper spurge (Euphorbia lathyris L.), and few 
other members were obtained in the course of studies on tumor promoting 
phorboids, mainly by Hecker.
4
 
Terpenes are classified based on the number and structural organization of 
carbons formed by the linear arrangement of isoprene units followed by 
cyclization and rearrangements of the carbon skeleton with an empirical feature 
known as the isoprene rule. The term terpene refers to a hydrocarbon molecule, 
while terpenoid refers to a terpene that has been modified, for example by the 
addition of oxygen.
5
 
Diterpenoids are, by definition, C20 compounds based on four isoprene (C5H8) 
units which arise from two molecules of acetyl-coenzyme A derived by 
carbohydrate, fat, or protein catabolism yielding acetoacetyl-coenzyme A (Fig. 
4.1). Further condensation with another molecule of  acetyl-coenzyme A, now in 
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aldol-type reaction, results in -hydroxy--methylglutaryl-coenzyme A (HMG-
CoA), which is irreversibly reduced through intervention of NADPH to R-
mevalonic acid (MVA), the building block of almost all isoprenoids. 
Phosphorylation of mevalonic acid by ATP, in two steps, leads to mevalonic acid 
5-pyrophosphate. The latter reacts on the enzyme with ATP generating 
isopentenyl pyrophosphate (IPP), the long-sought biological isoprene unit. This 
elimination reaction, which had no previous analogy in biochemistry, proceeds by 
a concerted trans-elimination. Next, isopentenyl pyrophosphate is converted by an 
isomerase into an equilibrium mixture with dimethylallyl pyrophosphate 
(DMAPP), in which the latter predominates. The two intermediates react as 
shown (Fig. 4.1) with the aid of a ‗prenyl transferase‘ generating geranyl 
pyrophosphate (GPP) in a stereospecific condensation. Further condensation of 
GPP and IPP will lead to farnesyl pyrophosphate (FPP) and, so on. Specifically, 
by this sequence of reactions geranylgeranyl pyrophosphate (GGPP) (Fig. 4.1) is 
generated and represents the acyclic precursor for further elaboration into cyclic 
diterpenoids.  
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Figure 4.1. Biosynthesis of geranylgeranyl PP 
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Cyclization reactions of the acyclic precursor GGPP can occur from either side of 
the molecule: tail (alcohol end) or head (isopropylidene end). Cyclization 
generally involves carbocations and proceeds by a concerted addition mechanism 
generating different cyclic systems, dictated by the folding of the acyclic substrate 
chain on the enzyme template.
6
 
In this way, many structural variants are produced. Indeed, diterpenoids constitute 
a so rich and diverse array of cyclic systems, that till now over 2000 diterpenes 
embracing more than 170 skeletal types have been recorded. The diterpene 
compounds are classified according to their biogenetic origin as acyclic 
(phytanes), bicyclic (labdanes, halimane, clerodanes), tricyclic (pimaranes, 
abietanes, cassanes, rosanes, vouacapanes, podocarpanes), (Fig. 4.2) tetracyclic 
(trachlobanes, kauranes, aphidicolanes, stemodanes, stemaranes, bayeranes, 
atisanes, gibberellanes), macrocyclic diterpenes (taxanes, cembranes, daphnanes, 
tiglianes, ingenanes) (Fig. 4.3) and mixed compounds, in accordance with the 
number and the cyclization patterns displayed by their skeletal structure.
7–11 
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Figure 4.2. Important diterpene skeletal types 
 
117 CHAPTER IV  -  Diterpenoids from Euphorbiaceae 
 
tigliane gibberellane kaurane
H
H
H
H
H
H
TETRACYCLIC AND PENTACYCLIC
aconane
taxane
H
MACROCYCLIC AND THEIR CYCLIZATION PRODUCTS
H
H
H
lathyrane
H
H
H
H
H
 pepluane  paraliane
H
jatrophane
H
H
H
segetane
H
tigliane
H
ingenane
H
daphnane
rhamnofolane phorbolpre-myrsinane
 
 
Figure 4.3. Important diterpene skeletal types 
 
The chemical investigation of Euforbiaceae plants carried out during my Ph.D., and 
described in this thesis, led to isolation (from Jatropha  curcas) of  a diterpenoid 
(spirocurcasone, 76) characterized by a novel carbon skeleton, including an 
unprecedented spiro-connection between a decaline system and a five-membered ring, for 
which we propose the trivial name of spirorhamnofolane.
12
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In my research work I isolated, from Euphorbia macroclada, a diterpenoid with a 
naturally unprecedented ring A-secophorboid skeleton
13
(77). 
 
OAc
O
O
O
H
H
O
O
77  
 
The majority of diterpenes isolated from Euphorbiaceae plants are from casbane, 
labdane or clerodane skeletons and some of them (tigliane, daphnane and 
ingenane) have proven to be limited to Crotonideae and Euphorbioideae 
subfamilies. These diterpenes esters are toxic to livestock and humans
14
 and they 
exert tumor promoting and skin irritant activities. Many species of Euphorbia are 
regarded as potentially toxic, and latex can produce severe irritant effects, 
especially on mucous membranes and the eyes. Most of the biological effects are 
due to diterpene esters, e.g. esters of phorbol (Fig. 4.4), which activate protein 
kinase C, an important and widely distributed enzyme responsible for 
phoshorylating many biochemical entities. The permanent activation of protein 
kinase C is thought to lead to the uncontrolled cancerous growth. The most 
commonly encountered ester of phorbol is 12-O-myristoylphorbol 13-acetate. The 
origins of phorbol are not fully delineated, but may be rationalized as in figure 
4.4. Casbene, via the ring closures shown in figure 4.4 is then likely to be the 
precursor of the phorbol ring system.
6
  
The diterpenoids of lathyrane and casbane skeleton obtained from different 
species of Euphorbiaceae have been found to exhibit anti-leukemic, cytotoxic, 
antitumor activities. The compounds in daphnane ester series also occur in 
complex mixtures. The most compounds in this class are intra molecular 9,13,14-
ortho-(2-hexadecanoic acid) esters. Clerodane diterpenes have shown to act as 
vasorelaxants.
15 
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Figure 4.4 Biosynthetic pathway of phorbol. 
 
Myrsinanes and cyclomyrsinanes are derived from lathyranes via premyrsinanes. 
In addition to the normal myrsinanes (6,12 cyclojatrophanes) with a 5/7/5-ring 
carbon framework, there are compounds with a hemiacetal ring, a 13,17-epoxy 
ring, or a 10,13-epoxy ring. The stereochemistry of all the frameworks and 
substituents are the same in myrsinanes.
3
 A recent report disclosed the 
identification of the myrsinane diterpenoid cheiradone (78) as a potent vascular 
endothelial growth factor receptor (VEGFR) antagonist with negligible affinity 
for epidermal growth factor receptor (EGFR).
16
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The structure of 78 is remarkable for a kinase inhibitor, since kinase ligands are 
generally unsophisticated flat molecules that act as ATP-mimics, while 78 is 
exuberant in terms of tridimensional chirality and structural complexity.  
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4.1. SECONDARY METABOLITES FROM  ROOT BARKS OF 
JATROPHA CURCAS 
4.1.1. Introduction 
Jatropha curcas L. (Euphorbiaceae) is a 
deciduous and drought-resistant shrub, 
originated in Central and South America and 
now widely distributed in tropical and 
subtropical areas of Africa and Southeast Asia 
(Fig. 4.5).  
   Figure 4.5 
 J. curcas has long been used around the world as a source of lamp oil and soap, 
and also as a hedging plant, but in recent years the interest in this plant has 
experienced an inconceivable explosion (―the Jatropha fever‖)17 due to the 
possible use of its seeds as a sustainable source for biodiesel production, 
outperforming biodiesels from rapeseed, sunflower and soya bean oil in terms of 
performance, efficiency and emissions, also in standard diesel engines. In many 
countries, extensive cultivation of J. curcas have been implanted in areas which 
do not compete with the food cultivation, as non-arable wastelands. For example, 
in 2007, China claimed to have 2 million hectares of J. curcas already under 
cultivation and announced plans to plant an additional 11 million hectares across 
its southern states by 2010.
17
 
Extracts from J. curcas have also found a number of traditional medical uses and 
they have been intensively investigated for their secondary metabolites content.
18-
21
 This plant continues to attract the interest of natural products chemists and the 
most recent report about its chemical composition has disclosed the presence of 
jatrophalactam, a diterpenoid lactam possessing a novel tricyclic skeleton.
22
  
As a result of a bioassay-guided purification of J. curcas root barks, I have 
isolated 11 known (79-85 and 87-90) and three new (86, 91, 76) diterpenoids, 
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including spirocurcasone (76), a novel diterpenoid possessing an unprecedented 
carbon framework which includes a spiro-[4,5]-decane junction.  
4.1.2. Isolation and structure elucidation of new secondary metabolities 
The dried and powdered root barks of J. curcas were extracted at room 
temperature sequentially with hexane and EtOAc. Both the obtained crude 
extracts proved to be active in preliminary cytotoxicity tests and were subjected to 
column chromatography fractionation. Selected bioactive fractions were further 
purified over silica gel HPLC to yield five diterpenoids of the 
jatrogrossidentadione family (79-83),
23,24
 multidione (84),
25 
jatropholone B (85),
26 
curcusones A-D (87-90),
27
 and three new diterpenoids which we have named 
acetoxyjatropholone (86), curcusone E (91), and spirocurcasone (76).   
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Acetoxyjatropholone (86), C22H26O4 by HR-ESIMS, was isolated as a colorless 
amorphous solid. Its 
1
H and 
13
C NMR data were fully assigned
12 
with the help of 
2D NMR experiments and appeared strongly suggestive of a molecular 
architecture of the jatropholone-type. Particularly, the network of the key HMBC 
cross-peaks (e.g. H2-1 with C-4, C-14, and C-15; H-2 with the ketone carbonyl C-
3, C-15 and C-4; the sp
2
 methylene H2-17 with C-5, C-6 and C-7; the 
cyclopropane methine H-11 with C-5, C-10, C-12 and the methyl-linking C-13) 
indicated the structure with a 5-6-7-3 membered condensed ring system. 
Accordingly, the 
1
H NMR spectrum of 86 closely resembled that of jatropholone 
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B (85)
27
 with the exception of the lack of one of the two high-field methyl 
singlets, and the appearance of an oxygenated diastereotopic methylene (δ 4.11 
and 3.95) and an acetyl singlet (δ 2.12). The HMBC cross-peak of the above 
methylene protons with C-9, C-10, C-11, C-18 and with the acetyl ester carbonyl 
indicated the attachment of an acetoxymethyl group at the cyclopropane 
unprotonated carbon C-10. The β-orientation of this group was deduced on the 
basis of the ROESY cross-peaks  H3-18/H-11 and H2-19/H-8a.  
O
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Curcusone E (91), C20H24O3 by HR-ESIMS, is a new rhamnofolane diterpene of 
the curcusone-type.
27 
It differs from curcusones C (89) and D (90) for the 
positional isomerization of both the hydroxyl group and one of the double bonds. 
Both these changes occurred at the five-membered ring and, accordingly, the 
1
H 
and 
13
C NMR resonances of the seven- and six-membered ring nuclei (and those 
of the attached substituents), fully assigned through 2D NMR experiments 
(COSY, HSQC, HMBC) were suggestive of an unchanged arrangement compared 
to the other curcusones. On the other hand, Me-19 (δH 1.83) was now an allylic 
methyl showing HMBC cross-peaks with the conjugated ketone carbonyl at C-1 
(δC 204.1) and with two sp
2
 carbons, the unprotonated C-2 (δC 145.7) and the 
methine C-3 (δC 152.1). In turn, the methine proton H-3 showed HMBC cross-
peaks with two ketone carbonyls, C-1 and C-5 (δC 206.3), with the oxygenated 
unprotonated carbon C-4 (δC 88.9, showing also HMBC correlation with the OH 
proton at δH 4.64), and with the methine at C-10 (δC 57.4), whose relevant proton 
(H-10, δH 3.32) was coupled with H-9 in the COSY spectrum. Once the planar 
structure of 91 was defined, its relative configuration could be established on the 
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basis of 2D NMR ROESY cross-peaks. In particular, coupling of H-14 with H-9 
and of Me-17 with H-8 indicated the relative arrangement around the six-
membered ring, supported by the high proton-proton coupling constants (J = 8.5 
Hz) showed by H-8 with both H-9 and H-14, indicative of pseudo axial-axial 
relationships. Finally, the ROESY cross-peaks of OH-4 with H-9 and of H-10 
with H-18a fully defined the relative configuration of the new curcusone E (91). 
 
4.1.3. Spirocurcasone, a diterpenoid with a novel carbon skeleton 
Spirocurcasone (76, Fig. 4.6)
 
 was obtained as a colorless amorphous solid. HR-
ESIMS established the molecular formula C20H24O2, which indicated nine degrees 
of unsaturation. The 
1
H NMR spectrum of 76  showed the presence of six broad 
singlets in the region between δ 4.10 and 7.30, a series of multiplets between δ 
1.50 and 3.20 and three allylic methyl singlets (δ 1.72, 1.74 and 1.84). The 13C 
NMR spectrum of 76 showed 20 carbon signals that, with the help of the 2D 
NMR HSQC experiment, were sorted into two ketone carbonyls, eight sp
2
 carbons 
(including two methylenes, two methines and four unprotonated carbons) 
identifying four carbon-carbon double bonds, three methyls, three sp
3
 methylenes, 
three sp
3
 methines and one sp
3
 unprotonated carbon (δ 60.7). This preliminary 
analysis pointed to a tricyclic skeleton for spirocurcasone (76). 
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Figure 4.6. Spirocurcasone (76) and its new diterpene skeleton, named 
spirorhamnofolane 
Analysis of the COSY spectrum allowed the definition of the two structural 
moieties drawn with bold lines in figure 4.7, namely a six-carbon fragment going 
from the sp
2
 methine H-7 to H2-12, with a methine branching, and a two-carbon 
fragment including only the downfield shifted sp
2
 methine H-3 (δ 7.27) and the 
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diastereotopic methylene H2-4 (δ 3.17 and 2.42). The HMBC cross-peaks (Fig. 
4.7) of H2-18 with C-9, C-11 and C-12 defined the structure of the six-membered 
ring, while the cross-peaks of H3-17 with C-14, C-15 and C-16 indicated the 
attachment of an isopropenyl group at C-14. Both the allylic methyls H3-19 and 
H3-19 showed HMBC correlations with a ketone carbonyl and two sp
2 
carbons, 
thus attaching two α-methyl-α,β-unsaturated ketone fragments to the spin systems 
above evidenced by the COSY spectrum. Finally, a series of HMBC cross-peaks 
of H2-4 and H-9 proved to be of pivotal importance to disclose the tricyclic planar 
structure of compound 76 (Fig. 4.7). Indeed, both H2-4 and H-9 were correlated 
with the two ketone carbonyls (C-1 and C-5) and with the unprotonated carbon at 
C-10, which must be the spiro-carbon connecting a five- and a six-membered ring. 
Hence, the planar structure of 76 was determined as a diterpenoid with a novel 
carbon skeleton, characterized by an unprecedented spiro-connection between a 
decaline system and a five-membered ring, for which we propose the trivial name 
of spirorhamnofolane (see Fig. 4.6).   
O
O
H CCOSY HMBC  
Figure 4.7. COSY and key HMBC correlation of spirocurcasone (76) 
 
The relative configuration of 76 has been assigned by a ROESY spectrum, in 
which the correlations H-14/H-9 and H-8/Me-17 defined the relative orientation 
of three adjacent stereogenic centers of the ―upper‖ six-membered ring. The 
ROESY correlation of H-4a with H-18b and with H-8 defined the relative 
configuration at the spiro-carbon C-10. 
Given the novelty of the tricyclic framework of spirocurcasone (76), an 
unambiguous determination of its absolute configuration appeared mandatory. We 
decided to face this problem by measurement of the electronic circular dichroism 
(ECD) spectrum and comparison with the ECD spectrum predicted from quantum 
mechanical TDDFT calculations, a recent approach increasingly applied for the 
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determination of absolute configurations of natural products.
28
 The 
conformational analysis of one of the two possible enantiomers of spirocurcasone 
(the one shown in Fig. 4.6 as 76) was performed by using the simulated annealing 
procedure (INSIGHT II package). This afforded a set of conformers which were 
ranked on the basis of their conformational energy values and grouped into two 
families, which were further optimized with the software package Gaussian 03
29
 
by using DFT at the RB3LYP/6-31G(d) level (Fig. 4.8). The excitation energies 
as well as the oscillator and rotatory strengths of the electronic excitation were 
calculated for both the conformational families using the TDDFT methodology 
and their ECD spectra were then simulated by the overlapping Gaussian 
function.
30 
 
 
Figure 4.8. The two conformational families of 76 
 
In order to obtain the final ECD spectrum, the simulated spectra of the lowest 
energy conformers were averaged on the basis of their Boltzmann distribution and 
were UV corrected. Figure 4.9 shows the close similarity between the obtained 
theoretical curve and the experimental spectrum, which allowed a confident 
assignment of the absolute configuration of spirocurcasone as shown in 76.   
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Figure 4.9.  Theoretical CD curve (red) of 76 vs experimental curve (black) 
 
The new spirorhamnofolane skeleton of 76 could biosynthetically derive from a 
rhamnofolane derivative related to curcusone E (91) following the mechanism 
shown in figure 4.10, which envisages, as key step, a [1,5] sigmatropic alkyl shift 
on a cyclopentadiene. Although the 5/7 bicyclic system of the rhamnofolane A/B 
rings is widely represented in the diterpene class (e.g. daphnanes, tiglianes, 
ingenanes), to our knowledge, this kind of rearrangement is unprecedented.  
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Figure 4.10. Proposed biogenesis for the spirorhamnofolane skeleton 
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4.1.4. Pharmacological activity 
All the 14 diterpenes obtained in this study have been tested for their 
antiproliferative activity on L5178Y (mouse lymphoma) cell line. A very potent 
activity was exhibited by curcusones A (87, IC50 = 0.21 µg/mL), B (88, IC50 = 
0.27 µg/mL), C (89, IC50 = 0.09 µg/mL), and D (90, IC50 = 0.16 µg/mL), and by 
compounds 79 (IC50 = 0.60 µg/mL), 81 (IC50 = 0.85 µg/mL), 82 (IC50 = 0.20 
µg/mL), and 83 (IC50 = 0.24 µg/mL). On the other hand, multidione  (84, IC50 = 
5.5 µg/mL), jatropholone (85, IC50 = 7.5 µg/mL), acetoxyjatropholone (86, IC50 = 
2.5 µg/mL), and compound 80 (IC50 = 2.1 µg/mL) showed a moderate activity, 
while the remaining compounds 91 and 76 were practically inactive  (IC50 > 10 
µg/mL). The mechanism of this antiproliferative activity has not been 
investigated, however, the presence of Michael acceptors should not fulfil the 
structural requirements of the pharmacophoric regions, since the inactive 
compounds 80, 91, and 76 all encompass more than one Michael acceptor sites in 
their structures.      
 
4.1.5 Experimental 
 Collection, extraction and isolation.  
A ground root bark of J. curcas (1.0 kg) was extracted with at room temp 
sequentially with hexane (2 x 3 L) and EtOAc (3 x 3 L), to give the respective 
crude extracts which were concentrated in vacuo. The hexane extract (10.5 g) was 
fractionated by gravity column chromatography on silica gel (60 g) using a n-
hexane/EtOAc gradient. Fractions eluted with n-hexane/EtOAc 9:1 were further 
purified by HPLC (n-hexane/EtOAc 9:1, flow 0.8 mL/min) to yield curcusones A 
(87, 85.2 mg), B (88, 99.7 mg), E (91, 11.5 mg). Fractions eluted with n-
hexane/EtOAc 8:2 were further purified by HPLC (n-hexane/EtOAc 8:2, flow 0.8 
mL/min) to yield curcusones C (89, 13.2 mg), D (90, 5.7 mg), 15-epi-4E-
jatrogrossidentadion (81, 15.5 mg), and 4Z-jatrogrossidentadion (79, 8.4 mg). 
Fractions eluted with n-hexane/EtOAc 7:3 were further purified by HPLC (n-
hexane/EtOAc 85:15, flow 0.8 mL/min) to yield multidione (84, 14.2 mg), 4E-
jatrogrossidentadion (80, 19.3 mg). Fractions eluted with n-hexane/EtOAc 6:4 
were further purified by HPLC (n-hexane/EtOAc 7:3, flow 0.8 mL/min) to yield 
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hydroxyisojatrogrossidion (82, 12.2 mg) and 2-epi-hydroxyisojatrogrossidion (83, 
7.1 mg). The EtOAc extract (11.2 g) of root barks was fractionated by gravity 
column chromatography on silica gel (60 g) using a n-hexane-EtOAc gradient. 
Fractions eluted with n-hexane/EtOAc 9:1 were further purified by HPLC (n-
hexane/EtOAc 9:1, flow 0.8 mL/min) to yield spirocurcasone (76, 14.5 mg). 
Fractions eluted with n-hexane/EtOAc 8:2 were further purified by HPLC (n-
hexane/EtOAc 8:2, flow 0.8 mL/min) to yield jatropholone B (85, 11.4 mg) and 
acetoxyjatropholone (86, 3.4 mg). 
Acetoxyjatropholone (86): colorless amorphous solid; [α]26
D
 + 18.1 (c 0.01 
CHCl3); UV (MeOH) λmax (log ε) 275 (3.84), 220 (4.11) 204 (4.30) nm; 
1
H NMR 
(500 MHz, CDCl3) δ 5.26 (bs, H-17a), 4.69 (bs, H-17b), 4.11 (d, J = 11.6 Hz, H-
19a), 3.95 (d, J = 11.6 Hz, H-19b), 3.19 (dd, J = 16.7, 8.3 Hz, H-1a), 2.70 
(overlapped, H-7a), 2.67 (overlapped, H-7b), 2.63 (overlapped, H-2), 2.52 (dd, J = 
16.7, 2.3 Hz, H-1b), 2.31 (bs, Me-20), 2.12 (s, OAc), 1.84 (m, H-8a), 1.34 (m, H-
8b), 1.30 (d, J = 6.9 Hz, Me-16), 0.93 (overlapped, H-9), 0.92 (overlapped, H-10), 
0.91 (s, Me-18); 
13
C NMR (125 MHz, CDCl3) δ 208.0 (C-3), 170.5 (OAc), 150.6 
(C-14), 145.5 (C-6), 137.5 (C-4), 136.0 (C-12), 134.0 (C-5), 131.8 (C-15), 131.0 
(C-13), 115.6 (C-17), 74.1 (C-19), 42.7 (C-2), 33.5 (C-7), 30.4 (C-1), 26.2 (C-9), 
23.3 (C-10), 23.1 (C-11), 20.9 (OAc), 17.3 (C-16), 13.2 (C-20), 12.5 (C-18); HR-
ESIMS m/z 377.1734 ([M + Na]
+ 
calcd for C22H26NaO4 377.1729). 
Curcusone E (91): colorless amorphous solid; [α]26
D
 – 155.5 (c 0.03 CHCl3); UV 
(MeOH) λmax (log ε) 239 (3.55) 207 (4.05) nm; 
1
H NMR (500 MHz, CDCl3) δ 
6.68 (bs, H-3), 5.77 (bd, J = 2.1 Hz, H-7), 4.95 (bs, H-18a), 4.80 (bs, H-18b), 4.76 
(bs, H-16a), 4.71 (bs, H-16b), 4.64 (s, 4-OH), 3.32 (bs, H-10), 2.65 (dt, J = 8.5, 
8.5, 2.1 Hz, H-8), 2.42 (td, J = 11.6, 2.5, 2.5 Hz, H-12a), 2.37 (bd, J = 8.5 Hz, H-
9), 2.05 (m, H-12b), 1.93 (dt, J = 8.5, 8.5, 2.5 Hz, H-14), 1.83 (s, Me-19), 1.75 
(bs, Me-20), 1.74 (partially overlapped, H-13a), 1.65 (s, Me-17), 1.60 (ddd, J = 
9.0, 8.5, 2.5 Hz, H-13b); 
13
C NMR (125 MHz, CDCl3) δ 206.3 (C-5), 204.1 (C-1), 
152.1 (C-3), 148.7 (C-11), 146.8 (C-15), 145.7 (C-2), 139.0 (C-7), 131.2 (C-6), 
112.5 (C-16), 108.0 (C-18), 88.9 (C-4), 57.4 (C-10), 53.7 (C-14), 45.7 (C-8), 42.8 
(C-9), 36.9 (C-12), 34.4 (C-13), 22.0 (C-20), 20.2 (C-17), 10.8 (C-19); HR-
ESIMS m/z 335.1630 M + Na]
+ 
(calcd for C20H24NaO3 335.1623). 
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Spirocurcasone (76): C20H24O2, colorless amorphous solid; [α]26
D 
+ 3.5 (c 0.02 
CHCl3); UV (MeOH) λmax (log ε) 230 (3.32) nm; ECD (MeOH) λmax (Δε) 208.0 (+ 
2.9) 266.5 (- 5.6); 
1
H NMR (700 MHz, CDCl3) δ 7.27 (bs, H-3), 6.60 (bs, H-7), 
4.94 (bs, H-16a), 4.85 (bs, H-16b), 4.66 (bs, H-18b), 4.18 (bs, H-18b), 3.17 (bd, J 
= 18.8 Hz, H-4a), 3.07 (bd, J = 10.8 Hz, H-9), 2.42 (bd, J = 18.8 Hz, H-4b), 2.35 
(bdd, J = 11.9, 10.8 Hz, H-8), 2.32 (ddd, J = 13.2, 3.5, 3.5 Hz, H-12a), 2.17 (ddd, 
J = 13.2, 11.9, 3.5 Hz, H-12b), 2.11 (ddd, J = 11.9, 11.0, 2.8 Hz, H-14), 1.89 (bs, 
H-19), 1.84 (dddd, J = 13.2, 3.5, 3.5, 2.8 Hz, H-13a), 1.74 (bs, H-20), 1.72 (bs, H-
17), 1.53 (m, H13b); 
13
C NMR (175 MHz, CDCl3) δ 208.8 (C-1), 199.7 (C-5), 
153.4 (C-3), 146.6(C-7), 146.2 (C-15), 145.3 (C-11), 144.3 (C-2), 133.5 (C-6), 
113.4 (C-16a), 106.7 (C-18a), 60.7 (C-10), 50.4 (C-14), 47.9 (C-9), 40.9 (C-8), 
36.8 (C-12), 33.6 (C-13), 33.0 (C-4), 19.4 (C-17); ESI-MS  m/z 297 [M + H]
+
 319 
[M + Na]
+
; HR-ESIMS m/z 319.1669 [M + Na]
+
 (calcd. for C20H24NaO2 
319.1674). 
Pharmacological tests.  
The extracts were subjected to in vitro cytotoxicity assay applying the MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (Sigma-Aldrich, 
Taufkirchen; Germany) method (Sarin PS, Sun D, Thornton A, Müller WEG J 
Natl. Cancer Inst., 1987, 78, 663-666). L5178y mouse lymphoma cells have been 
selected for in vitro toxicity testings (The cells were grown in RPMI 1640 
medium (Gibco BRL, Eggenstein; Germany), supplemented with 10 mM Hepes 
[hydroxyethyl-piperazineethane-sulfonic acid], 10% fetal calf serum (FCS) (PAA, 
Cölbe, Germany) and 0.1 % gentamycin. The cells were routinely passaged twice 
weekly. The cells were kept in a humidified atmosphere of 95% air and 5% CO2 
at 37
o
C.  
To estimate the EC50 values, L5178Y, PC12 or HeLa cells were incubated for 72 
hrs in the presence of different concentrations (0.1; 0.3; 1.0; 3.0, and 10.0 μg/ml) 
of the respective compounds. The final volumes in the assay were 200 μL. All 
compounds/extracts were dissolved in DMSO and stored at -20
o
C. The viability of 
the cells was determined using the MTT colorimetric assay system. The 
evaluation was performed in 96-well plates at 595 nm using an ELISA plate 
reader, after overnight incubation at 37
o
C as described (Schröder HC, Sarin PS, 
Rottmann M, Wenger R, Maidhof A, Renneisen K, Müller WEG. Biochem 
Pharmacol, 1988, 37, 3947-3952). The 50% effective concentration (IC50), 
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representing that concentration at which the growth rate of the infected cells was 
reduced by 50%, was estimated by logit regression as described (Weiler BE, 
Schröder HC, Stefanovich V, Stewart D, Forrest JMS, Allen LB, Bowden BJ, 
Kreuter MH, Voth R, Müller WEG. J Gen. Virol 1990, 71, 1957-1963). The 
means (±SD) from 10 separate experiments are given.  
Computational Details. 
 A preliminary conformational search on spirocurcasone (76) was performed by 
Simulated Annealing in the INSIGHT II package. The CHCl3 solution phases 
were mimicked through the value of the corresponding dielectric constant. Using 
the steepest descent followed by quasi-Newton–Raphson method (VA09A) the 
conformational energy was minimized. Restrained simulations were carried out 
for 500 ps using the CVFF force field as implemented in Discover software 
(Accelrys, San Diego, USA). The simulation started at 1000 K, and then the 
temperature was decreased stepwise to 300 K. The final step was again the energy 
minimization, performed in order to refine the structures obtained, using the 
steepest descent and the quasi-Newton–Raphson (VA09A) algorithms 
successively. Both dynamic and mechanic calculations were carried out by using 
1 (kcal/mol)/A˚ 2 flat well distance restraints. One hundred structures were 
generated. To simulate the solvent chosen for NMR analysis, a distance-
dependent dielectric constant set to the value of CHCl3 (ε 4.8) was used during the 
calculations. All optimizations were performed with the software package 
Gaussian 03,
a
 by using the DFT functional RB3LYP and the basis set 6-31G(d). 
The B3LYP/6-31G(d) harmonic vibrational frequencies were further calculated to 
confirm their stability. Rotatory strength values for the electronic transitions from 
the ground state to the singly excited states for all conformers of 76 were obtained 
by TDDFT calculations RB3LYP/6–31G(d,p) with Gaussian 03. The excitation 
energies as well as the oscillator and rotatory strengths of the electronic excitation 
were calculated for both the conformational families using the TDDFT 
methodology and their ECD spectra were then simulated by overlapping the 
Gaussian functions for each transition. The simulated spectra of the lowest energy 
conformers were averaged on the basis of their Boltzmann distribution. Δε values 
were calculated by forming sums of Gaussian functions centred at the 
wavelengths of the respective electronic transitions and multiplied by the 
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corresponding rotatory strengths. The obtained ECD spectra were UV-corrected 
and compared with the experimental ones. 
 
a
Gaussian 03-Revision B05: Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; 
Scuseria, G. E.; Robb, M. A.; Cheeseman, J. A.;  Montgomery, Jr., J. A.; Vreven, 
T.; Kudin, K. N.;  Burant, J. C.;  Millam, J. M.; Iyengar, S. S.; Tomasi, J.;  
Barone, V.; Mennucci, B.;  Cossi, M.; Scalmani, G.;  Rega, N.; Petersson, G. A.; 
Nakatsuji, H.;  Hada, M.; Ehara, M.;  Toyota, K.; Fukuda, R.; Hasegawa, J.; 
Ishida, M.;  Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.;  Klene, M.; Li, X.;  
Knox, J. E.;  Hratchian, H. P.; Cross, J. B.;  Bakken, V.;  Adamo, C.; Jaramillo, J.;  
Gomperts, R.; Stratmann, R. E.;  Yazyev, O.; Austin, A. J.;  Cammi, R.;  Pomelli, 
C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.;  Salvador, P.;  
Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; 
Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; 
Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.;  Cioslowski, J.; Stefanov, B. B.; 
Liu, G.; Liashenko, A.;  Piskorz, P.;  Komaromi, I.;  Martin, R. L.; Fox, D. J.; 
Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; 
Gill, P. M. W.; Johnson, B.;  Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. 
Gaussian03W, Revision B05, Inc., Wallingford CT, 2004 
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4.2. DITERPENOIDS FROM THE IRANIAN PLANT Euphorbia 
macroclada Boiss. 
4.2.1. Introduction  
Given the current great interest for selective VEGFR antagonists in the realm of 
cancer and eye diseases,
31 
a systematic investigation on the druggability of the 
myrsinane chemotype would therefore be of great medicinal relevance. However, 
compounds of this type are generally of limited availability from natural sources, 
and usually occur as complex mixtures of related analogues. With the aim of 
finding a source of myrsinane derivatives sufficient to sustain a medicinal 
chemistry effort, I have screened several spurges for the occurrence of mysrinane 
diterpenes, identifying E. macroclada Boiss. as a novel source of this type of 
compounds. This spurge is native to the Iranian Plateau, and also grows in Syria, 
Armenia and Turkey.
32
 Cytotoxicity has been reported for extracts of E. 
macroclada,
33 
but no specific reference to this plant could  be found in the rich 
Iranian ethnopharmacology of spurges (Farphyun in Farsi).
34 
 
4.2.2. Pre-myrsinane derivates 
A diterpenoid-rich fraction was obtained by liquid-liquid partition of a crude 
EtOAc extract from the aerial parts of E. macroclada (Fig. 4.11).  
 
 
 
Figure 4.11. Euphorbia macroclada 
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By a combination of gravity column chromatography and repeated HPLC 
purifications detailed in the Experimental paragraph, four new (92-95) diterpenoid 
polyesters were obtained in the pure state (Fig. 4.12). 
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Figure 4.12. The four new pre-myrsinanes (92-95) 
 
HR-ESIMS identified C37H49NO11 as the molecular formula of compound 92. 
Analysis of its 
13
C NMR spectrum (CDCl3, Table 4.1) revealed the presence of 
four ester carbonyls (δ 164.9, 168.8, 170.2, 174.1), which were subsequently 
assigned to a nicotinate, a tiglate, an acetate and a butyrate unit, respectively, 
basing on diagnostic resonances in 
1
H and 
13
C NMR spectra. The presence of 
these groups was further supported by 2D NMR COSY, HSQC and HMBC 
spectra, which allowed also complete assignment of their NMR resonances.  
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Table 4.1. 
1
H (500 MHz)  and 
13
C (125 MHz) NMR data of  compound 92 in 
CDCl3. 
Pos. δH, mult., 
J in Hz 
δC,         
mult. 
 Pos. δH, mult., 
J in Hz 
δC, 
mult. 
1a 3.14, dd, 13.7, 7.9 42.9, t  3-O-Bu   
1b 1.62, dd, 13.7, 9.4   1‘  174.1, s 
2 1.85, m 37.0, d  2‘ 2.21a   36.3, t 
3 5.30, t, 3.2 78.9, d 
49.5, d 
 3‘ 1.53, m   18.1, t 
4 2.38, dd, 11.4, 3.2  4‘ 0.88, t, 7.2   14.8, q 
5 6.26, d, 11.4 70.7, d  5-O-Tig   
6 
 
49.2, s  1‘‘  168.8, s 
7 3.89, d, 8.7 66.2, d  2‘‘  127.8, s 
8a 2.21
a 
24.4, t  3‘‘ 6.64, q, 7.2 140.6, d 
8b 1.92, d, 16.3   4‘‘ 1.36, d, 7.2   14.5, q 
9 0.84, bd, 7.5 20.0, d  5‘‘ 1.49, s   11.8, q 
10  18.9, s  13-O-Ac   
11 0.69, dd, 7.5, 6.6 24.2, d  1‘‘‘  170.2, s 
12 3.39, d, 6.6 34.3, d  2‘‘‘ 2.11, s   21.5, q 
13  86.4, s
 
 17-O-Nic   
14  204.4, s  CO  164.9, s 
15 
 
79.0, s  2
‘‘‘‘
 9.02, s     
15-OH 4.72, s
 
  3
‘‘‘‘
  127.2, s 
16 0.87, d, 7.2 14.3, q  4
‘‘‘‘
 8.13, d, 8.1 137.4, d 
17a 4.93, d, 11.9 64.5, t
 
 5
‘‘‘‘
 7.40, dd, 8.1, 5.1 123.8, d 
17b 4.50, d, 11.9 
 
 6
‘‘‘‘
 8.78, d, 5.1 153.3, d 
18 1.12, s 15.5, q     
19 1.06, s 29.8, q     
20 1.71, s 24.4, q     
       
 
 
The diterpenoid core of compound 92, showing resonances of four methyls (three 
singlets and a doublet) bound to sp
3
 carbons, three oxymethines and one 
uncoupled oxymethylene resonating as AB system, must be responsible for the 
remaining five unsaturation degrees requested by the molecular formula. Since 
one ketone carbonyl was present (δ 204.4), 92 must be tetracyclic. Analysis of the 
COSY spectrum allowed the identification of the two spin systems depicted in 
bold in Fig. 4.13: the first spans from a pair of diastereomeric protons H2-1 (δ 
3.14 and 1.62) to H-5 and includes a methyl branching (δ 0.87, d) and two 
oxymethines; the second spin system connects the third oxymethine (H-7) to H-
12. All the proton resonances were then associated to those of the relevant carbon 
atoms by 2D HSQC data and this allowed the interpretation of the 
2,3
JH,C HMBC 
spectrum. This, allowing the connection of the different moieties was instrumental 
to the assembling of the diterpenoid skeleton of compound 92. The most 
important HMBC cross-peaks are shown in figure 4.13. In particular correlations 
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of H2-1 with C-4, with the oxygenated C-15 and with the ketone carbonyl (C-14) 
indicated the presence of the five-membered ring; correlations of the Me-20 with 
C-12, with the oxygenated C-13 and with C-14 provided the first connection 
between the two spin systems. The second connection was established on the 
basis of the HMBC cross-peaks exhibited by the oxymethylene H2-17 with C-5, 
C-6, C-7 and C-12, indicating the presence of the condensed seven- and six-
membered rings. Finally, the pre-myrsinane skeleton of 92 was deduced form the 
HMBC correlation of Me-18 and Me-19, which were in accordance with the 
presence of a dimethylcyclopropane ring, also suggested by the high field 
chemical shift of methines H-9 (δ 0.84) and H-11 (δ 0.69).  
O
O
HO
O OAc
OH
O
O N
O
O
H CCOSY HMBC  
Figure 4.13. COSY (in bold) and key 
2,3
J (H→C) HMBC cross peaks detected for 
compound 92. 
 
The pre-myrsinane core of 92 includes six oxygenated sp
3
 carbons which could 
potentially link the four previously identified acyl groups. HMBC cross-peaks of 
H-3, H-5, and H2-17 with the relevant ester carbonyls allowed the location of the 
butyrate, the tiglate and the nicotinoate groups, respectively. The relatively high-
field 
1
H NMR resonance of H-7 and the absence of HMBC correlation with ester 
carbonyls indicated that C-7 should not be an acylating position and, 
consequently, the acetate group should be attached at one of the two oxygenated 
quaternary carbons flanking the ketone group. Since the exchangeable proton at δ 
4.72 showed a 
2
J HMBC correlation with C-15, the acetate attachment site was 
identified as C-13,  in agreement with its relatively low-field resonance (δ 86.4) in 
the 
13
C NMR spectrum.   
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The relative configuration of the eleven stereogenic centers of 92 was deduced 
from the network of cross-peaks present in the ROESY spectrum (summarized in 
Fig. 4.14) and by comparison of 
1
H-
1
H coupling constants with those reported in 
the literature for other pre-myrsinanes.
35
 Finally, the ROE correlation of the two 
tiglate methyls disclosed also the E geometry of the tiglate double bond.  
BuO
HO
O
OAc
H H
H
OH
ONic
TigO
H
H
H
H
H
 
Figure 4.14. Key ROESY cross-peaks detected for compound 92.  
 
The myrsinane fraction proved to contain also three additional polyesters (93-95), 
sharing with 92 the same diterpenoid core and differing for the esterification 
pattern. Their stereostructures and, particularly the location of the acyl groups, 
were established on the basis of full MS and NMR analysis, following the same 
approach above reported in detail for compound 92 (complete NMR assignment is 
reported in the Experimental). Thus, compound 93, C36H47NO11, is a close 
analogue of 92, differing only for the replacement of the butyrate with a 
propionate unit. On the other hand, both compounds 94 and 95 showed a fifth acyl 
group, which, in both cases, was identified as an acetate group linked at C-7; 
accordingly, a consistent low-field shift was observed for H-7. In addition, 
compound 94 differs from 92 also for the replacement of the butyrate unit with an 
isobutyrate, while compound 95 differs from 92 also for the replacement of the 
tiglate unit with a 2-methylbutyrate.  
 
4.2.3. Tigliane derivates       
The aerial parts of E. macroclada afforded also five diterpenes belonging to the 
tigliane class (77, 96-99, Fig. 4.15).  
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Figure 4.15. The known β-phorboid 96, the three new α-phorboids (97-99) and 
the new A-secophorboid (77) 
 
Compound 96 proved to be a known β-phorboid, previously isolated in trace 
amounts from a Sardinian collection of Euphorbia pithyusa subsp. cupanii,
35 
as 
confirmed by comparison of available spectroscopic data. Detailed analysis of 1D 
and 2D NMR spectra  of compound 97 allowed the full assignment of all its NMR 
resonances (Table 4.2), and the assembly of a planar structure identical to that of 
96. On the other hand, the strong NOE coupling H-4/H-10, together with the 
characteristic upfield shift of H-1 (δ 7.55 in 96 and 6.99 in 97), and the consistent 
shifts of H-4 (δ 2.40 in 96 and 2.75 in 97) and H2-5 (δ 2.80 and 2.10 in 96 and 
3.42 and 2.44 in 97) in the 
1
H NMR spectrum, unambiguously indicated that this 
compound was the 4-α analogue of 96.  
Compounds 98 and 99 are close analogues of the α-phorboid 97. Compound 98, 
C27H38O6 by HR-ESIMS, showed a 2-methylbutyrate in place of the 2,3-
dimethylbutyrate as C-13 acylating group. Compound 99, C26H36O5 b HR-ESIMS, 
proved to differ from 97 for the presence of an aldehyde group (δH 9.33, δC 193.0) 
in place of the acetoxymethyl at C-20. The 
1
H NMR resonance of the conjugated 
double bond proton H-7 was accordingly downfield shifted at δH 6.07 (instead of 
δH 5.16). 
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Table 4.2. 
1
H (500 MHz)  and 
13
C (125 MHz) NMR data of  compound s 97 and 77 in 
CDCl3.  
 
 97  77  
Pos. δH, mult., J in Hz δC, mult. δH, mult., J in Hz δC, mult. 
1 6.99, bs,     156.1, d 6.07, bs 118.1, d 
2     143.5, s  197.2, s 
3     212.2, s 
49.8, d 
 176.7, s 
4 2.75, m 4.24, bt, 3.5   44.0, d 
5a 3.43
a
 26.7, t 2.98, dd, 15.5, 3.5   33.4, t 
5b 2.44, dd, 16.5, 3.5  2.76
a 
 
6 
 
   136.5, s  141.8, s 
7 5.16, bs      130.2, d 5.49, bs 130.0, d 
8 1.79, bd, 5.0
 
41.9, d 1.98, bs   45.1, d 
9  75.5, s    88.8, s 
10 3.47
a 
47.0, d  159.3, s 
11 1.57, m 37.2, d 1.81, m   36.0, d 
12a 2.13
a 
    31.1, t 2.75
a 
  31.5, t 
12b 1.93
a 
 1.63, m  
13  62.9, s
 
   64.5, s 
14 0.52, d, 5.0 33.4, d 0.73, d, 5.0   30.3, d 
15 
 
22.4, s    24.8, s 
16 1.07, s 14.9, q 1.14, s   16.2, q 
17 1.16, s 23.9, q 1.14, s   23.9, q 
18 1.05, d, 7.2 15.5, q 0.92, d, 7.2   21.3, q 
19 1.75, bs  11.0, q 2.28, s    32.1, q 
20a 4.46, d, 11.5 71.3, t 4.44, s   71.4, t 
20b 4.35, d, 11.5  4.44, s  
13-O-2’,3’-diMeBu    
1‘     178.7, s  178.5, s 
2‘ 2.17a 46.5, d 2.20, m  46.6, d 
3‘ 1.92a  30.5, d 1.92, m  30.5, d 
4‘ 0.94, d, 7.2 21.2, q 0.91, d, 7.2   19.5, q 
5‘ 1.09, d, 7.2 14.0, q 1.10, d, 7.2   14.0, q 
6‘ 0.91, d, 7.2 19.5, q 0.87, d, 7.2   19.2, q 
20-O-Ac     
1‘‘‘  171.4, s  171.0, s 
2‘‘‘ 2.13, s   21.7, q 2.07, s   21.8, q 
   a
 Overlapped with other signals. 
 
 
Compound 77, C28H38O7, by HR-ESIMS, is a new phorbol derivative showing a 
seco-A structure. The presence of 2,3-dimethylbutyrate and acetate groups was 
easily determined by analysis of 1D (Table 4.2) and 2D NMR spectra, as well as 
by comparison with data of compounds 96 and 97. Inspection of COSY, HSQC, 
and HMBC spectra of 77 revealed that the skeletal arrangements of rings B 
(seven-membered), C (six-membered) and D (three-membered) should be 
identical to those of compound 96, including also the placement of the two acyl 
groups. Consequently, the additional oxygen atom and the additional unsaturation 
degree implied by the molecular formula of 77 should be accounted by 
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modification(s) at ring A. The downfield shifted Me-19
36
 (δH 2.28 in place of 
1.75; δC 32.1 in place of 11.0) showed HMBC cross-peaks with the ketone 
carbonyl at δC 197.2 and with the sp
2
 methine at δC 118.1 (C-1). A signal at δC 
159.3 (C-10) completed the enone system, attached at the seven-membered ring, 
as confirmed also by HMBC cross-peaks of the markedly downfield shifted H-4 
(δH 4.24) with signals at δC 118.1 and 159.3. H-4 showed also 
2
J HMBC cross-
peak with a novel carbonyl resonance at δC 176.7, implying the cleavage of ring 
A, and accounting for the additional oxygen atom. The downfield shift of C-9 (δC 
88.8) and the further unsaturation degree were both accounted by the presence of 
an ester linkage connecting C-3 and C-9 to build a γ-lactone ring and completely 
define the structural arrangement of the A-seco-phorbol 77. A ROESY 
experiment secured the relative configuration of ring C stereogenic centers and 
indicated the E-geometry of the exocyclic double bond (cross-peak H-1/H-11).  
While unprecedented in Nature, an A-seco-phorbol skeleton has been previously 
obtained by treatment of a phorbol derivative with 0.2 M NaOMe in MeOH under 
oxygen atmosphere for two weeks.
37 
The mild conditions used for the extraction 
of E. macroclada and all the fractionation steps suggests a non-artifact origin for 
77. The formation of this compound could be rationalized through an 
intramolecular rearrangement of the C-2 hydroperoxide derivative obtained from 
β-phorbol 96, as shown in figure 4.16. The E-geometry of the exocyclic double 
bond gives support to this hypothesis. 
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Figure 4.16. Postulated biogenesis for the A-secophorboid 77 
 
In conclusion, a phytochemical investigation of the aerial parts of E. macroclada 
from Iran afforded eight new diterpene polyesters, four belonging to the 
premyrsinane class, three to the α-phorbol class, and one to an unprecedented type 
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for natural diterpenoids. Both premyrsinanes- and α-phorbol esters have a 
valuable biological potential, binding to VEGFR
16
 and the transient receptor 
potential vanilloid channel
38
 (TRPV4), and qualifying E. macroclada as an 
interesting source of chemical diversity to explore these important 
pharmacological targets.  
 
4.2.4. Experimental 
Plant material, extraction and isolation 
Euphorbia macroclada Boiss. was collected in the surroundings of Naein 
(Isfahan, Iran) in April 2007. The plant material was identified by Prof. 
Mohammad Reza Rahimnejad, Department of Biology, University of Isfahan, 
Isfahan, and a voucher specimen (No. 1117) has been deposited at the Herbarium 
of Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. 
The air dried aerial parts of E. macroclada (2 kg) were exhaustively extracted 
with EtOAc at room temperature. After removal the solvent in vacuo, the residue 
(50g) was dissolved in methanol (1000 mL), water was added (500 mL), and the 
suspension was sequentially extracted with petroleum ether and dichloromethane, 
respectively. Evaporation of the petroleum ether left a residue (30 g) that was 
purified by vacuum chromatography using mixtures of heptanes and chloroform 
to afford 4 fractions (A-D). NMR analysis showed that fraction A contained fats 
and alkanes, fraction B triterpenoids, and fraction D a mixture of polar 
compounds, while fraction C was characterized by a mixture of diterpenoids.  
This was purified by MPLC on RP18 silica by using a MeOH: H2O gradient (6:4 
to 10:0) as eluant. Fraction C2 was further purified by normal phase column 
chromatography to afford 5 fractions (C2a-e). Final purification of fraction C2a 
by Biotage fractionator and prep. HPLC on normal phase (petroleum ether-EtOAc 
7: 3 and 6:4) afforded  the phorboids 98 (16 mg), 96 (35 mg, 0.00175% of dry 
wt), 97 (84 mg), 77 (18 mg), and 99 (55 mg). After repeated HPLC purification 
(on petroleum ether-EtOAc 6:4 and 5:5), fraction C2b, C2c and C2d afforded pre-
myrsinanes 92 (352 mg), 94 (185 mg), 93 (19 mg) and 95 (2 mg).  
Compound 92: 0.0176 % of dry wt. Colorless amorphous solid; [α]D + 2.1 (c 0.12, 
CHCl3); 
1
H NMR (CDCl3, 500 MHz) Table 4.1; 
13
C NMR (CDCl3, 125 MHz) 
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Table 4.1; (+) ESI-MS m/z 684 [M + H]
+
, 706 [M + Na]
+
. HR-ESIMS found 
706.3212; C37H49NNaO11 requires 706.3203. 
 Compound 93: ≈ 0.00095 % of dry wt. Colorless amorphous solid; [α]D -5.6 (c 
0.18, CHCl3); 
1
H NMR (CDCl3, 500 MHz, J in Hz): δ 9.02 (1H, bs, Nic-2‘‘‘), 
8.76 (1H, d, J = 6.5, H-5‘‘‘), 8.12 (1H, d, J = 8.0, Nic-4‘‘‘), 7.39 (1H, dd, J = 8,0, 
6.5, Nic-5‘‘‘), 6.64 (1H, q, J = 7.2, Tig-3‘‘), 6.26 (1H, d, J = 11.5, H-5), 5.30 (1H, 
t, J = 3.2, H-3), 4.93 (1H, d, J = 12.0, H-17a), 4.49 (1H, d, J = 12.0, H-17b), 3.88 
(1H, bd, J = 8.5, H-7), 3.37 (1H, d, J = 6.6, H-12) 3.13 (1H, dd, J = 13.7, 8.0, H-
1a), 2.38 (1H, dd, J = 11.5, 3.2, H-4), 2.25 (2H, overlapped, Prop-2‘), 2.23 (1H, 
overlapped, H-8a), 2.12 (1H, overlapped, H-8b), 2.11 (3H, s, Ac), 1.86 (1H, m, H-
2), 1.71 (3H, s, H-20), 1.61 (1H, dd, J = 13.7, 11.5, H-1b), 1.49 (3H, bs, Tig-5‘‘), 
1.36 (3H, d, J = 7.2, Tig-4‘‘), 1.11 (3H, s, H-18), 1.05 (3H, s, H-19), 1.01 (3H, t, J 
= 7.2, Prop-3‘), 0.86 (3H, d, J = 7.2, H-16), 0.84 (1H, d, J = 7.5, H-9), 0.70 (1H, 
dd, J = 7.5, 6.6, H-11); 
13
C NMR (CDCl3, 125 MHz): δ 204.5 (s, C-14), 174.1 (s, 
Prop-C-1‘), 172.0 (s, Ac), 168.8 (s, Tig-C-1‘‘), 165.0 (s, Nic-CO), 153.5 (d, Nic-
C-6‘‘‘) 150.5 (d, Nic-C-2‘‘‘), 140.6 (d, Tig-C-3‘‘), 137.3 (d, Nic-C-4‘‘‘), 127.8 (s, 
Tig-C-2‘‘), 126.0 (s, Nic-C-3‘‘‘), 123.6 (d, Nic-C-5‘‘‘), 86.5 (s, C-13), 79.0 (s, C-
15), 78.8 (d, C-3), 70.7 (d, C-5), 66.2 (d, C-7), 64.4 (t, C-17), 49.7 (d, C-4), 48.8 
(s, C-6), 42.9 (t, C-1), 37.7 (d, C-2), 34.3 (d, C-12), 29.8 (q, C-19), 27.8 (t, Prop-
C-2‘), 25.3 (q, C-20), 24.6 (t, C-8), 24.1 (d, C-11), 21.9 (t, Ac), 20.0 (d, C-9), 18.9 
(s, C-10), 15.4 (q, C-18), 14.6 (q, C-16), 14.5 (q, Tig-C-4‘‘), 11.9 (q, Tig-C-5‘‘), 
9.0 (q, Prop-C-3‘). (+) ESI-MS m/z 692 [M + Na]+. HR-ESIMS found 692.3042; 
C36H47NNaO11 requires 692.3047. 
Compound 94: 0.00925% of dry wt. Colorless amorphous solid; [α]D -2.7 (c 0.11, 
CHCl3); 
1
H NMR (CDCl3, 500 MHz, J in Hz): δ 9.12 (1H, bs, Nic-2‘‘‘), 8.78 (1H, 
d, J = 6.5, H-5‘‘‘), 8.10 (1H, d, J = 8.0, Nic-4‘‘‘), 7.40 (1H, dd, J = 8,0, 6.5, Nic-
5‘‘‘), 6.52 (1H, q, J = 7.2, Tig-3‘‘), 6.25 (1H, d, J = 11.5, H-5), 5.28 (1H, t, J = 
3.2, H-3), 4.93 (1H, overlapped, H-17a), 4.92 (1H, overlapped, H-7), 4.56 (1H, d, 
J = 12.0, H-17b), 3.56 (1H, d, J = 6.6, H-12) 3.17 (1H, dd, J = 13.7, 8.0, H-1a), 
2.33 (1H, dd, J = 11.5, 3.2, H-4), 2.14 (2H, overlapped, MeBu-2‘), 2.15 (3H, s, 
Ac), 2.13 (3H, s, Ac), 2.00 (1H, m, MeBu-3‘), 1.96 (1H, overlapped, H-8a), 1.92 
(1H, overlapped, H-8b), 1.89 (1H, overlapped, H-2), 1.74 (3H, s, H-20), 1.66 (1H, 
m, H-1b), 1.47 (3H, bs, Tig-2‘‘-Me), 1.29 (3H, d, J = 7.2, Tig-4‘‘), 1.08 (3H, s, H-
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18), 0.92 (6H, d, J = 7.2, MeBu-4‘,5‘), 0.97 (3H, s, H-19), 0.89 (3H, d, J = 7.2, H-
16), 0.80 (1H, d, J = 7.5, H-9), 0.70 (1H, dd, J = 7.5, 6.6, H-11); 
13
C NMR 
(CDCl3, 125 MHz): δ 204.5 (s, C-14), 174.5 (s, MeBu-C-1‘), 172.0 (s, Ac), 172.5 
(s, Ac), 166.4 (s, Tig-C-1‘‘), 164.9 (s, Nic-CO), 153.3 (d, Nic-C-6‘‘‘) 150.6 (d, 
Nic-C-2‘‘‘), 140.6 (d, Tig-C-2‘‘), 137.6 (d, Nic-C-4‘‘‘),  128.4 (s, Tig-C-3‘‘), 
126.0 (s, Nic-C-3‘‘‘), 123.7 (d, Nic-C-5‘‘‘), 84.4 (s, C-13), 79.1 (s, C-15), 78.6 (d, 
C-3), 70.8 (d, C-7), 69.5 (d, C-5), 64.2 (t, C-17), 50.9 (d, C-4), 48.5 (s, C-6), 43.6 
(t, MeBu-C-2‘), 43.3 (t, C-1), 37.8 (d, C-2), 35.5 (d, C-12), 29.5 (q, C-19), 25.4 
(d, MeBu-C-3‘), 25.3 (q, C-20), 24.1 (d, C-11), 22.4 (t, C-8), 23.3, (q, MeBu-C-
4‘,5‘), 22.1 (t, Ac), 21.9 (t, Ac), 19.2 (d, C-9), 18.6 (s, C-10), 15.3 (q, C-18), 14.4 
(q, C-16), 14.3 (q, Tig-C-4‘‘), 11.9 (q, Tig-C-2‘‘-Me); (+) ESI-MS m/z 762 [M + 
Na]
+
. HR-ESIMS found 762.3470; C40H53NNaO12 requires 762.3465. 
Compound 95: ≈ 0.0001 % of dry wt. Colorless amorphous solid; [α]D -2.4 (c 
0.04, CHCl3); 
1
H NMR (CDCl3, 500 MHz, J in Hz): δ 9.22 (1H, bs, Nic-2‘‘‘), 
8.84 (1H, d, J = 6.5, H-5‘‘‘), 8.10 (1H, d, J = 8.0, Nic-4‘‘‘), 7.49 (1H, dd, J = 8,0, 
6.5, Nic-5‘‘‘), 6.22 (1H, d, J = 11.5, H-5), 5.22 (1H, t, J = 3.2, H-3), 4.90 (1H, d, J 
= 12.0, H-17a), 4.70 (1H, bd, J = 8.5, H-7), 4.50 (1H, d, J = 12.0, H-17b), 3.48 
(1H, d, J = 6.6, H-12), 3.17 (1H, dd, J = 13.7, 8.0, H-1a), 2.40 (1H, m, MeBu-2‘‘), 
2.31 (1H, dd, J = 11.5, 3.2, H-4), 2.29 (2H, overlapped, Bu-2‘), 2.11 (6H, s, Ac), 
1.96 (1H, overlapped, H-8a), 1.94 (1H, overlapped, H-8b), 1.88 (1H, m, H-2), 
1.72 (3H, s, H-20), 1.63 (1H, overlapped, H-1b), 1.62 (2H, overlapped, Bu-3‘), 
1.56 (1H, m, MeBu-3‘‘a), 1.15 (1H, m, MeBu-3‘‘b), 1.06 (3H, s, H-18), 0.96 (3H, 
t, J = 7.2, Bu-4‘), 0.95 (3H, s, H-19), 0.85 (3H, d, J = 7.2, H-16), 0.80 (3H, J = 
7.2, MeBu-5‘‘), 0.77 (1H, overlapped, H-9), 0.70 (1H, dd, J = 7.5, 6.6, H-11) 0.63 
(3H, t, J = 7.2, MeBu-4‘‘); 13C NMR (CDCl3, 125 MHz): δ 204.6 (s, C-14), 175.3 
(s, Bu-C-1‘), 174.6 (s, MeBu-C-1‘‘), 171.0 (s, Ac), 170.1 (s, Ac), 165.0 (s, Nic-
CO), 153.5 (d, Nic-C-6‘‘‘) 150.5 (d, Nic-C-2‘‘‘), 137.6 (d, Nic-C-4‘‘‘), 126.0 (s, 
Nic-C-3‘‘‘), 123.6 (d, Nic-C-5‘‘‘), 86.5 (s, C-13), 79.0 (s, C-15), 78.6 (d, C-3), 
71.0 (d, C-7), 70.7 (d, C-5), 64.4 (t, C-17), 49.5 (d, C-4), 48.8 (s, C-6), 43.8 (t, C-
1), 41.0 (s, MeBu-C-2‘‘), 38.0 (d, C-2), 36.8 (t, Bu-C-2‘), 34.3 (d, C-12), 29.9 (q, 
C-19), 26.3 (t, MeBu-C-3‘‘), 25.3 (q, C-20), 24.6 (t, C-8), 23.8 (d, C-11), 21.9 (t, 
Ac), 21.5 (t, Ac), 20.0 (d, C-9), 18.9 (s, C-10), 18.2 (t, Bu-C-3‘), 16.6 (q, MeBu-
C-4‘‘), 15.2 (q, C-18), 14.6 (q, C-16), 14.0 (q, Bu-C-4‘), 11.0 (q, MeBu-C-5‘‘); 
 
143 CHAPTER IV  -  Diterpenoids from Euphorbiaceae 
 
(+) ESI-MS m/z 750 [M + Na]
+
. HR-ESIMS found 750.3469; C39H53NNaO12 
requires 750.3465. 
Compound 97: ≈ 0.0042% of dry wt. Colorless amorphous solid; [α]D – 34.3 (c 
0.06, CHCl3); 
1
H NMR (CDCl3, 500 MHz) Table 4.2; 
13
C NMR (CDCl3, 125 
MHz) Table 4.2; (+) ESI-MS m/z 472 [M + Na]
+
. HR-ESIMS found 495.2722; 
C28H40NaO6 requires 495.2723.  
Compound 98: ≈ 0.0008% of dry wt. Colorless amorphous solid; [α]D – 39.5 (c 
0.08, CHCl3); 
1
H NMR (CDCl3, 500 MHz, J in Hz): δ 6.99 (1H, bs, H-1), 5.17 
(1H, bs, H-7), 4.46 (1H, d, J = 12.0, H-20a), 4.35 (1H, d, J = 12.0, H-20b), 3.45 
(1H, overlapped, H-10), 3.43 (1H, overlapped, H-5a), 2.76 (1H, m, H-4), 2.44 
(1H, dd, J = 16.5, 3.5, H-5b), 2.32 (1H, hex, J = 7.2, MeBu-2‘), 2.15 (1H, 
overlapped, H-12a), 2.08 (3H, s, Ac), 2.00 (1H, overlapped, H-12b), 1.80 (1H, m, 
H-8), 1.75 (3H, bs, H-19), 1.57 (1H, m, H-11), 1.48 (2H, m, MeBu-3‘), 1.15 (3H, 
s, H-17), 1.11 (3H, d, J = 7.2, MeBu-5‘), 1.07 (3H, s, H-16), 1.03 (3H, d, J = 7.2, 
H-18), 0.89 (3H, t, J = 7.2, MeBu-4‘), 0.50 (1H, d, J = 5.2, H-14); 13C NMR 
(CDCl3, 125 MHz): δ 211.9 (s, C-3), 174.6 (s, MeBu-C-1‘), 172.0 (s, Ac), 155.9 
(d, C-1), 143.7 (s, C-2), 136.9 (s, C-6), 130.3 (d, C-7), 76.0 (s, C-9), 71.5 (t, C-
20), 63.1 (s, C-13), 49.8 (d, C-4), 47.1 (d, C-10), 42.0 (d, C-8), 41.3 (d, MeBu-C-
2‘), 37.2 (d, C-11), 33.4 (d, C-14), 31.3 ( t, C-12), 26.8 (t, C-5), 26.3 (t, MeBu-C-
3‘), 24.0 (q, C-17), 22.6 (s, C-15), 21.0 (q, Ac), 16.9 (q, MeBu-C-4‘), 15.6 (q, C-
18), 14.7 (q, C-16), 11.0 (q, C-19), 10.5 (q, MeBu-C-5‘); (+)-ESI-MS m/z 481 [M 
+ Na]
+
. HR-ESIMS found 481.2569; C27H38NaO6 requires 481.2566.  
Compound 99: ≈ 0.0027% of dry wt. Colorless amorphous solid; [α]D – 2.7 (c 
0.02, CHCl3); 
1
H NMR (CDCl3, 500 MHz, J in Hz): δ 9.33 (1H, bs, H-20), 7.02 
(1H, bs, H-1), 6.07 (1H, bs, H-7), 3.58 (1H, bs, H-10), 3.28 (1H, dd, J = 15.5, 4.5, 
H-5a), 3.21 (1H, dd, J = 15.5, 1.5, H-5b), 2.88 (1H, m, H-4), 2.19 (1H, 
overlapped, diMeBu-2‘), 2.17 (1H, overlapped, H-8), 2.10 (1H, overlapped, H-
12a), 1.95 (1H, overlapped, diMeBu-3‘), 1.94 (1H, overlapped, H-12b), 1.75 (3H, 
bs, H-19), 1.60 (1H, m, H-11), 1.14 (3H, s, H-17), 1.10 (3H, d, J = 7.2, H-18), 
1.09 (3H, d, J = 7.2, diMeBu-5‘), 1.08 (3H, s, H-16), 0.94 (3H, d, J = 7.2, MeBu-
4‘), 0.92 (3H, d, J = 7.2, MeBu-6‘), 0.61 (1H, d, J = 5.2, H-14); 13C NMR (CDCl3, 
125 MHz): δ 208.9 (s, C-3), 193.0 (t, C-20), 174.0 (s, diMeBu-C-1‘), 160.3 (d, C-
7), 155.9 (d, C-1), 143.0 (s, C-2), 142.9 (s, C-6), 78.0 (s, C-9), 64.5 (s, C-13), 52.1 
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(d, C-10), 46.3 (d, diMeBu-C-2‘), 44.8 (d, C-4), 42.0 (d, C-8), 37.2 (d, C-11), 33.4 
(d, C-14), 31.3 ( t, C-12), 29.6 (d, MeBu-C-3‘), 24.5 (t, C-5), 24.0 (q, C-17), 22.6 
(s, C-15), 21.2 (q, MeBu-C-4‘), 19.5 (q, MeBu-C-6‘), 15.6 (q, C-18), 14.7 (q, C-
16), 14.5 (q, MeBu-C-5‘), 11.0 (q, C-19),; (+)-ESI-MS m/z 481 [M + Na]+. HR-
ESIMS found 451.2469; C26H36NaO5 requires 451.2460.  
Compound 77: 0.00035% of dry wt. Colorless amorphous solid; [α]D -42.7 (c 
0.01, CHCl3); 
1
H NMR (CDCl3, 500 MHz) Table 4.2; 
13
C NMR (CDCl3, 125 
MHz) Table 4.2; (+) ESI-MS m/z 509 [M + Na]
+
. HR-ESIMS found 509.2521; 
C28H38NaO7 requires 509.2515. 
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4.3. DITERPENOIDS FROM THE IRANIAN PLANT Euphorbia 
bungei Boiss  
4.3.1. Introduction 
About 70 species of Euphorbia grow in Iran, and 17 of them are endemic.
32
 Their 
ethnopharmacology is not basically different from that of hardy spurges from 
other parts of the world, with these plants being mainly used in folk medicine as 
cathartic and, topically, to remove warts.
39
 I have undertaken the phytochemical 
analysis of E. bungei Boiss., a species endemic to Iran, and previously poorly 
characterized from the phytochemical point of view, since only its flavonoid 
profile has been described in a certain detail.
40
 A leishmanicidal activity has been 
reported for preparations of E. bungei,
41
 a finding inspired by the 
ethnopharmacology of this plant, but the activity was not associated to a specific 
class of compounds. 
From this plant I have isolated three novel diterpenoids, two of them belonging to 
the jatrophane class (101-102) and one to the lathyrane class (104), along with the 
known jatrophane 103
42
 and several cycloartane triterpenoids, two of which (105a  
and 105b) were assayed for antiviral activity. 
 
4.3.2. Structure elucidation 
Diterpenoid-rich fractions were obtained by liquid-liquid partition of a crude 
acetone extract of the aerial parts of E. bungei. By a combination of gravity 
column chromatography and repeated HPLC purifications, as detailed in the 
Experimental Section, one known (103) and three new (101, 102, 104), 
diterpenoid polyesters were obtained in the pure state, along with various known 
cycloartane triterpenoids (105a-f). 
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The HR-ESIMS data of compound 101, a colorless amorphous solid, indicated the 
molecular formula C35H42O12, in agreement with the presence of 15 unsaturation 
degrees. Analysis of the 
13
C NMR spectrum of 101 (CDCl3, Table 4.3) revealed 
the presence of five ester carbonyls (δ 164.8, 170.1, 170.3, 170.4, 170.8), which 
were easily assigned to one benzoate and four acetate groups, respectively, based 
on diagnostic resonances in 
1
H and 
13
C NMR spectra. Analysis of 2D NMR 
COSY, HSQC and HMBC spectra confirmed the presence of these groups and 
allowed also the complete assignment of their NMR resonances, as reported in 
Table 4.3. Interestingly, while three acetyl methyls resonated at typical values for 
these groups (δH 2.14, 2.10, 2.08), the fourth acetyl methyl exhibited a severely 
shielded resonance (δH 1.40, singlet) in the 
1
H NMR spectrum of 101.  
All the remaining 
1
H and 
13
C NMR signals were assigned to the diterpenoid core 
of 101 using 2D NMR experiments. In particular, the 
13
C NMR spectrum of 101 
showed resonances of two ketone carbonyls (δC 205.3 and 204.1), one exo-
methylene group (δC 124.1, HSQC associated with the proton broad singlets at δH 
5.60 and 5.70), and one vic-disubstituted double bond (δC 135.3 and 134.4, HSQC 
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associated with the proton signals at δH 5.96 and 5.92, respectively). The four 
unsaturations corresponding to the above moieties added up to the nine 
unsaturations of the acyl groups, implying a bicyclic nature of the C20 core of 101. 
This penta-acylated diterpenoid included also four methyl groups (two singlets at 
δH 1.35 and 1.24, two doublets at δH 1.03 and 1.43), four oxymethines (δH 5.96, bs; 
5.85, bs; 5.73, d; 5.35, bs) and one oxygenated unprotonated carbon atom (δC  
91.9).  
 
Table 4.3. 
1
H (500 MHz)  and 
13
C (125 MHz) NMR data of  compounds 101 and 104 
in CDCl3  
 101   104  
Pos. δH, mult., J in Hz δC, mult.  δH, mult., J in Hz δC, mult. 
1a 2.13
a 
45.2, t  2.28, dd, 13.0, 10.5 32.8, t 
1b  2.93
a
   2.01, dd,13.0, 7.5  
2 2.41, m 39.1, d  2.12
a
 32.7, d 
3 5.73, bd, 4.5 77.1, d  5.34, d, 5.5 77.5, d 
4 2.94, bd, 4.5 49.7, d   71.3, s 
5 5.96, bs 73.4, d  5.87, s       115.7, 
d 
6  137.1, s 
  
      141.9, s 
7 5.85, bs 63.3, d  4.22, bs 76.8, d 
8 5.35, bs 72.9, d  4.57, dd, 10.7, 1.5 73.8, d 
9  205.3, s  1.39, t, 10.7
 
      24.0, d 
10  49.4, s   19.2, s 
11 5.96, d, 16.0 135.3, d  1.14, t, 10.7 31.1, d 
12 5.92, d, 16.0 134.5, d  4.86, dd, 10.7, 3.8
 
71.4, d 
13 3.50, m 43.9, d  2.93, m 44.0, d
 
14 
 
204.1, s         207.6, s 
15  91.9, s   73.5, s 
16
 
1.03, d, 7.0 14.1, q  0.96, d, 6.4
 
12.1, q 
17a 5.60, bs 124.1, t  2.03, s
 
17.3, q 
17b
 
5.70, bs     
18 1.35, s 26.2, q  1.09, s 29.5, q 
19 1.24, s  24.1, q  0.86, s  16.9, q 
20 1.43, d, 6.8 20.6, q  1.06, d, 7.0 13.3, q 
3-O-Ac      
1‘  170.4, s         170.4, s 
2‘ 2.14, s 20.8, q  2.14, s 20.8, q 
   a
 Overlapped with other signals. 
Additional acyl groups of compound 101: 5-O-Bz [δH 7.90 (2H), 7.53 (1H), 7.40 (2H); δC 164.8 
(1C), 129.8 (1C), 129.2 (2C), 129.1 (2C), 133.4 (1C)]. 7-O-Ac [δH 1.40 (3H); δC 170.8 (1C), 
20.4 (3C)]. 8-O-Ac [δH 2.10 (3H); δC 170.3 (1C), 20.1 (3C)]. 15-O-Ac [δH 1.98 (3H); δC 170.1 
(1C), 20.9 (3C)]. 
Additional acyl groups of compound 104: 8-O-Isoval [δH 2.26 (1H), 2.12 (2H), 0.96 (3H) 0.93 
(3H); δC 173.1 (1C), 44.3 (1C), 25.2 (1C), 22.9 (2C)]. 12-O-Ac [δH 2.11 (3H); δC 170.8 (1C), 
20.3 (3C)]. 
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The COSY spectrum of 101 identified three spin systems, highlighted in bold in 
figure 4.17. Fragment A spans from a pair of diastereotopic protons H2-1 (δ 2.93 
and 2.13) to the oxymethine H-5 (δ 5.96) and includes a methyl branching at C-2 
and another oxymethine at position 3 (δC 77.1, δH 5.73); the second spin system 
(fragment B) includes only the mutually coupled oxymethines H-7 and H-8, while 
the third spin system (fragment C) shows the connection of the trans (JH-11/H-12 = 
16.0 Hz) disubstituted double bond Δ11 with H-13, in turn coupled to the methyl 
doublet Me-20 (δ 1.43). Having associated all the proton resonances to those of 
the relevant carbon atoms by 2D HSQC, interpretation of the 
2,3
JH,C HMBC 
spectrum was instrumental to link these moieties to quaternary carbons and 
tertiary methyls (key HMBC cross-peaks are shown in Fig. 4.17).  
O
O
O OAc
OAc
AcO
AcO
O
A
B
C
 
Figure 4.17. COSY (in bold) and key 
2,3
J (H→C) HMBC cross peaks detected for 
compound 101. 
 
Correlations of H2-17 with C-4, C-5, and C-6 indicated that fragments A and B 
were connected through the sp
2
 carbon C-6. The quaternary carbon C-10 and the 
ketone carbonyl at C-9 were long-range coupled with H-8 and with Me-18/Me-19, 
which also showed HMBC coupling with C-11, thus establishing the connection 
between fragments B and C. Finally, Me-20, H-13, H2-1, and H-4 showed 
coupling with the ketone C-14, while both H2-1 and H-4 were coupled also to the 
oxygenated quaternary carbon C-15. These correlations defined the connections 
between fragments A and C and the linkage between C-4 and C-15, showing the 
presence of condensed five- and twelve-membered rings. Therefore, compound 
101 is a penta-acylated jatrophane derivative with keto groups at C-9 and C-14. 
Since the jatrophane core of 101 includes five oxygenated sp
3
 carbons (C-3, C-5, 
C-7, C-8, C-15), all these carbons must bear acyl groups. The HMBC cross-peak 
of H-5 with the ester carbonyl at δC 164.8 located the benzoyl group at C-5, and, 
therefore, all the remaining oxygenated carbons were acetylated.  
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The relative configuration of the eight stereogenic centers of 101 was deduced 
from the network of cross-peaks present in the ROESY spectrum (summarized in 
Fig. 4.18) and by comparison of 
1
H-
1
H coupling constants with those reported in 
the literature for similar jatrophanes
42,43
. In this context, especially diagnostic 
were the low values of JH-H displayed by H-5, H-7 and H-8, all resonating as broad 
singlets. The proton at the ring junction (H-4) displayed ROESY correlations with 
H-2, H-3, H-7 and H-13 indicating their cis (conventionally α-) orientation, while 
the ROESY cross-peak observed between Me-16 and the acetoxy methyl at C-15 
revealed their β-orientation. Further diagnostic ROESY cross-peaks were those 
between H-12/Me-18, Me-18/H-8, H-4/H-11, OAc-3/H-5, which allowed the 
complete and unambiguous definition of the stereostructure of the new jatrophane 
101.  
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Figure 4.18. Key ROESY cross-peaks detected for compound 101 
 
The diterpene fraction of E. bungei contained also two additional jatrophanes (102 
and 103), closely related to compound 101. Compound 102, C40H44NaO12 by HR-
ESIMS, is a new jatrophane polyester sharing with 101 the same diterpenoid core 
but a slightly different esterification pattern, with a benzoate rather than an acetate 
at C-7. The stereostructure of 102 was established on the basis of full MS and 
NMR analysis, following the same approach detailed for compound 101, and full 
NMR assignments are reported in the Experimental Section. Compound 103, 
which differs from 101 for the replacement of the ketone at C-9 with a further 
acetoxy group, is a known compound previously reported from the aerial parts of 
Euphorbia mongolica as an inhibitor of the efflux pump in multidrug-resistant 
L5178 mouse lymphoma cells.
42
  
The aerial parts of E. bungei afforded also a new diterpene (104) belonging to the 
lathyrane class. The HR-ESIMS data of compound 104 indicated the molecular 
formula C29H42O9, in agreement with of nine degrees of unsaturation. 
1
H and 
13
C 
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NMR data (Table 4.3) showed the presence of an isovalerate and two acetate 
groups (δH 2.11 and 2.14, s) linked to a diterpenoid core. The stereostructure of 
this moiety was deduced on the basis of a detailed analysis of 2D NMR spectra. 
Combined inspection of COSY and HSQC spectra of 104 disclosed the two 
structural moieties depicted in bold in figure 4.19, namely the methyl branched 
fragment from C-1 to C-3 and the seven-carbon moiety spanning C-7 to C-20. The 
sp
2
 methine singlet at δH 5.87 (H-5) showed five diagnostic 
2,3
JH,C HMBC 
correlations with the oxygenated quaternary carbons C-4 and C-15 and with C-3, 
C-6, and C-7, and these two latter carbons were also HMBC-correlated to the 
methyl singlet at δH 2.03 (H-17). The above cross-peaks allowed the definition of 
a first connection between the two moieties through the oxygenated C-4 and the 
methylated double bond Δ5. The second connection point and the linkage of C-4 
with C-15 were established on the basis of the HMBC correlations of both H2-1 
and H-13 with C-15 and with the ketone carbonyl resonating at δC 207.6 (C-14). 
Finally, the lathyrane carbon framework of 104 was defined on the basis of the 
HMBC cross-peaks of both Me-18 and Me-19 with C-9, C-11 and with the 
unprotonated C-10, in agreement with the presence of a cyclopropane ring.  
O
O
OH
O
O
O
O
O
O
 
Figure 4.19. COSY (in bold) and key 
2,3
J (H→C) HMBC cross peaks detected for 
compound 104 
 
At this stage, we reasoned that the structure of compound 104 should include four 
oxygenated sp
2
 carbons (three esters and one ketone) and six oxygenated sp
3
 
carbons, three of which must be acylated, with therefore, ten oxygenated carbons. 
The presence of an ether linkage could rationalize the nine oxygen atoms and the 
additional unsaturation degree present in the molecular formula of 104. The 
HMBC cross-peaks of H-3, H-8, and H-12 with the corresponding ester carbonyls 
allowed the placement of the acyl groups, leaving C-4, C-7, and C-15 as non-
acylated positions. The lack of HMBC correlations of H-7 with C-4 or C-15, and 
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comparison with literature data
44
 were both indicative that C-7 must bear a 
hydroxyl group, while C-4 and C-15 should be involved in an epoxide ring, thus 
defining an ingol-type structure for 104.    
The NOE correlation of H-5 with H-7 indicated the E configuration of the 
endocyclic double bond of 104, while the pattern of chemical shifts and coupling 
constants for the fragment going from C-5 to C-13, strictly paralleling the values 
reported for other ingol esters,
44,45 
indicated that compound 104 shares with them 
the configurational and conformational arrangements of the 11-membered ring. 
Thus, substituents at C-7, C-8, C-12, and C-13 are α-oriented, while both the 
cyclopropane and the epoxide rings are β-oriented. As for the relative 
configuration at C-2 and C-3, we could assign a 2α,3α orientation on the basis of 
the coupling constant value JH-2/H-3 = 5.5 Hz. As reported by Marco et al.
44
, all the 
other possible relative orientations would be associated with very different 
coupling constant values (JH-2/H-3 = 9 Hz for 2β,3β and 2α,3β and 1.5 Hz for 
2β,3α). Thus, compound 104 was identified as 2,3-diepiingol 7,12-diacetate 8-
isovalerate, a relatively rare class of ingol derivatives.  
A complex mixture of cycloartane triterpenoids was also characterized. 
Remarkably, its composition was similar to the one reported from the totally 
unrelated plant Juncus effusus.
46
 The major constituents were the isomeric diols 
105a and 105b,
46
 that were the only compounds that could be obtained in pure 
form. In other subfractions, four related compounds (105c-105f) were identified. 
Since they are all known compounds and the biological evaluation of 105a and 
105b was disappointing (see infra), no attempt was done to obtain them in pure 
form.  
The evaluation of the biological profile of the macrocyclic diterpenoids from E. 
bungei will be reported independently as a part of a structure-activity study on this 
type of compounds. On the other hand, several Euphorbia-triterpenoids show 
potent anti-HIV activity,
47
 providing a rationale to investigate the cycloartanes 
105a and 105b in anti-HIV assays. However, neither of them showed significant 
activity in an assay of NF-B-dependent transcription of the HIV-LTR-luc.48 
In conclusion, a phytochemical investigation of the aerial parts of the Iranian 
spurge E. bungei afforded, in addition to known triterpenoids, three new 
macrocyclic diterpene polyesters, two belonging to the jatrophane class and one to 
the lathyrane class. While the two major triterpenoids did not show anti HIV 
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activity, the availability of the new macrocyclic polyesters will be useful for 
studies to evaluate the potential of Euphorbia diterpenoids as modulators of 
multidrug resistance in cancer chemotherapy
49
 and as adjuvants in the anti-AIDS 
therapy.
50
  
 
4.3.3. Experimental 
Plant material, extraction and isolation   
Aerial parts of Euphorbia bungei Boiss. were collected in the surroundings of 
Fereydan (Isfahan, Iran) in April 2007. The plant material was identified by Mr. 
Bahram Zehzad, Department of Biology, University of Shahid Beheshti, Isfahan, 
and a voucher specimen (No. 2143) has been deposited at the Herbarium of 
School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.  
The air dried aerial parts of E. bungei (2440 g) were exhaustively extracted with 
acetone at room temperature. After removal of solvent in vacuo, the residue (210 
g) was dissolved in EtOH (1.5 L) and treated with the same volume of  3% 
lead(II) acetate. After two hours, the black suspension was filtered on a bed of 
Celite, obtaining a light brown filtrate. After evaporation of ethanol, the filtrate 
was saturated with NaCl and extracted with dichloromethane (1,5 L × 3). The 
organic extract was dried over anhydrous Na2SO4 and evaporated, affording a 
brown residue (14 g) which was filtered on neutral alumina (140 g, petroleum 
ether (PE):EtOAc (50:50) as solvent) to remove fatty acids, eventually obtaining 
3.0 g of a terpenoid-rich extract. The latter was purified by normal phase gravity 
column chromatography eluting with mixtures PE:EtOAc of increasing polarity, 
affording  8 fractions (F1 to F8), all containing complex mixtures.  Inspection of 
the NMR spectrum of  F3-F5 showed several signals typical of triterpenoids, and 
were purified by HPLC (PE:EtOAc 8:2, 75:25, and 6:4, respectively) to afford the 
cycloartane triterpenoids 105b, 105c, 105d, 105e and 105f in different mixtures 
(totally 38 mg ≈ 0.0016%) from F3, as well as 105a (50 mg ≈ 0.0020%) and 105b 
(24 mg ≈ 0.00098%) from F5. This fraction also afforded the lathyrane 
diterpenoid 104 (2.5 mg ≈ 0.00010%). The more polar fraction F6 was further 
purified through reversed phase flash chromatography (MeOH:H2O 70% to 
100%) to afford the new jatrophane diterpenoids 101 (33 mg ≈ 0.00135%) and 
102 (3.5 mg ≈ 0.00014%), finally purified by normal phase HPLC (PE:EtOAc 
5:5). Fraction F7 was purified by reversed phase flash chromatography 
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(MeOH:H2O 60% to 100%) to yield the jatrophane diterpenoid 103 (2.5 mg ≈ 
0.00010%). 
Compound 101: 0.00135% of dry wt. Colorless amorphous solid; [α]D + 6.3 (c 
0.07, CHCl3); 
1
H NMR (CDCl3, 500 MHz) Table 4.3; 
13
C NMR (CDCl3, 125 
MHz) Table 4.3; (+) ESI-MS m/z 677 [M + Na]
+
. HR-ESIMS found 677.2570; 
C35H42NaO12 requires 677.2574. 
Compound 102: 0.00014% of dry wt. Colorless amorphous solid; [α]D +5.4 (c 
0.02, CHCl3); 
1
H NMR (CDCl3, 500 MHz, J in Hz): δ 7.60 (2H, overlapped, 5-O-
Bz), 7.60 (2H, overlapped, 7-O-Bz), 7.25 (1H, t, J = 7.0 Hz, 5-O-Bz), 7.19 (1H, t, 
J = 7.0 Hz, 7-O-Bz), 7.10 (2H, t, J = 7.0 Hz, 5-O-Bz), 6.99 (2H, t, J = 7.0 Hz, 7-
O-Bz), 6.20 (1H, bs, H-7), 6.07 (1H, d, J =5.5 Hz, H-5), 5.96 (1H, d, J = 16.0 Hz, 
H-11), 5.92 (1H, d, J = 16.0 Hz, H-12), 5.73 (1H, bd, J = 3.0 Hz, H-3), 5.70 (1H, 
bs, H-17a), 5.60 (1H, bs, H-8), 5.40 (1H, bs, H-17b), 3.52 (1H, m, H-13), 3.03 
(1H, dd, J = 5.5, 3.0 Hz, H-4), 2.93 (1H, dd, J =15.7, 9.2 Hz, H-1a), 2.41 (1H, m, 
H-2), 2.13 (1H, overlapped, H-1b), 2.08 (3-O-Ac, s), 2.07 (15-O-Ac), 1.92 (8-O-
Ac, s), 1.32 (3H, s, H-18), 1.42 (3H, d, J = 6.8 Hz, H-20), 1.24 (3H, s, H-19), 1.01 
(1H, d, J = 7.0 Hz, H-16); 
13
C NMR (CDCl3, 125 MHz): δ 205.3 (s, C-9), 204.1 
(s, C-14), 170.7 (s, 15-O-Ac), 170.3 (s, 3-O-Ac), 170.2 (s, 8-O-Ac), 163.9 (s, 5-O-
Bz), 163.3 (s, 7-O-Bz), 137.7 (s, C-6), 135.3 (d, C-11), 134.5 (d, C-12), 133.1-
128.5 (5-O-Bz and 7-O-Bz carbons), 126.1 (t, C-17), 92.0 (s, C-15), 77.4 (d, C-3), 
73.5 (d, C-5), 72.9 (d, C-8), 71.6 (s, C-7), 49.5 (d, C-4), 49.1 (s, C-10), 45.2 (t, C-
1), 43.9 (d, C-13), 39.1 (d, C-2), 26.2 (q, C-18), 24.1 (q, C-19), 20.6 (s, C-20), 
20.7 (q, 15-O-Ac), 20.4 (q, 8-O-Ac), 20.1 (q, 3-O-Ac), 14.4 (q, C-16). ESI-MS 
m/z 739 [M + Na]
+
. HR-ESIMS found 739.2734; C40H44NaO12 requires 739.2730. 
Compound 104: 0.00010% of dry wt. Colorless amorphous solid; [α]D + 2.9 (c 
0.01, CHCl3); 
1
H NMR (CDCl3, 500 MHz) Table 4.3; 
13
C NMR (CDCl3, 125 
MHz) Table 4.3; (+) ESI-MS m/z 557 [M + Na]
+
. HR-ESIMS found 557.2733; 
C29H42NaO9 requires 557.2727. 
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5.1. General methods 
This paragraph describes the chromatographic and spectroscopic methods 
employed for the execution of the research. This techniques have been applied for 
all the projects.  
Low and high resolution ESI-MS spectra were performed on a LTQ OrbitrapXL 
(Thermo Scientific) mass spectrometer. Optical rotations (CHCl3) were measured 
at 589 nm on a P2000 Jasco polarimeter using a 10 cm microcell. UV spectra 
were measured on a Thermo Scientific (mod. Nanodrop 2000c) instrument. CD 
spectra were registered on a Jasco J-710 instrument.
 1
H (700 and 500 MHz) and 
13
C (175 and 125 MHz) NMR spectra were measured on Varian INOVA 
spectrometers. Chemical shifts were referenced to the residual solvent signal 
(CDCl3: δH 7.26, δC 77.0). Homonuclear 
1
H connectivities were determined by the 
COSY experiment. Through-space 
1
H connectivities were evidenced using a 
ROESY experiment with a mixing time of 500 ms. One-bond heteronuclear 
1
H-
13
C connectivities was determined by the HSQC experiment; two- and three-bond 
1
H-
13
C connectivities by gradient-HMBC experiments optimized for a 
2,3
J of 8 
Hz. Medium pressure liquid chromatography was performed on a Büchi apparatus 
using a silica gel (230-400 mesh) column. HPLC were achieved on a Knauer 
apparatus equipped with a refractive index detector and LUNA (Phenomenex) 
SI60 or C18 (250 × 4 mm) columns.  
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5.2. NMR spectra 
 
1
H NMR spectrum (500 MHz) of Haplosamate A (11) in CD3OD. 
 
 
HSQC 2D NMR spectrum (700 MHz) of Desulfohaplosamate (12) in CD3OD. 
 
 
159 CHAPTER V  -  Supporting Data 
 
1
H NMR spectrum (500 MHz) of compound 33 in CD3OD. 
 
 
COSY 2D NMR spectrum (500 MHz) of compound 33 in CD3OD. 
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ROESY 2D NMR spectrum (500 MHz) of compound 60b in CDCl3. 
 
1
H NMR spectrum (500 MHz) of Neemfruitin A (67) in CDCl3. 
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COSY 2D NMR spectrum (500 MHz) of Neemfruitin A (67) in CDCl3. 
 
 
HMBC 2D NMR spectrum (500 MHz) of Neemfruitin A (67) in CDCl3. 
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1
H NMR spectrum (500 MHz) of Neemfruitin B (68) in CDCl3. 
 
 
COSY NMR spectrum (500 MHz) of Neemfruitin B (68) in CDCl3. 
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HMBC 2D NMR spectrum (500 MHz) of Neemfruitin B (68) in CDCl3. 
 
 
1
H NMR spectrum (700 MHz) of Spirocurcasone (76) in CDCl3. 
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HMBC 2D NMR spectrum (700 MHz) of Spirocurcasone (76) in CDCl3. 
 
 
HSQC 2D NMR spectrum (700 MHz) of Spirocurcasone (76) in CDCl3. 
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1
H NMR spectrum (500 MHz) of A-secophorboid 77 in CDCl3. 
 
 
COSY 2D NMR spectrum (500 MHz) of A-secophorboid 77 in CDCl3. 
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1
H NMR spectrum (500 MHz) of Acetoxyjatropholone (86) in CDCl3. 
 
 
1
H NMR spectrum (500 MHz) of Curcusone E (91) in CDCl3. 
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COSY 2D NMR spectrum (500 MHz) of Curcusone E (91) in CDCl3. 
 
 
HMBC 2D NMR spectrum (500 MHz) of Curcusone E (91) in CDCl3. 
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HSQC 2D NMR spectrum (500 MHz) of Curcusone E (91) in CDCl3. 
 
 
ROESY 2D NMR spectrum (500 MHz) of Curcusone E (91) in CDCl3. 
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1
H NMR spectrum (500 MHz) of compound 92 in CDCl3. 
 
 
COSY 2D NMR spectrum (500 MHz) of compound 92 in CDCl3. 
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HMBC 2D NMR spectrum (500 MHz) of compound 92 in CDCl3. 
 
 
HSQC 2D NMR spectrum (500 MHz) of compound 92 in CDCl3. 
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1
H NMR spectrum (500 MHz) of compound 93 in CDCl3. 
 
 
 
1
H NMR spectrum (500 MHz) of compound 94 in CDCl3. 
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1
H NMR spectrum (500 MHz) of compound 97 in CDCl3. 
 
 
COSY 2D NMR spectrum (500 MHz) of compound 97 in CDCl3. 
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HMBC 2D NMR spectrum (500 MHz) of compound 97 in CDCl3. 
 
 
1
H NMR spectrum (500 MHz) of compound 98 in CDCl3. 
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1
H NMR spectrum (500 MHz) of compound 101in CDCl3. 
 
 
COSY 2D NMR spectrum (500 MHz) of compound 101 in CDCl3. 
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5.3. Computational details of compounds 57-63 
 
Table 5.1. Occurrence rate (%) of 1,2-dioxane ring conformations of 8-14 
considering PM6 conformers within 5 Kcal/mol from the global minimum 
Cm
p 
Chair A 
O
O
R2
R1
R3
R5
R4
 
Chair B 
O
O
R1
R2
R3R4
R5
 
Skew Boat A 
O
O
R4
R5 R1
R2
R3
 
Skew Boat B 
O
O
R3
R2
R1
R4
R5
 
 
57 48 13 26 13 
58 43 13 34 10 
59a 60 6 30 4 
59b 49 17 29 5 
60a 54 4 38 3 
60b 58 4 35 2 
60c 61 9 23 7 
60d 52 16 25 7 
61a 72 2 21 5 
61b 62 4 28 6 
61c 77 4 17 2 
62a 67 5 26 2 
62b 53 15 30 2 
63a 71 2 25 2 
63b 66 6 24 4 
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Table 5.2. Occurrence rate (%) of PM6 conformers within 5 Kcal/mol
 
from the global minimum 
owning interatomic distances suitable for a radical shift from O1 or O2 (≤ 3Å) and steric 
accessibility of the endoperoxide oxygens lone pairs. 
 
 
C3            
axial alkyl 
side chain 
C3 
equatorial 
alkyl side 
chain 
C6           
axial alkyl 
side chain 
C6 
equatorial 
alkyl side 
chain 
Cmp 
1,4H-
shift 
1,5H- 
shift 
1,4H-
shift 
1,5H- 
shift 
1,4H-
shift 
1,5H- 
shift 
1,4H-
shift 
1,5H- 
shift 
8 0 0 0 0 0 0 0 0 
9 0 0 32 0 0 0 0 0 
10a 0 0 24
a
 3
a
 0 0 0 0 
10b 17 1 0 0 0 0 0 0 
11a 0 0 0 0 0 0 18
a
 6
a
 
11b 0 0 0 0 21
a
 3
a
 0 0 
11c 0 0 0 0 0 0 22
a
 3
a
 
11d 0 0 0 0 20
a
 3
a
 0 0 
12a 0 0 30
a
 2
a
 0 0 20 5 
12b 0 0 23
a
 5
a
 20 1 0 0 
12c 30 0 0 0 0 0 22
a
 4
a
 
13a 0 0 0 0 14
a
 3
a
 16
a
 4
a
 
13b 0 0 0 0 22
a
 1
a
 20
a
 4
a
 
14a 0 0 13
a
 4
a
 9 0 16 2 
14b 17 1 0 0 11
a
 0 18
a
 4
a
 
a 
Putative bioactive conformations. 
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5.4. Computational details of compound 76. 
 
 
 
 
 
 
 
 
 
 
Table 5.3. Conformational Analysis of 14 in the Gas 
Phase  ΔE
a
 ΔGb P%c 
76A 0.00 0.00 65.00 
76B 0.42 0.37 35.00 
a
Relative energy (kcal/mol). 
b
Relative Gibbs free energy (kcal/mol). 
c
Conformational distribution calculated at the at the B3LYP/6-
31G(d) level in the gas phase. 
Table 5.4. Optimized Z-Matrices of 76 in the Gas Phase (A). 
1 
C       -0.070760000     -2.050208000     -0.274246000 
C       -3.913568000      0.046237000      0.152298000 
C       -4.810933000      0.625830000     -0.653821000 
C       -4.165775000     -0.073315000      1.638590000 
C        0.856030000     -2.825262000      0.296794000 
C       -0.296527000      3.833596000     -0.392523000 
O        2.106351000      2.407140000     -0.336890000 
C        1.574426000      0.077759000      1.626604000 
C        3.054420000     -0.216214000      1.628428000 
C        3.581752000     -0.406334000      0.407341000 
C        2.506450000     -0.266220000     -0.606165000 
O        2.599698000     -0.479117000     -1.799055000 
C        4.986977000     -0.729736000      0.012673000 
H       -0.073353000     -0.320574000     -1.477810000 
H       -1.347444000     -0.144187000      1.283738000 
H       -2.308758000      2.072938000      0.085809000 
H       -2.605762000     -0.298270000     -1.488073000 
H       -2.637361000     -2.356110000      0.778330000 
2 
C       -0.075803000     -2.048953000     -0.186025000 
C       -3.910849000      0.046667000      0.290581000 
C       -4.081294000      0.301917000      1.592557000 
C       -5.031886000      0.239315000     -0.702356000 
C        0.856893000     -2.818340000      0.382839000 
C       -0.263921000      3.832228000     -0.417017000 
O        2.127545000      2.384919000     -0.434473000 
C        1.641581000      0.115066000      1.617300000 
C        3.118380000     -0.192959000      1.581927000 
C        3.606284000     -0.420324000      0.350826000 
C        2.501319000     -0.297833000     -0.632658000 
O        2.555793000     -0.543938000     -1.821576000 
C        4.996042000     -0.766249000     -0.078075000 
H       -0.105400000     -0.344111000     -1.422688000 
H       -1.299576000     -0.108954000      1.370763000 
H       -2.266014000      2.101371000      0.197464000 
H       -2.612162000     -0.282624000     -1.370447000 
H       -2.637157000     -2.301468000      0.919173000 
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H       -3.476062000     -2.496864000     -0.767142000 
H       -1.297472000     -3.748963000     -0.772517000 
H       -1.310589000     -2.459780000     -1.976209000 
H       -4.643076000      0.720718000     -1.724113000 
H       -5.750560000      1.020733000     -0.274689000 
H       -3.403093000      0.456064000      2.224769000 
H       -5.140077000      0.346679000      1.905433000 
H       -4.147701000     -1.118160000      1.972477000 
H        1.770656000     -2.446118000      0.736906000 
H        0.734961000     -3.905890000      0.313430000 
H        0.134865000      4.102095000     -1.363491000 
H        0.299414000      4.357998000      0.362904000 
H       -1.325938000      4.201891000     -0.351151000 
H        1.351629000      0.990110000      2.195225000 
H        1.010259000     -0.731800000      2.106742000 
H        3.617572000     -0.272150000      2.557204000 
H        5.402330000      0.072712000     -0.608725000 
H        5.633461000     -0.866367000      0.884736000 
H        5.014930000     -1.641232000     -0.595771000 
 
H       -3.490372000     -2.475955000     -0.611589000 
H       -1.325755000     -3.747907000     -0.624765000 
H       -1.347628000     -2.485860000     -1.856962000 
H       -3.289218000      0.169516000      2.324852000 
H       -5.033948000      0.654951000      1.979180000 
H       -4.765349000      0.996672000     -1.452447000 
H       -5.235496000     -0.687188000     -1.256441000 
H       -5.959681000      0.553199000     -0.214424000 
H        1.782160000     -2.436272000      0.797453000 
H        0.729417000     -3.897551000      0.424176000 
H        0.367207000      4.364906000      0.303164000 
H       -1.287610000      4.210589000     -0.339185000 
H        0.128499000      4.079548000     -1.409893000 
H        1.444566000      1.044620000      2.167246000 
H        1.085120000     -0.675139000      2.136966000 
H        3.709240000     -0.229291000      2.494302000 
H        4.996797000     -1.689586000     -0.668935000 
H        5.401092000      0.019500000     -0.727033000 
H        5.666449000     -0.892500000      0.777323000 
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Table 5.5. Frequencies of 76 at the B3LYP/6-31G* Level in the Gas 
Phase (cm
-1
). 76A 42.2907        47.6641        58.4454        63.3436        87.2221        114.5908       120.2151       
124.547        136.468        164.525        179.3605       195.3316       197.4674       211.7265       
221.3312       258.4839       261.8258       276.0028       292.44         301.5613       322.8498       
338.7079       359.9033       366.5604       390.0987       400.6622       457.6766       477.0069       
493.1077       506.7708       530.321        561.7681       601.7547       647.7869       656.0384       
661.8678       674.4815       707.3434       724.4083       744.2789       756.6094       775.0509       
829.3904       835.0724       849.2338       862.296        901.8237       916.2502       924.4245       
933.6563       939.8286       947.8196       956.0303       987.5944       990.0369       1008.2543      
1028.8456      1030.2146      1039.3976      1046.3244      1063.1193      1072.8041      
1077.3564      1081.5512      1086.1222      1093.1754      1102.4072      1123.4503      
1145.4719      1166.3199      1188.3065      1220.5579     1233.6207      1250.9439      
1260.0417      1271.1844      1293.0659      1306.6538      1311.457       1335.9208      
1339.2221      1356.2095      1362.5401      1375.9573      1377.6923      1388.8397      
1401.9142      1407.7623      1442.3338      1443.8204      1445.8063      1479.306       
1486.8753      1502.6772      1503.3955      1512.0612      1514.4399      1515.6168      
1516.4056      1517.6075      1521.6609      1528.7934      1712.5058      1716.229       
1725.0077      1732.1592      1749.5169      1812.0345      2983.6497      3000.341       
3016.8478      3023.6982      3040.6049      3044.8273     3045.5841      3052.2372      
3055.9831      3073.7577      3086.1064      3090.1059      3092.992       3107.6916      
3112.7198      3129.8892      3134.5196      3136.1322      3155.7446      3164.0639      
3170.4858          3195.5639          3231.9488           3259.5264       
76B 36.4624        42.7754        52.9919        62.9927        89.0895        110.8221       117.4908       
127.7412       140.8402       157.1063       179.7207       194.8828       203.2207       212.2353       
221.3514       256.0121       260.7923       275.9933       293.4209       299.3921       312.9682       
340.3318       359.9515       367.2302       387.169        401.4726       452.1482       478.7054       
484.1783       510.3931       530.0829       556.1544       600.6975       648.0219       654.8333       
662.609          674.7846       708.7558       721.8678       730.8519       757.713        774.9311       
833.8788         841.665        860.0717       864.6116       902.0668       917.4658       921.9904       
923.7945           939.3075       947.5559       956.4659       983.8215       988.5362       1002.8369      
1028.9326     1029.4597      1038.0781      1043.8545      1061.2735      1071.7843      
1077.0966      1081.0541      1086.2537      1094.5006      1101.0214      1125.0682      
1145.5555      1166.5133      1187.4177      1222.7026      1234.4904      1246.4951      
1256.5293      1267.6352      1276.0575      1293.6704      1311.7978      1335.6897      
1348.6194      1356.2668      1362.1969      1376.7278      1384.4323      1391.7043      
1404.6474      1411.0028      1439.5295      1442.0153      1443.5456      1473.267       
1486.5035      1502.2716      1503.1142      1508.2355      1513.1116      1514.351       
1516.4773      1516.9964      1520.5199      1523.9366      1712.5363      1715.1377      
1730.5573      1732.8016      1749.6701      1812.1789      2986.7384      2997.2034      
3009.0043       3016.754        3030.9268      3043.7845      3045.47        3052.3365      
3055.9235       3073.9689      3076.3456      3083.9187      3090.8322      3107.8497      
3112.8119      3127.5734      3134.5213      3135.4914      3162.8547      3170.6582      
3171.6506           3195.4086         3235.7317           3260.1101       
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